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Summary 
In eukaryotic cells, mitochondria produce the vast majority of ATP, the universal energy 
currency of life. To do so, they maintain a highly reduced genome as well as the molecular 
machinery necessary for its expression. Transcription in mitochondria is carried out by a 
dedicated mitochondrial RNA polymerase (mtRNAP), which is related to single-subunit RNA 
polymerases (RNAPs) found in bacteriophages. In contrast to these self-sufficient enzymes, 
however, mtRNAP requires additional protein factors for all steps of transcription, suggesting 
a complex regulation. Moreover, it also produces the RNA primers necessary to initiate DNA 
synthesis, placing this enzyme at the heart of mitochondrial gene expression and organelle 
maintenance. Structures of mtRNAP have provided a first glimpse at the central actor 
orchestrating these important processes, but the mechanistic principles governing the individual 
steps of mitochondrial transcription remain poorly understood. In this study, we expand our 
understanding of these processes by investigating the structural basis of transcription initiation 
and processive elongation, two steps of regulatory importance. 
To initiate transcription, mtRNAP associates with the two initiation factors TFAM and TFB2M 
and promoter DNA to form an initiation complex (IC). Here, I present the structure of human 
TFB2M at 1.75 Å resolution and of the human initiation complex at 4.5 Å resolution. Together 
with published structures of mtRNAP and TFAM, this allows for construction of a pseudo-
atomic model of the IC. The structures reveal how mtRNAP is recruited to the promoter by 
TFAM and suggest that TFB2M induces a rearrangement in mtRNAP to facilitate promoter 
opening. The open complex is further stabilized by interactions between TFB2M and the melted 
non-template DNA strand. Structural comparisons demonstrate that transition to elongation is 
accompanied by a profound re-arrangement of the upstream DNA. 
Following initiation, mtRNAP associates with the elongation factor TEFM for processive 
transcription elongation. This factor enables mtRNAP to transcribe through a G-quadruplex 
forming sequence in the mitochondrial genome, which otherwise leads to transcription 
termination and primer formation for replication. However, the mechanistic basis for this anti-
termination activity of TEFM is unknown. Here, I present crystal structures of the human 
TEFM domains and, in a collaborative effort with the Temiakov Lab, we functionally define 
their roles in transcription. In addition, I have determined the structure of an anti-termination 
complex, comprised of the functional domains of TEFM bound to transcribing mtRNAP. These 
structures demonstrate that TEFM stabilizes the elongation complex by enclosing the 
downstream DNA in a “sliding clamp” and by interacting with the non-template strand in the 
transcription bubble. Moreover, these data suggest that TEFM prevents formation of the G-
quadruplex in the RNA exit path, thereby mediating the switch between transcription and DNA 
replication. 
Taken together, these results greatly advance our understanding of mitochondrial transcription 
and elucidate the mechanistic basis for the factor dependence of mtRNAP. Furthermore, they 
provide a framework for future studies aimed at deciphering the regulatory mechanisms of 
transcription and DNA replication in human mitochondria. 
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1. Introduction 
1.1. The flow of genetic information 
The genetic information of all life on earth is encoded in nucleic acid. With few exceptions, the 
molecule in which information is stored is deoxyribonucleic acid (DNA). First isolated by 
Friedrich Miescher in 1869, it was not until the mid-20th century that DNA was identified as 
the carrier of hereditary information in famous experiments by Avery, MacLeod and McCarty 
(Avery et al., 1944) and later by Hershey and Chase (Hershey and Chase, 1952). Shortly after, 
the structure of DNA was unraveled by Watson and Crick, with the help of X-Ray fiber 
diffraction data produced by Wilkins, Stokes and Franklin (Watson and Crick, 1953; Wilkins 
et al., 2003). The emerging field of molecular biology was moving at a fast pace, and in 1958 
led Francis Crick to postulate the so-called “central dogma of molecular biology”, which 
proposes a unidirectional flow of genetic information from nucleic acids to proteins (Crick, 
1958). Specifically, Crick proposed that sequence information is passed from DNA on to RNA 
and from there to proteins (Crick, 1970) (Figure 1). Although some additional information 
transfers have been discovered since (RNA to DNA and RNA to RNA) (Baltimore, 1970; 
Baltimore and Franklin, 1962), this general concept still holds true today. The process of 
information transfer from DNA to RNA is called “transcription” and the information transfer 
from RNA to protein is referred to as “translation”. In multi-cellular organisms, all cells contain 
the same DNA. The specific fate and function of a cell, its phenotype, is thus determined by 
which genetic information is activated or repressed in the particular cell. Therefore, 
understanding the fundamental principles and mechanisms governing the expression of genetic 
information is prerequisite to understanding complex biology.  
 
 
Figure 1. The central dogma of molecular biology.  
The flow of genetic information is represented as arrows. Thick, solid arrows represent the main avenues 
of information flow during gene expression. The dashed arrows represent other directions of information 
flow that have been observed in nature (Baltimore, 1970; Baltimore and Franklin, 1962). Adapted from 
(Crick, 1970). 
1.2. Transcription 
It comes as no surprise that in all organisms, from unicellular life to mammals, gene expression 
is heavily regulated at the level of transcription, the first step in gene expression. Regulating 
expression of genetic information at this step is highly efficient in terms of resource usage and 
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nevertheless allows the cell to respond to changing cellular needs or environmental conditions. 
Chemically, the transfer of information encoded in DNA to RNA requires the synthesis of a 
linear polymer of ribonucleotides using the linear, polymeric deoxyribonucleotides of DNA as 
template. Such catalytic activity for template-dependent nucleotide polymerization is required 
for both replication and expression of genetic information, and thus it may be one of the most 
ancient enzymatic activities (Steitz, 1998). The enzymes which catalyze transcription are called 
DNA-dependent RNA polymerases, or short RNAPs, and can be found in all domains of life. 
However, the molecular architecture of the transcription apparatus differs significantly between 
organisms. RNAPs can be divided into two evolutionarily unrelated classes: single-subunit and 
multi-subunit RNAPs (Cramer, 2002a). However, structural comparison demonstrates that they 
share similarities in the topology of nucleic acid binding, suggesting that their mode of action 
has evolved through convergent evolution dictated by mechanistic principles (Cramer, 2002a). 
The process of transcription can be divided into three distinct steps common to all types of 
RNA polymerases: initiation of RNA synthesis, chain elongation, and termination of 
transcription. During initiation, the RNA polymerase associates with the DNA template at a 
specific region within the genome called a promoter. Before RNA synthesis can commence, 
the two DNA strands must be unwound in order to expose the template strand around the 
transcription start site. Following initial ribonucleotide polymerization, the polymerase 
transitions to a productive elongation state, which is characterized by high fidelity and 
processivity. Chain elongation typically continues until a termination signal is encountered, 
which leads to dissociation of the RNA polymerase from the DNA template and the newly 
synthesized RNA (Hippel et al., 1984). 
The various RNA polymerases found in nature utilize different strategies to achieve the 
aforementioned steps, ranging from small enzymes which act on a limited number of promoters 
and have all functions combined in one polypeptide to complex multi-subunit enzymes which 
rely on auxiliary factors for each step. 
1.3. Single-subunit RNA polymerases 
The simplest type of RNA polymerases are single-subunit DNA-dependent RNAPs (ssRNAPs), 
which consist of only one polypeptide chain and were initially identified in bacteriophages 
(Chamberlin et al., 1970). Structurally, these enzymes show similarity to the pol I family of 
DNA polymerases, which includes the E.coli DNA polymerase Klenow fragment and the 
Human Immunodeficiency Virus 1 reverse transcriptase (Kohlstaedt et al., 1992; McAllister 
and Raskin, 1993; Sousa, 1996). These proteins display a conserved fold of the catalytic domain 
resembling a right hand, consisting of palm, fingers and thumb subdomains (Figure 2) 
(Cheetham et al., 1999; Ollis et al., 1985; Sousa et al., 1993). Single-subunit RNAPs are 
widespread in nature, as sequences encoding ssRNAPs can be found not only in viruses but 
also in eukaryotic genomes and in linear plasmids in the mitochondria of certain fungi and 
plants (Cermakian et al., 1996; Kempken et al., 1992; Masters et al., 1987; Tiranti et al., 1997). 
Based on phylogenetic analysis, single-subunit RNAPs can be further sub-divided into three 
families: bacteriophage-encoded, eukaryotic nucleus-encoded and mitochondrial linear 
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plasmid-encoded (Cermakian et al., 1997). These three classes generally share a high degree of 
conservation in their C-terminal part, which constitutes the catalytic domain, while the N-
terminal regions are highly divergent across species and families (Cermakian et al., 1997). 
Arguably the most well-studied single-subunit RNAP is the bacteriophage T7 RNA polymerase 
(T7 RNAP), which has thus become a paradigm for single-subunit RNAP function. This 
roughly 100 kDa enzyme is capable of performing the entire transcription cycle without the 
requirement of any further protein factors. The mechanistic basis of transcription initiation and 
elongation by T7 RNAP has been elucidated by visualizing structural snapshots of each of the 
steps involved. To initiate transcription, T7 RNAP interacts with the promoter DNA upstream 
of the transcription start site via the “specificity loop”, a b-hairpin structure within its C-
terminal domain, and the “AT-rich recognition loop” located in the N-terminal promoter 
binding domain (Cheetham and Steitz, 1999; Cheetham et al., 1999; Durniak et al., 2008). DNA 
strand separation is facilitated by the “intercalating hairpin”, which also guides the template 
strand towards the active site (Cheetham and Steitz, 1999; Cheetham et al., 1999). As initial 
RNA synthesis proceeds, the growing RNA-DNA hybrid induces a profound structural re-
arrangement of the N-terminal domain of T7 RNAP, effectively destroying the promoter 
binding domain and allowing the polymerase to transition to elongation (Durniak et al., 2008; 
Yin and Steitz, 2002). During elongation, the polymerase processively undergoes cycles of 
substrate binding, nucleotide addition and translocation of the RNA-DNA hybrid (Tahirov et 
al., 2002; Temiakov et al., 2004; Yin and Steitz, 2002; 2004). 
1.4. Multi-subunit RNA polymerases 
Transcription in prokaryotes, archaea and in the nuclei of eukaryotic cells is carried out by the 
more complex multi-subunit RNAPs, which, depending on the organism, are comprised of 5 – 
15 subunits (Cramer, 2002b; Werner and Grohmann, 2011). The prokaryotic RNAP consists of 
a highly conserved five-subunit core with a total mass of approximately 400 kDa (Lane and 
Darst, 2010a). In order to initiate transcription, this core associates with a promoter-specific s-
factor to form the so-called “holoenzyme” (Saecker et al., 2011). The level of complexity is 
markedly increased in eukaryotic cells, in which three multi-subunit RNA polymerases can be 
found: RNA Polymerase I, II and III (Pol I – III) (Roeder and Rutter, 1969). While Pol I 
transcribes the highly structured ribosomal RNA precursors (pre-rRNA), Pol II is the enzyme 
which transcribes protein coding genes to produce messenger RNA (mRNA), and Pol III 
transcribes small and transfer RNAs (tRNAs) (Cramer, 2002b).  In plants, two further multi-
subunit RNAPs were found, Pol IV and Pol V, which are related to Pol II and are involved in 
the transcription of small interfering RNAs (siRNAs) (Haag and Pikaard, 2011; Ream et al., 
2009). 
Although composed of a much larger number of subunits, sequence analysis suggests that 
eukaryotic multi-subunit RNAPs are evolutionarily related to prokaryotic RNAPs and these 
enzymes share a common core (Lane and Darst, 2010b; Sweetser et al., 1987; Werner and 
Grohmann, 2011). This was confirmed around the turn of the millennium, when crystal 
structures of both bacterial RNAP as well as yeast RNA Pol II became available (Cramer et al., 
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2001; 2000; Gnatt et al., 2001; Lane and Darst, 2010b; Zhang et al., 1999). The conserved core 
of multi-subunit RNAPs resembles a “crab claw” with a large cleft that accommodates nucleic 
acid and is spanned by the “bridge helix”, which may functionally resemble the O-helix found 
in single-subunit RNAPs (Figure 2) (Cramer, 2002a). 
Despite the vast structural differences between single-subunit and multi-subunit RNAPs, 
numerous mechanistic similarities can be found. Both seem to utilize a similar two-ion 
dependent catalytic mechanism for chain elongation (Sosunov et al., 2003; Steitz et al., 1994) 
and  both have evolved to neatly accommodate an approximately 8 base pair A-form DNA-
RNA hybrid, partially explaining the preference for RNA over DNA as substrate (Kettenberger 
et al., 2004; Tahirov et al., 2002; Yin and Steitz, 2002). Moreover, the topology of nucleic acid 
binding appears similar for both types of RNAPs, with the entering DNA duplex being bent by 
approximately 90° with respect to the exiting DNA-RNA hybrid duplex (Cramer, 2002a; 
Schwinghammer et al., 2013). 
 
Figure 2. Comparison of single and multi-subunit RNA polymerases. 
The structures of T7 RNAP (PDB ID: 1S76; elongation complex with nucleic acid removed) (Yin and 
Steitz, 2004), T.aquaticus RNAP (PDB ID: 1HQM) (Minakhin et al., 2001; Zhang et al., 1999) and the 
S.cerevisiae RNA Pol II 10 subunit core (PDB ID: 1I50) (Cramer et al., 2001) are shown in ribbon 
representation in grey. The O-helix and bridge helices are shown in orange and active site magnesium 
ions are shown as magenta spheres. 
1.5. Mitochondria 
Mitochondria are subcellular, membraneous organelles present in virtually all eukaryotic cells. 
They are often referred to as the “power houses” of the cell, because the machinery driving 
ATP synthesis by oxidative phosphorylation as well as numerous key metabolic pathways are 
compartmentalized in these organelles (Ernster and Schatz, 1981). In addition, mitochondria 
play important roles in various cellular processes, such as cell signaling, calcium homeostasis, 
autophagy and apoptosis (Hamanaka and Chandel, 2010; Kroemer and Reed, 2000; Perocchi et 
al., 2010; Pozzan and Rizzuto, 2000). Consequently, mitochondrial dysfunctions have been 
implicated in a plethora of human pathologies (Nunnari and Suomalainen, 2012). Furthermore, 
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due to their high exposure to reactive oxygen species, a byproduct of oxidative phosphorylation, 
mitochondria are especially prone to molecular damage and this has been implicated in ageing 
(Nunnari and Suomalainen, 2012). 
Phylogenetic analysis suggests that mitochondria have originated from an endosymbiotic event, 
which marked a decisive step in the evolution of eukaryotic cells (Gray et al., 1999). During 
this event, an early a-proteobacterium was engulfed by a precursor cell of modern eukaryotes, 
giving rise to an endosymbiotic relationship that has endured to the present day. This hypothesis 
is underlined by the finding that mitochondria possess their own genome as well as the entire 
molecular machinery necessary for the independent expression of genetic information 
(Hällberg and Larsson, 2014). Apart from the mitochondrial DNA (mtDNA), this includes a 
full set of transfer RNAs, a mitochondrial RNA polymerase and a dedicated mitochondrial 
ribosome, which is related to the bacterial ribosome but differs substantially in its protein to 
RNA ratio (Amunts et al., 2015; Friedman and Nunnari, 2014; Greber and Ban, 2016; Greber 
et al., 2015). Moreover, mitochondria utilize a distinct genetic code, which requires fewer 
tRNAs than the universal genetic code (Barrell et al., 1979). The size and organization of the 
mitochondrial genome is highly divergent, indicating that it evolved in response to varying 
evolutionary needs in different eukaryotic species (Burger et al., 2003; Gray et al., 1999). 
Mitochondrial DNA is inherited maternally, as sperm mitochondria are specifically destroyed 
in the oocyte following fertilization (Sutovsky et al., 1999).  
 
Figure 3. Organization of the human mitochondrial genome. 
Schematic depiction of the circular human mitochondrial DNA. Non-coding regions are shown in grey, 
mRNA coding regions in blue, rRNA coding regions in green and tRNA coding regions in orange. 
Promoters and origins of replication are indicated. The tRNAPhe gene is labeled with an “F”. LSP: light 
strand promoter; HSP1/2: heavy strand promoter 1/2; CSB: conserved sequence block; OH/L: origin of 
replication on the heavy / light strand; Cytb: cytochrome b; ND6: NADH dehydrogenase subunit 6; 
ND5: NADH dehydrogenase subunit 5; ND4: NADH dehydrogenase subunit 4; COXIII: cytochrome c 
oxidase subunit III; ATP6: ATP synthase F0 subunit 6; ATP8: ATP synthase F0 subunit 8; COXII: 
cytochrome c oxidase subunit II; COXI: cytochrome c oxidase subunit I; ND2: NADH dehydrogenase 
subunit 2; ND1: NADH dehydrogenase subunit 1. Note that the schematic is not drawn to scale. Adapted 
from (Falkenberg et al., 2007). 
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In humans, mtDNA is a circular molecule of approximately 16.5 kilo basepairs (kb), encoding 
for only 13 essential proteins as well as 22 tRNAs and 2 ribosomal RNAs (Figure 3) 
(Falkenberg et al., 2007). The human mitochondrial proteome, however, is comprised of at least 
1500 proteins (Calvo et al., 2016; Mootha et al., 2003; Taylor et al., 2003). Hence, the vast 
majority of mitochondrial proteins are encoded in the nuclear genome, synthesized in the 
cytosol and subsequently imported into mitochondria (Neupert, 1997). One hypothesis on the 
origin of this peculiar situation is that, over the course of evolution, most genes have been 
transferred from the mtDNA to the nuclear genome (Andersson et al., 2003), leaving only genes 
in the mitochondrial genome for which synthesis within the organelle is crucial. Strikingly, 
many of the 13 proteins encoded in human mtDNA are intramembranous components of the 
respiratory chain and synthesis by a dedicated, specialized ribosome may have been beneficial 
over the course of evolution (Heijne, 1986). 
1.6. Transcription in human mitochondria 
The mitochondrial genome is transcribed by a dedicated DNA-dependent RNA polymerase 
(mtRNAP). Somewhat surprisingly, mtRNAP is not related to multi-subunit RNAPs but to 
single-subunit bacteriophage RNAPs (Masters et al., 1987; Ringel et al., 2011). However, in 
contrast to these self-sufficient enzymes, mtRNAP requires additional protein factors for 
promoter specific initiation, transcript elongation and termination (Gustafsson et al., 2016). 
Thus, mitochondrial transcription represents an evolutionary “hybrid” between the simple 
single-subunit RNAPs and the very complex multi-subunit RNAPs. It is interesting to note that 
not only the mitochondrial transcription machinery, but also the DNA replication machinery 
seems to be of bacteriophage-origin (Shutt and Gray, 2006). 
The individual strands of human mitochondrial DNA can be separated according to their density 
and are thus designated as the heavy strand and the light strand.  Each strand contains one major 
promoter, termed light strand promoter (LSP) and heavy strand promoter (HSP1), respectively 
(Figure 3) (Anderson et al., 1981; Montoya et al., 1982; Walberg and Clayton, 1983). It has 
been proposed that the heavy strand contains a second initiation site, HSP2, located downstream 
of HSP1 within the tRNAPhe gene (Montoya et al., 1982; 1983). However, the biological 
relevance of this second promoter is under debate, as transcription from this promoter has been 
difficult to reconstitute in-vitro (Litonin et al., 2010). LSP and HSP drive transcription of 
polycistronic, near genome-length RNA transcripts, which are further processed by an intricate 
RNA processing machinery (Aloni and Attardi, 1971a; 1971b; Ojala et al., 1981). Transcription 
from LSP produces the mRNA for ND6 and eight tRNAs, while transcription from the heavy 
strand yields 12 mRNAs, both rRNAs and 14 tRNAs (Falkenberg et al., 2007). 
1.6.1. Mitochondrial transcription initiation 
Human mtRNAP requires two auxiliary proteins, TFAM and TFB2M, to achieve promoter 
specific transcription initiation (Gustafsson et al., 2016). TFAM, an HMG-Box protein, was the 
first mammalian mitochondrial transcription factor to be identified (Fisher and Clayton, 1988; 
Parisi and Clayton, 1991). Biochemical experiments have shown that TFAM binds upstream of 
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the LSP initiation site and stimulates transcription from both the LSP and the HSP1 promoter 
in-vitro (Dairaghi et al., 1995a; Litonin et al., 2010). Cross-linking studies suggest a role for 
TFAM in recruiting mtRNAP to the promoter DNA (Morozov et al., 2014). TFAM has 
furthermore been demonstrated to bind to DNA non-specifically (Fisher and Clayton, 1988), 
and it is thus thought to be a packaging factor for mtDNA involved in forming chromatin-like 
structures called nucleoids (Alam et al., 2003; Chen and Butow, 2005; Fisher et al., 1992). In 
vivo studies have shown that TFAM has a role in regulating mtDNA copy number (Ekstrand et 
al., 2004) and super-resolution as well as electron microscopic analysis suggest that the rate of 
compaction of mtDNA is a function of TFAM concentration, and this may be involved in 
regulating gene expression (Kukat et al., 2015; 2011). 
The TFBM family of proteins were initially identified as transcriptional activators based on 
homology to the yeast protein Mtf1 (Falkenberg et al., 2002; McCulloch et al., 2002). In yeast, 
the TFAM homolog is not part of the transcriptional machinery and Mtf1 is the only factor 
required for promoter-specific transcription initiation by the mitochondrial RNA polymerase 
(Schinkel et al., 1987). In mammals, two paralogous proteins with sequence homology to Mtf1 
exist, which are called TFB1M and TFB2M in humans (Falkenberg et al., 2002). Surprisingly, 
neither Mtf1 nor the mammalian TFBM proteins show significant sequence homology to 
known proteins involved in transcription. Instead, both show strong sequence similarity to 
prokaryotic S-adenosylmethionine-dependent methyltransferases that modify ribosomal RNA 
(Falkenberg et al., 2002; Schubot et al., 2001). In vitro studies using recombinant proteins 
indicate  that TFB2M is a transcriptional activator (Litonin et al., 2010), whereas TFB1M seems 
to function as a methyltransferase, modifying mitochondrial ribosomal RNA at a conserved 
position (Metodiev et al., 2009; Seidel-Rogol et al., 2003). Thus, only TFB2M is thought to be 
a transcription initiation factor in human mitochondria (Litonin et al., 2010). Biochemical 
experiments have established that it is involved in promoter opening, as mtRNAP can initiate 
transcription in the absence of TFB2M on a pre-melted DNA template, but not on a fully 
double-stranded DNA template (Matsunaga and Jaehning, 2004; Posse and Gustafsson, 2016; 
Sologub et al., 2009). It has been suggested that Mtf1 may interact with the non-template DNA 
strand in the transcription bubble, mechanistically resembling eukaryotic multi-subunit RNAP 
initiation factors or the bacterial s-factor (Paratkar and Patel, 2010).  In addition, cross-linking 
studies indicate that the N-terminus of TFB2M may interact with the priming nucleotide in the 
initially transcribing complex, suggesting a further role for TFB2M in de novo RNA synthesis 
(Sologub et al., 2009). 
Based on biochemical and cross-linking experiments, Morozov et al. have proposed a 
sequential model for transcription initiation in human mitochondria (Figure 4) (Morozov et al., 
2014). According to this model, mtRNAP is recruited to the promoter DNA by TFAM to form 
the closed pre-initiation complex (preIC). TFB2M then binds to this preIC to form the complete 
initiation complex (IC), capable of unwinding the duplex DNA around the transcription start 
site to form an open complex and initiate RNA synthesis (Morozov et al., 2014). Using 
chemical cross-linking and photo-reactive non-natural amino acids, it was possible to map 
interactions between the components of the preIC and the IC, respectively. This revealed that 
the highly divergent N-terminal extension of mtRNAP is the major interaction element with 
Introduction  
 8 
TFAM (Morozov et al., 2014; 2015). In addition to the previously described interaction of the 
N-terminus of TFB2M with the priming nucleotide (Sologub et al., 2009), it was proposed that 
the C-terminal domain of TFB2M may be positioned close to the intercalating hairpin of 
mtRNAP (Morozov et al., 2015). However, despite these extensive efforts to characterize 
mitochondrial transcription initiation, both biochemically and by mapping interaction sites, the 
mechanistic basis of this process remains elusive. 
 
 
Figure 4. The sequential model of transcription initiation in human mitochondria. 
Schematic representation of the steps that lead to transcription initiation. TFAM binds to promoter DNA 
and recruits mtRNAP to form the closed pre-initiation complex. TFB2M binding leads to formation of 
the complete initiation complex capable of melting the DNA and initiating RNA synthesis. Adapted 
from (Morozov et al., 2014) 
1.6.2. Transcription and DNA replication are coupled in 
mitochondria 
A further peculiarity of the mitochondrial transcription system is that the mitochondrial RNA 
polymerase seems to serve a dual function in transcription and in mtDNA replication. This 
realization emerged when it was found that mtRNAP produces the RNA primer required for 
initiation of DNA replication (Chang and Clayton, 1985; Kang et al., 1997), somewhat 
reminiscent of the role of T7 RNA polymerase in replication of the bacteriophage genome 
(Sugimoto et al., 1987). Mitochondrial DNA contains two major origins of replication, one on 
each strand, designated OH and OL (Figure 3). Several models for the mechanism of 
mitochondrial DNA replication have been suggested. According to the strand-displacement 
model, replication of mtDNA is initiated at OH and proceeds continuously until about two thirds 
of the genome have been copied and the OL is exposed. Replication then commences at this 
second origin and proceeds continuously in the opposite direction until both strands have been 
faithfully copied (Kang et al., 1997; Robberson et al., 1972; Tapper and Clayton, 1981). Other 
experiments have suggests that DNA replication in mitochondria may employ conventional, 
coupled leading- and lagging-strand synthesis, as is the case for nuclear DNA (Holt et al., 2000; 
Yang et al., 2002). Furthermore, it has been proposed that lagging strand replication may 
involve transient ribonucleotide incorporation, giving rise to yet another model for mtDNA 
replication (Yasukawa et al., 2006). As evident from these numerous models, the molecular 
mechanism of replication in mitochondria remains under debate (Holt and Reyes, 2012). 
However, recent in vivo single-molecule studies strongly support the original strand-
displacement model (Phillips et al., 2017). In all models, the RNA primer for initiation of 
leading strand synthesis at OH is generated by transcription from the LSP promoter and 
Introduction  
  
 9 
premature termination at conserved sequence block II (CSBII) approximately 100 bp 
downstream of the initiation site (Gillum and Clayton, 1979; Pham et al., 2006). This sequence 
encodes two consecutive runs of guanines, which have been demonstrated to form a G-
quadruplex structure in the nascent RNA and this is thought to be the major determinant for 
transcription termination (Wanrooij et al., 2010). Furthermore, mtRNAP also produces the 
RNA primer for lagging strand synthesis originating at OL (Phillips et al., 2017; Wanrooij et 
al., 2008). Interestingly, this seems to involve a unique initiation mechanism by mtRNAP at a 
stem-loop structure in the single-stranded template OL DNA, without the need for initiation 
factors (Fusté et al., 2010). 
1.6.3. Mitochondrial transcription elongation 
The recent discovery of the mitochondrial transcription elongation factor TEFM  (Minczuk et 
al., 2011) revealed a new player in mammalian mitochondrial transcription. TEFM shows only 
very limited sequence homology to other transcription factors, and this homology is confined 
to its N-terminal domain (Minczuk et al., 2011). A much more prominent sequence similarity 
can be found between its larger C-terminal domain and Holliday Junction resolvases, 
particularly the yeast mitochondrial Holliday Junction resolvase Cce1/Ydc2 (Minczuk et al., 
2011). TEFM localizes to mitochondria and was shown to be essential for oxidative 
phosphorylation activity in vivo (Minczuk et al., 2011). Moreover, it was demonstrated to 
interact with mtRNAP and enhance its processivity as well as raise the abundance of promoter-
distal transcripts both in vivo and in vitro (Minczuk et al., 2011; Posse et al., 2015). In addition 
to its role as a general elongation factor, TEFM was recently found to have a striking effect on 
transcription through the CSBII site, where, in the absence of TEFM, mtRNAP terminates 
transcription to yield the replication primer for OH (Gillum and Clayton, 1979; Pham et al., 
2006). In the presence of TEFM, however, mtRNAP faithfully transcribes through this 
sequence region, which has been suggested to form extensive secondary structure in the nascent 
RNA (Agaronyan et al., 2015; Wanrooij et al., 2010). Thus, TEFM seems to be a key player in 
regulating the switch between productive transcription and mtDNA replication. However, the 
molecular mechanisms by which TEFM interacts with the elongation complex to enable 
mtRNAP to transcribe through CSBII and produce long transcripts are not known. 
1.7. Previous structural studies of mitochondrial 
transcription 
Over the last decades, the basal mitochondrial transcription machinery has been identified and 
characterized biochemically. However, it was only over the course of the last years that 
structural information on the proteins involved in mitochondrial transcription has become 
available. The first milestone in the structural characterization of this system was the crystal 
structure of human mitochondrial RNA polymerase, which provided structural evidence for the 
homology of the catalytic core of mtRNAP to bacteriophage polymerases (Figure 5A and C) 
(Ringel et al., 2011). In addition, the structure revealed profound differences between T7 RNAP 
and mtRNAP, providing initial clues for the structural basis of its factor-dependence. Firstly, 
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mtRNAP contains an N-terminal PPR domain not found in bacteriophage RNAPs. Secondly, 
the AT-rich recognition loop, a structural element involved in promoter recognition by T7 
RNAP, is sequestered in mtRNAP and not available to interact with DNA. Thirdly, the apo 
form of mtRNAP seems to adopt a conformation in which the major DNA-melting element of 
T7 RNAP, the intercalating hairpin, is not positioned accordingly to melt DNA (Ringel et al., 
2011). 
The structure of a transcribing elongation complex (EC), comprised of mtRNAP bound to a 
DNA/RNA nucleic acid scaffold, offered the first insight into the active conformation of this 
enzyme (Figure 5B) (Schwinghammer et al., 2013). While the catalytic mechanism of chain 
elongation seems to be conserved, comparison to T7 RNAP demonstrates further substantial 
differences between the two polymerases. T7 RNAP undergoes a dramatic re-arrangement of 
its N-terminal promoter binding domain during the transition from initiation to elongation (Yin 
and Steitz, 2002), whereas mtRNAP does not refold in a similar fashion (Schwinghammer et 
al., 2013). Instead, the intercalating hairpin, which is putatively involved in initiation, separates 
the RNA-DNA hybrid at the upstream edge of the transcription bubble in the mitochondrial EC 
(Figure 5B) (Schwinghammer et al., 2013). 
 
Figure 5. Structures of human mitochondrial RNA polymerase. 
(A) Ribbon representation of the structure of free human mtRNAP (PDB ID: 3SPA) (Ringel et al., 2011). 
Important structural features are indicated. Coloring according to (C). (B) Ribbon representation of the 
human mitochondrial transcription elongation complex (PDB ID: 4BOC) (Schwinghammer et al., 
2013). Depiction as in (A), with nucleic acid depicted as sticks. The non-template strand is colored in 
cyan, the template strand in blue and the RNA in red. (C) Schematic representation of human mtRNAP 
and T7 RNAP with important structural elements indicated. Partially adapted from (Ringel et al., 2011). 
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In 2011, the structure of TFAM in complex with a duplex DNA segment encompassing the LSP 
binding site was reported by two groups independently (Ngo et al., 2011; Rubio-Cosials et al., 
2011). This structure confirmed previous predictions, as it demonstrated that TFAM engages 
with nucleic acid with both its HMG box domains, each inducing a sharp 90° bend in the bound 
DNA, resulting in a 180° overall bend (Fisher et al., 1992; Ngo et al., 2011; Rubio-Cosials et 
al., 2011). The C-terminal tail of TFAM, which is known to be important for transcriptional 
activation (Dairaghi et al., 1995b), is positioned close to the DNA at the upstream edge of the 
TFAM binding site. Further structures of TFAM bound to various DNA sequences 
demonstrated that bending of substrate DNA is not sequence dependent (Ngo et al., 2014). 
Compared to the LSP promoter-bound structure, the structure of TFAM bound to a part of the 
HSP promoter sequence suggested a reverse orientation of TFAM with respect to the 
transcription start site, thus raising a controversy about the architecture of the initiation complex 
at these two promoters (Ngo et al., 2014). Recent cross-linking experiments, however, argue 
against different mechanisms of initiation at the different promoters and suggest a conserved 
architecture for the mitochondrial initiation complex (Morozov and Temiakov, 2016). 
Although structures of the yeast TFB2M homolog Mtf1 (Schubot et al., 2001) and mouse 
TFB1M have been reported (Guja et al., 2013), no structural information on TFB2M is 
available. These related, isolated structures cannot provide compelling evidence on how Mtf1 
or TFB2M may work to promote transcription initiation. In particular, structural information 
on the interaction between TFB2M, the polymerase and nucleic acid is lacking, thus preventing 
a mechanistic understanding of how TFB2M assists in transcription initiation. 
Taken together, the structural and mechanistic characterization of mitochondrial transcription 
is still in its infancy compared to the T7 or multi-subunit RNAP transcription systems. 
Important first steps towards a structural understanding of the mitochondrial transcription cycle 
have been made by determining the structures of individual proteins and the basal elongation 
complex. However, structural information on a number of key players and their interaction with 
the polymerase to form functional complexes is lacking (Figure 6). In particular, structural 
snapshots of the interplay of initiation factors with mtRNAP and promoter DNA would be 
needed to decipher the mechanism of factor dependent initiation in mitochondria. Similarly, 
structural information on TEFM and its interaction with the elongation complex holds promise 
to unravel the mechanistic basis of how this factor acts to promote processivity and regulate the 
switch between transcription and replication.   
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Figure 6. The structural basis of mitochondrial transcription is poorly understood. 
Schematic depiction of the transcription cycle in human mitochondria. Known structures are shown in 
ribbon representation with transparent surfaces, unknown structures are depicted schematically. PDB 
accession codes of structures used: TFAM: 3TMM (Ngo et al., 2011); mtRNAP: 3SPA (Ringel et al., 
2011); mTERF1: 3MVA (Yakubovskaya et al., 2010); EC: 4BOC (Schwinghammer et al., 2013). 
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1.8. Aim and scope 
Despite considerable advances towards understanding transcription and its regulation in human 
mitochondria, the molecular mechanisms underlying this important process have remained 
largely enigmatic. This is to a large degree owed to the lack of structural information of the 
proteins involved and, in particular, of their interplay with each other and nucleic acid during 
initiation and elongation. Why does mtRNAP require protein factors for all steps of 
transcription, whereas the related bacteriophage polymerases are self-sufficient? What is the 
mechanism by which these protein factors, which are evolutionarily unrelated to transcription 
factors from other systems, act in concert with mtRNAP? 
In this study, we attempted to answer these questions by determining the structural basis of 
transcription initiation and processive elongation. 
To decipher the mechanisms governing transcription initiation in human mitochondria, I first 
determined the structure of human TFB2M at 1.75 Å resolution. This completes our structural 
picture of the individual components of the basal transcription initiation machinery. In a second 
step, I then determined the structure of a complete human mitochondrial transcription initiation 
complex, consisting of mtRNAP, TFAM and TFB2M assembled on a nucleic acid scaffold, at 
4.5 Å resolution. This structure reveals how mtRNAP is recruited to promoter-bound TFAM 
via a novel element in the N-terminal extension of the polymerase, thus positioning it above the 
transcription start site. It further demonstrates that TFB2M binds near the point of DNA 
melting, renders mtRNAP capable of promoter melting and stabilizes the melted non-template 
DNA strand. In collaboration with the Temiakov Lab, we confirmed these findings by 
biochemical analysis of structure-guided protein mutants. 
To unravel the molecular mechanism by which TEFM acts as an elongation factor, I first 
determined the structure of individual TEFM domains to high resolution (1.3 – 1.9 Å). These 
data unveil an unusual combination of a Holliday Junction resolvase-like dimerization core with 
a globular N-terminal domain. In a joint effort with the Temiakov Lab and the Urlaub Lab, we 
defined the functional roles of the TEFM domains and their interaction with the polymerase 
and nucleic acids in the elongation complex using transcription assays, nuclease foot-printing 
and chemical cross-linking. Guided by this data, I crystallized an anti-termination complex 
comprised of mtRNAP, nucleic acid and the transcriptionally active parts of TEFM. The 
resulting structure explains how TEFM enhances processivity by stabilizing the open 
transcription bubble and mobile elements in mtRNAP. Furthermore, it suggests that TEFM 
prevents formation of a bulky G-quadruplex in the nascent RNA while transcribing through 
CSBII, thus evading premature transcription termination by mtRNAP.  
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2. Materials and Methods 
This section lists materials and methods used as part of this thesis. Materials and methods 
performed predominantly by collaborators are not listed here, but can be found in sections 5.1.1, 
5.2.1 and 5.2.2. 
2.1. Materials 
2.1.1. Bacterial strains 
Table 1. Bacterial strains used in this study. 
Strain Genotype Source 
BL21-CodonPlus (DE3)-RIL B F– ompT hsdS(rB- mB-) dcm+ TetR gal λ 
(DE3) endA Hte [argU ileY leuW CamR] 
Agilent Technologies 
Rosetta2 F- ompT hsdSB(rB- mB-) gal dcm pRARE2 
(CamR) 
Merck Millipore 
Rosetta2 pLysS F- ompT hsdSB(rB- mB-) gal dcm (DE3) 
pLysSRARE2 (CamR) 
Merck Millipore 
XL-1 Blue recA1 endA1 gyrA96 thi-1 hsdR17 supE44 
relA1 lac [F ́ proAB lacIqZ∆M15 Tn10 
(TetR)]  
Stratagene 
 
2.1.2. Growth media for E.coli and additives 
Table 2. Growth media for E.coli 
Media Application Description 
LB Purification of mtRNAP, 
TFAM, TEFM 
1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 0.5% (w/v) NaCl 
SeMet Expression Media Purification of 
selenomethionine-labeled 
proteins 
21.6 g/l SelenoMet Base, 5.1 g/l 
SelenoMet Nutrient Mix, 0.04 mg/ml L-
methionine or L-selenomethionine (all 
from Molecular Dimensions) 
ZYP 
(modified from (Studier, 
2005)) 
Purification of TFB2M 1% (w/v) tryptone, 0.5% (w/v) yeast 
extract, 50 mM KH2PO4, 50 mM 
Na2HPO4, 25 mM (NH4)SO4, 0.5% (v/v) 
glycerol, 0.05% (w/v) D-glucose, 2 mM 
MgSO4 
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Table 3. Additives to growth media 
Additive Used for Stock 
concentration 
Working 
concentration 
Ampicillin Resistance selection 100 mg/ml in H2O 100 µg/ml 
Chloramphenicol Resistance selection 30 mg/ml in EtOH 30 µg/ml 
D-Glucose Purification of TEFM 20% (w/v) in H2O 1% (w/v) 
IPTG (Isopropyl-b-D-
thiogalactopyranoside) 
Induction of protein 
expression 
1 M in H2O 0.1 – 0.8 mM 
Methionine biosynthesis 
inhibition mix I 
Purification of 
selenomethionine-
labeled proteins 
10 mg/ml L-Lysine, 
10 mg/ml L-
Threonine, 10 mg/ml 
L-Phenylalanine 
0.1 mg/ml L-Lysine, 
0.1 mg/ml L-Threonine, 
0.1 mg/ml L-
Phenylalanine 
Methionine biosynthesis 
inhibition mix II 
Purification of 
selenomethionine-
labeled proteins 
5 mg/ml L-Leucine, 
5 mg/ml L-
Isoleucine, 5 mg/ml 
L-Valine 
0.05 mg/ml L-Leucine, 
0.05 mg/ml L-
Isoleucine, 0.05 mg/ml 
L-Valine 
2.1.3. Plasmids 
Table 4. Plasmids used in this study. 
Name Protein variant Purification tags Vector Source 
∆104 mtRNAP 
tagless 
h.sapiens mtRNAP 
E555A1, lacking 
residues 1-104 
N-terminal 6xHIS, 
TEV cleavage site 
pProEx-
Htbmut2 
This study 
∆108 mtRNAP 
tagless 
h.sapiens mtRNAP 
E555A1, lacking 
residues 1-108 
N-terminal 6xHIS, 
TEV cleavage site 
pProEx-
Htbmut2 
This study 
∆119 mtRNAP h.sapiens mtRNAP 
E555A1, lacking 
residues 1-119 
N-terminal 6xHIS pProEx-
Htbmut2 
(Morozov et al., 
2014) 
∆119 mtRNAP 
R601E 
h.sapiens mtRNAP 
E555A1, lacking 
residues 1-119, 
R601E 
N-terminal 6xHIS pProEx-
Htbmut2 
Temiakov lab 
∆42 TFAM 
“cysless” 
h.sapiens TFAM, 
lacking residues 1-
42 and 246, C49S 
N-terminal 6xHIS pET22b (Sologub et al., 
2009) 
∆42 TFAM 
“cysless” tagless 
h.sapiens TFAM, 
lacking residues 1-
42 and 246, C49S 
N-terminal 6xHIS, 
TEV cleavage site 
pET22b This study 
∆20 TFB2M h.sapiens TFB2M, 
lacking residues 1-
20 
N-terminal 6xHIS pTYB11 
∆intein 
(Sologub et al., 
2009) 
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∆20 TFB2M 
tagless 
h.sapiens TFB2M, 
lacking residues 1-
20 
N-terminal 6xHIS, 
TEV cleavage site 
pTYB11 
∆intein 
This study 
∆62 TFB2M  h.sapiens TFB2M, 
lacking residues 1-
62 
N-terminal 6xHIS, 
TEV cleavage site 
pTYB11 
∆intein 
This study 
∆20 TFB2M-
∆268-294-GSSG  
h.sapiens TFB2M, 
lacking residues 1-
20; residues 268-
294 replaced by 
GSSG 
N-terminal 6xHIS, 
TEV cleavage site 
pTYB11 
∆intein 
This study 
TFB2Mcryst h.sapiens TFB2M, 
lacking residues 1-
62, residues 268-
294 replaced by 
GSSG 
N-terminal 6xHIS, 
TEV cleavage site 
pTYB11 
∆intein 
This study 
∆20 TFB2M 
H326A 
h.sapiens TFB2M, 
lacking residues 1-
20, H326A 
N-terminal 6xHIS pTYB11 
∆intein 
Temiakov lab 
∆20 TFB2M 
R198A K201A 
R202A 
h.sapiens TFB2M, 
lacking residues 1-
20, R198A, 
K201A, R202A 
N-terminal 6xHIS pTYB11 
∆intein 
Temiakov lab 
∆20 TFB2M ∆8 
CTD 
h.sapiens TFB2M, 
lacking residues 1-
20 and 388-396 
N-terminal 6xHIS pTYB11 
∆intein 
Temiakov lab 
∆20 TFB2M 
R330A R331A 
h.sapiens TFB2M, 
lacking residues 1-
20, R330A, R331A 
N-terminal 6xHIS pTYB11 
∆intein 
Temiakov lab 
∆35 TEFM h.sapiens TEFM, 
lacking residues 1-
35 
C-terminal 6xHIS, 
codon optimized 
pET21b Generated by 
Kathrin 
Schwinghammer 
∆50 TEFM h.sapiens TEFM, 
lacking residues 1-
50 
C-terminal 6xHIS, 
codon optimized 
pET21b Temiakov lab 
∆135 TEFM h.sapiens TEFM, 
lacking residues 1-
135 
C-terminal 6xHIS, 
codon optimized 
pET21b Temiakov lab 
∆144 TEFM h.sapiens TEFM, 
lacking residues 1-
144 
C-terminal 6xHIS, 
codon optimized 
pET21b This study 
∆159 TEFM h.sapiens TEFM, 
lacking residues 1-
159 
C-terminal 6xHIS, 
codon optimized 
pET21b This study 
∆50 TEFM-
sub140-144 
h.sapiens TEFM, 
lacking residues 1-
50, residues 140-
144 substituted by 
AAGAA 
C-terminal 6xHIS, 
codon optimized 
pET21b Temiakov lab 
∆50 TEFM-
sub149-153 
h.sapiens TEFM, 
lacking residues 1-
C-terminal 6xHIS, 
codon optimized 
pET21b Temiakov lab 
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50, residues 149-
153 substituted by 
AAGAA 
∆50 TEFM R152A 
R153A 
h.sapiens TEFM, 
lacking residues 1-
50, R152A R153A 
C-terminal 6xHIS, 
codon optimized 
pET21b Temiakov lab 
1 Compared to UniProt sequence (accession code O00411); natural variant. 
2 pProEx plasmid backbone with mutation in Htb site. 
2.1.4. Primers 
Table 5. Primers used in this study. 
Name Sequence (5’ to 3’) Used to clone Type 
HH 25 TTA ACT TTA AGA AGG AGA TAT 
ACA TAT GAG TCC GGA AAA TCG 
TTT TCT GCG 
pET21b-∆144TEFM Site-directed 
mutagenesis 
HH 26 CGC AGA AAA CGA TTT TCC GGA 
CTC ATA TGT ATA TCT CCT TCT 
TAA AGT TAA 
pET21b-∆144TEFM Site-directed 
mutagenesis 
HH 29 TTA ACT TTA AGA AGG AGA TAT 
ACA TAT GGA ACG TGA ACG TCT 
GAA AGC CG 
pET21b-∆149TEFM Site-directed 
mutagenesis 
HH 30 CGG CTT TCA GAC GTT CAC GTT 
CCA TAT GTA TAT CTC CTT CTT 
AAA GTT AA 
pET21b-∆149TEFM Site-directed 
mutagenesis 
HH 46 GTC ATC ACC ATC ACC ATC ACG 
AAA ACC TGT ACT TCC AAT CCA 
ATG CAC GGT TTT GCA TTT TAG 
GGT C 
pTYB11-∆intein-His6-
TEV-∆20TFB2M 
Site-directed 
mutagenesis 
HH 47 GAC CCT AAA ATG CAA AAC CGT 
GCA TTG GAT TGG AAG TAC AGG 
TTT TCG TGA TGG TGA TGG TGA 
TGA C 
pTYB11-∆intein-His6-
TEV-∆20TFB2M 
Site-directed 
mutagenesis 
HH 58 CGA AAA CCT GTA CTT CCA ATC 
CAA TGC AAA GGC GTC TAA GGC 
CAG CTT AGA CTT TAA GCG 
pTYB11-∆intein-His6-
TEV-∆62TFB2M 
Site-directed 
mutagenesis 
HH 59 CGC TTA AAG TCT AAG CTG GCC 
TTA GAC GCC TTT GCA TTG GAT 
TGG AAG TAC AGG TTT TCG 
pTYB11-∆intein-His6-
TEV-∆62TFB2M 
Site-directed 
mutagenesis 
HH 74 GCA TCA CCA TCA CCA TCA CGA 
AAA CCT GTA CTT CCA ATC CAA 
TGC ATC ATC TGT CTT GGC AAG 
TAG 
pET22b-His6-TEV-
∆42TFAM-cysless 
Site-directed 
mutagenesis 
HH 75 TGC ATT GGA TTG GAA GTA CAG 
GTT TTC GTG ATG GTG ATG GTG 
ATG CAT ATG TAT ATC TCC TTC 
TTA AAG TTA AAC 
pET22b-His6-TEV-
∆42TFAM-cysless 
Site-directed 
mutagenesis 
HH 991 ATG GGG GCC AAG GAT GCC ACC 
CCG GTG CCC TGT GGC CGC TGG 
GCA AAG ATA CTG G 
pProEx-Htbmut-His6-
TEV-∆104mtRNAP 
Around the 
Horn 
HH 1001 AGG AAG GTC CAG ATG GGG GCC 
AAG GAT GCC ACC CCG GTG CCC 
pProEx-Htbmut-His6-
TEV-∆104mtRNAP 
Around the 
Horn 
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TGT GGC CGC TGG GCA AAG ATA 
CTG G 
HH 1011 TGC ATT GGA TTG GAA GTA CAG 
GTT TTC GTG ATG 
pProEx-Htbmut-His6-
TEV-∆104mtRNAP, 
pProEx-Htbmut-His6-
TEV-∆108mtRNAP 
Around the 
Horn 
HH 1021 GAT ATG GAA GCA AGC CTG TAT 
GCC GAT CTG AAT AAA ACC TTT 
GCA CAG G 
pET21b-∆35TEFM-
F244E-L248D-I252D-
M256S-L260D 
Around the 
Horn 
HH 1031 ATG AAA GTG ATC CAG AAT CGG 
TTC CAG GCT GCT ATT CTG AAT 
GC 
pET21b-∆35TEFM-
F244E-L248D-I252D-
M256S-L260D 
Around the 
Horn 
HH 1331 AAG CTG TAT CTT ATT CAA ATG 
ATT CCT CGT C 
pTYB11-∆intein-His6-
TEV-∆62TFB2M-∆268-
294-GSSG, pTYB11-
∆intein-His6-TEV-
∆20TFB2M-∆268-294-
GSSG 
Around the 
Horn 
HH 1351 ACC GGA GGA GCC AGG CTC CAT 
GTG CAG AAC C 
pTYB11-∆intein-His6-
TEV-∆62TFB2M-∆268-
294-GSSG, pTYB11-
∆intein-His6-TEV-
∆20TFB2M-∆268-294-
GSSG 
Around the 
Horn 
T7 
promoter 
TAA TAC GAC TCA CTA TAG GGG 
 
- sequencing 
T7 
terminator 
CTA GTT ATT GCT CAG CGG TG - sequencing 
M13 pUC 
rev 
AGC GGA TAA CAA TTT CAC ACA 
GG 
- sequencing 
pTRCHis 
rev 
CTG ATT TAA TCT GTA TCA GG - sequencing 
mtRNAP 
seq1 for 
ACT GTT CTG AAG GCC GTG C - sequencing 
mtRNAP 
seq2 for 
AGA TGC CAT GCA GCC TGG - sequencing 
mtRNAP 
seq3 for 
AGT TCG CCC AGG GCC GCC - sequencing 
mtRNAP 
seq4 for 
TTC AGA GCA TCA CCT ACA CCC - sequencing 
mtRNAP 
seq5 rev 
AGG GTC TTC AGG GTC TTC C - sequencing 
1 Synthesized with 5’-phosphate group. 
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2.1.5. Synthetic oligonucleotides 
Table 6. Synthetic oligonucleotides used for reconstitution of transcription complexes. 
Name Sequence (5’ to 3’)1 Application Source 
HH NT2 TGT TAG TTG GGG GGT GAC 
TGT TAA AAG TGC ATA CCT 
ATC CCC GAT AG GCC 
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH TS1 GGC CTA TCT TTT GGC GGT 
ATG CAC TTT TAA CAG TCA 
CCC CCC AAC TAA CA 
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH NT6 CAC CGC TGC TAA CCC CAT 
ACC CCG AAC CAA CCA AAT 
TAT CCC GAC AGG CC 
In-vitro reconstitution of HSP 
initiation complex 
for crystallization 
This study 
HH TS3 GGC CTG TCT TTG GGG TTT 
GGT TGG TTC GGG GTA TGG 
GGT TAG CAG CGG TG 
In-vitro reconstitution of HSP 
initiation complex 
for crystallization 
This study 
HH TS1-
Bromine1 
GGC C-5Br-dU-A 5Br-dU- CT 
TTT GGC GGT ATG CAC TTT 
TAA CAG TCA CCC CCC AAC 
TAA CA  
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH NT2-
Bromine2 
TGT TAG TTG GGG GGT GAC 
TGT TAA AAG TGC ATA CC-5-
Br-dU ATC CCC GAT AG-5-Br-
dU CC  
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH TS50 GGA CTA TCT TTT GGC GGT 
ATG CAC TTT TAA CAG TCA 
CCC CCC AAC TAA CA  
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH TS1-
Bromine3 
GGC CTA TCT TTT GGC GG-5-
Br-dU ATG CAC TTT TAA CAG 
TCA CCC CCC AAC TAA CA 
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH NT-
Bromine4 
TGT TAG TTG GGG GGT GAC 
TGT TAA AAG 5-Br-dU-GC ATA 
CCT ATC CCC GAT AGG CC 
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH TS1-
Bromine5 
GGC CTA TCT TTT GG-5Br-dU  
GGT ATG CAC TTT TAA CAG 
TCA CCC CCC AAC TAA CA 
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH NT67 TGT TAG TTG GGG GGT GAC 
TGT TAA AAG TGC ATA CAT 
ATC CCC GAT AGG CC 
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH TS-
Bromine6 
GGC CTA TCT TTT GGC 5Br-
dU-GT ATG CAC TTT TAA CAG 
TCA CCC CCC AAC TAA CA  
In-vitro reconstitution of LSP 
initiation complex 
for crystallization 
This study 
HH NT25 GAA CAT GGT GTA ATT ATT 
TCG ACG CCA GAC GAA C 
In-vitro reconstitution of EC-
TEFM complex 
for crystallization 
This study 
HH TS22 GTT CGT CTG GCG TGC GCG 
CCG CTA CAC CAT GTT C 
In-vitro reconstitution of EC-
TEFM complex 
for crystallization 
This study 
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HH 
RNA16 
agu cug cgg cgc gc In-vitro reconstitution of EC-
TEFM complex 
for crystallization 
(Schwingha
mmer et al., 
2013) 
HH NT19 CAT GGG GTA ACT AGT TCG 
ACG CCA GAC G 
In-vitro reconstitution of EC-
TEFM complex 
for BS3 / EDC crosslinking 
This study 
HH TS16 CGT CTG GCG TGA TCA CGA 
CTA CCC CAT G 
In-vitro reconstitution of EC-
TEFM complex 
for BS3 / EDC crosslinking 
This study 
HH 
RNA14 
uga ugg uaa ugc ucc ugu 
cgu gau c 
In-vitro reconstitution of EC-
TEFM complex 
for BS3 / EDC crosslinking 
This study 
1 5-Br-dU = 5-Bromo-Uracil; 
UPPERCASE = DNA; lowercase = RNA 
 
2.1.6. Buffers and solutions 
Table 7. General solutions 
Name Description or Source Application 
100x Protease Inhibitor Mix 0.028 mg/ml Leupeptin, 0.137 mg/ml Pepstatin 
A, 0.017 mg/ml PMSF, 0.33 mg/ml 
benzamidine in 100% EtOH (p.a.) 
Protein 
purification 
10x TAE 2.5 M Tris-acetate, 50 mM EDTA pH 8.0 Agarose gels 
20 x MES SDS running buffer 1M MES pH 7.3, 1M Tris Base, 2% SDS, 20 
mM EDTA (Thermo Fisher Scientific) 
SDS-PAGE 
20 x MOPS SDS running buffer 1M MOPS pH 7.7, 1M Tris Base, 2% SDS, 20 
mM EDTA (Thermo Fisher Scientific) 
 
5x SDS-PAGE sample buffer 250 mM Tris-HCl pH 6.8 at 20 °C, 50% (v/v) 
glycerol, 0.03% (w/v) bromophenol blue, 7.5% 
(w/v) SDS, 100 mM DTT 
SDS-PAGE 
Gel staining solution InstantBlue, Expedion SDS-PAGE 
visualization 
NuPAGE 4x LDS Sample 
Buffer 
Invitrogen SDS-PAGE 
PageRuler Prestained Protein 
Ladder, 10 to 180 kDa 
Thermo Fisher Scientific SDS-PAGE 
PBS 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4, 1.8 mM KH2PO4 
various 
Protein gel electrophoresis 
running buffer 
NuPAGE MES or MOPS SDS running buffer 
(Invitrogen) 
SDS-PAGE 
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Table 8. Buffers used for purification of mtRNAP 
Name Description 
mtRNAP lysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 10 mM imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x 
PI 
mtRNAP Ni-NTA wash buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 1.5 M NaCl, 20 mM 
MgCl2, 10 mM imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x 
PI 
mtRNAP Ni-NTA elution buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 250 mM imidazole, 5% (v/v) glycerol, 2 mM DTT 
mtRNAP dialysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
Ion exchange buffer A 40 mM Tris-HCl pH 8.0 at 23 °C, 5% (v/v) glycerol, 2 mM 
DTT 
Ion exchange buffer B 40 mM Tris-HCl pH 8.0 at 23 °C, 2 M NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
mtRNAP size exclusion buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 5% (v/v) glycerol, 10 mM DTT 
 
Table 9. Buffers used for purification of TFAM 
Name Description 
TFAM lysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 2 mM 
imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x PI 
TFAM Ni-NTA wash buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 1.5 M NaCl, 2 mM 
imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x PI 
TFAM Ni-NTA elution buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 250 mM 
imidazole, 5% (v/v) glycerol, 2 mM DTT 
TFAM dialysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
Ion exchange buffer A 40 mM Tris-HCl pH 8.0 at 23 °C, 5% (v/v) glycerol, 2 mM 
DTT 
Ion exchange buffer B 40 mM Tris-HCl pH 8.0 at 23 °C, 2 M NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
TFAM size exclusion buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 100 mM NaCl, 5% (v/v) 
glycerol, 10 mM DTT 
 
Table 10. Buffers used for purification of TFB2M 
Name Description 
TFB2M lysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 20 mM imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x 
PI 
TFB2M Ni-NTA wash buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 1.5 M NaCl, 20 mM 
MgCl2, 20 mM imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x 
PI 
TFB2M Ni-NTA elution buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 250 mM imidazole, 5% (v/v) glycerol, 2 mM DTT 
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TFB2M dialysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
Ion exchange buffer A 40 mM Tris-HCl pH 8.0 at 23 °C, 5% (v/v) glycerol, 2 
mM DTT 
Ion exchange buffer B 40 mM Tris-HCl pH 8.0 at 23 °C, 2 M NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
TFB2M size exclusion buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 100 mM NaCl, 5% (v/v) 
glycerol, 10 mM DTT 
 
Table 11. Buffers used for purification of TEFM 
Name Description 
TEFM lysis buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 20 mM imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x 
PI 
TEFM Ni-NTA wash buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 1.5 M NaCl, 20 mM 
MgCl2, 20 mM imidazole, 5% (v/v) glycerol, 2 mM DTT, 1 x 
PI 
TEFM Ni-NTA elution buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 300 mM NaCl, 20 mM 
MgCl2, 250 mM imidazole, 5% (v/v) glycerol, 2 mM DTT 
Ion exchange buffer A 40 mM Tris-HCl pH 8.0 at 23 °C, 5% (v/v) glycerol, 2 mM 
DTT 
Ion exchange buffer B 40 mM Tris-HCl pH 8.0 at 23 °C, 2 M NaCl, 5% (v/v) 
glycerol, 2 mM DTT 
TEFM size exclusion buffer 40 mM Tris-HCl pH 8.0 at 23 °C, 100 mM NaCl, 5% (v/v) 
glycerol, 10 mM DTT 
 
2.2. Methods 
2.2.1. General methods 
Site-directed mutagenesis PCR 
QuikChange PCR was carried out in 20 µl reactions containing Phusion High Fidelity 
Polymerase (homemade), Phusion High Fidelity Buffer (New England Biolabs), 0.2 mM 
dNTPs, 0.05 µM of each primer and 2.5 ng of template DNA. The reaction was carried out for 
25 cycles each consisting of a 1 min denaturation step at 95 °C, followed by an annealing step 
at 55 °C for 1 min and an elongation step at 72 °C, for which the time was adjusted to the length 
of the template. Following thermocycling, 1 µl of DpnI (New England Biolabs) was added and 
the reaction was incubated at 37 °C for at least 1 h prior to transformation of the entire reaction 
into competent E.coli XL1-Blue cells. 
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Around-the-Horn PCR 
For „Around-the-Horn“ PCR, primer pairs either containing an insertion or generating a 
deletion were designed to anneal in opposite orientations to the respective template sequence 
and purchased as chemically synthesized, 5’-phosphate containing oligonucleotides. PCR 
reactions were typically performed in Q5 Polymerase reaction buffer (New England Biolabs) 
with 0.5 µM of each primer, 0.2-2.0 ng of template DNA, 0.2 mM of each dNTP and 20 units 
of Q5 High-Fidelity DNA Polymerase (New England Biolabs). Reaction conditions (annealing 
temperature and extension time) were adjusted to the respective template and PCR reactions 
were carried out for 35 cycles. Template DNA was subsequently digested by addition of 1µl 
DpnI (20 units/µl, New England Biolabs) and incubation for at least 1 h at 37 °C. The reaction 
products were analyzed by electrophoresis in 0.5 – 1.5% agarose gels containing Sybr Safe® 
(Thermo Fisher) and run in 1 x TAE buffer at 100 V. Bands corresponding to PCR products 
were excised, purified using a Gel Extraction Kit (Qiagen) and eluted in 25 µl ddH2O. The 
linear reaction products were ligated by addition of 3 µl T4 DNA Ligase Buffer (New England 
Biolabs) and 2 µl T4 DNA Ligase (400 units/µl, New England Biolabs) and incubation at 16°C 
for 2 h. 
Transformation of E.coli cells 
For transformation, 50 µl aliquots of chemically competent E.coli cells were incubated with 
either purified plasmid DNA (50 – 200 ng) or PCR products (entire reaction) on ice for 20 min. 
Cells were heat-shocked at 42 °C for 45 s and immediately placed on ice again for 5 min. The 
cells were recovered by addition of 1 ml of LB media and incubation at 37 °C and 600 rpm for 
1 h. The cells were pelleted by centrifugation at 3000 rpm in a table top centrifuge for 5 min 
and resuspended in 100 µl of fresh LB media. The cells were plated on LB-agar plates 
containing the respective antibiotics for selection and incubated at 37 °C overnight. 
Isolation of plasmid DNA and sequence verification 
Single colonies were picked from agar plates and used to inoculate 6 ml of LB media containing 
the appropriate antibiotics for selection. The culture was incubated at 37 °C and 160 rpm 
overnight. Plasmid purification was performed using a Mini Prep Kit (Qiagen) according to the 
manufacturer’s instructions. Plasmid DNA was eluted in ddH2O and stored at -20 °C. 
Sequences were verified by sequencing (Seqlab) using appropriate primers. 
Preparation of glycerol stocks for protein expression 
Following transformation of the respective expression plasmid into chemically competent 
E.coli cells and plating on LB agar plates containing the appropriate antibiotics for selection, 
an initial overnight culture of LB media containing the appropriate antibiotics was inoculated 
from multiple colonies and incubated at 37 °C and 160 rpm overnight. A glycerol stock was 
prepared by mixing an equal volume of the overnight culture and 50% (v/v) glycerol (25% (v/v) 
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final concentration) and stored at -80 °C. Glycerol stocks were used to inoculate subsequent 
overnight cultures for large scale protein expression.  
Protein and nucleic acid concentration determination 
Concentrations for purified proteins and protein complexes were determined using a NanoDrop 
spectrophotometer (Thermo Fisher) using theoretical extinction coefficients calculated using 
the Expasy ProtParam server (Wilkins et al., 1999) (for proteins) or the IDT UV spectrum 
analyzer (http://biophysics.idtdna.com/UVSpectrum.html) (for nucleic acid). 
Protein identification by mass spectrometry 
Protein identification by mass spectrometry was performed in the laboratory of Henning Urlaub 
at the Max-Planck-Institute for Biophysical Chemistry in Göttingen, Germany. 
Sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-
PAGE) 
SDS-PAGE analysis was used to monitor progress of protein purifications and estimate the 
purity of protein preparations. Furthermore, it was used to estimate stoichiometry of in-vitro 
reconstituted protein complexes. For analysis, protein samples were mixed with either 5 x SDS-
PAGE sample buffer (homemade) or 4 x LDS sample buffer (Thermo Fisher) (Table 7) and 
boiled at 95 °C for 3-5 min. The samples were spun down, loaded on a NuPage 4 – 12% BIS-
TRIS gel (Thermo Fisher) together with 5 µl of PageRuler Prestained Protein Ladder (Thermo 
Fisher) and separated by electrophoresis at 200 V in either NuPage MES or MOPS Running 
Buffer (Thermo Fisher). Bands were visualized using InstantBlue stain (Expedeon). 
 
2.2.2. Protein purification 
Purification of human mitochondrial RNA polymerase 
Human mtRNAP was expressed in E.coli BL21 (DE3) RIL cells (Agilent) and purified using 
an optimized protocol based on the previously published purification (Sologub et al., 2009). 
Cells were grown at 37 °C and 160 rpm until the OD600 reached 0.6 units and expression was 
induced by addition of 0.15 mM IPTG and carried out at 16 °C for 18 h. The cells were 
harvested by centrifugation at 7,800 g for 20min and the cell pellets were flash frozen in liquid 
nitrogen and stored at -80 °C. For purification, cell pellets were thawed and resuspended in cold 
mtRNAP lysis buffer. The cells were lysed by ultrasonification (0.4 s pulses on, 0.6 s off, 60% 
amplitude, 10 min total time) and cell debris was pelleted by centrifugation at 57,900 g for 30 
min twice. 20 ml of nickel-nitrilotriacetic acid agarose (Ni-NTA beads, Qiagen) equilibrated 
with mtRNAP lysis buffer were added to the supernatant and incubated on a rotating wheel at 
Materials and Methods  
  
 25 
4 °C for 1.5 h. The beads were washed twice with 10 bead volumes of mtRNAP Ni-NTA wash 
buffer for 30 min and subsequently with 10 bead volumes of lysis buffer to remove high salt. 
Bound protein was eluted in 5 bead volumes of mtRNAP Ni-NTA elution buffer. Protein 
variants bearing a non-cleavable purification tag were immediately subjected to heparin affinity 
chromatography. For constructs containing a TEV-cleavable 6xHIS-tag, TEV protease (2-4 mg, 
homemade) was added and the sample was dialyzed overnight at 4 °C against mtRNAP dialysis 
buffer using SnakeSkin® dialysis tubing (7 kDa cut-off, Thermo Fisher). Heparin affinity 
chromatography was carried out using multiple HiTrap HP 5ml Heparin columns (GE 
Healthcare) equilibrated with a buffer containing 85% (v/v) ion exchange buffer A and 15% 
(v/v) ion exchange buffer B. The protein was eluted with a linear gradient from 15 to 50% ion 
exchange buffer B over 15 CV. Peak fractions corresponding to mtRNAP were collected and 
concentrated in a centrifugal concentrator (30 kDa cut-off, Amicon). The protein was then 
subjected to size exclusion chromatography using a Superdex 200 10/300 Increase column (GE 
Healthcare) equilibrated with mtRNAP size exclusion buffer. Peak fractions corresponding to 
mtRNAP were pooled and concentrated in a centrifugal concentrator (30 kDa cut-off, Amicon) 
to a final concentration of 8-10 mg/ml. The protein was aliquoted, flash-frozen in liquid 
nitrogen and stored at -80 °C. 
Purification of human TFAM 
Human TFAM was expressed in E.coli BL21 Rosetta2 pLysS cells (Merck Millipore) and 
purified using an optimized protocol based on the previously published purification (Sologub 
et al., 2009). Cells were grown at 37 °C and 160 rpm until the OD600 reached 0.8-1.0 units and 
expression was induced by addition of 0.8 mM IPTG and carried out at 37 °C for 1.5 h. The 
cells were harvested by centrifugation at 7,800 g for 20min and the cell pellets were flash frozen 
in liquid nitrogen and stored at -80 °C. For purification, cell pellets were thawed and 
resuspended in cold TFAM lysis buffer. The cells were lysed by ultrasonification (0.4 s pulses 
on, 0.6 s off, 60% amplitude, 15 min total time) and cell debris was pelleted by centrifugation 
at 57,900 g for 30 min twice. The supernatant was loaded on a HisTrap HP 5ml column (GE 
Healthcare) equilibrated with TFAM lysis buffer and the column was washed with 40 CV of 
TFAM Ni-NTA wash buffer followed by 20 CV of TFAM lysis buffer to remove excess salt. 
TFAM was eluted with 10 CV of TFAM Ni-NTA elution buffer. Protein variants bearing a non-
cleavable purification tag were immediately subjected to heparin affinity chromatography. For 
constructs containing a TEV-cleavable 6xHIS-tag, TEV protease (4 mg, homemade) was added 
to cleave the purification tag and the sample was dialyzed overnight against TFAM dialysis 
buffer using SnakeSkin® dialysis tubing (7000 kDa cut-off, Thermo Fisher). To remove un-
cleaved protein and the 6xHIS-tagged TEV protease, the sample was subjected to a second Ni-
NTA affinity chromatography step. For this, the sample was supplemented with imidazole to 
approx. 60 mM final concentration and applied to a HisTrap HP 5 ml column (GE Healthcare). 
The flow-through was collected and the column was washed wih 5 CV of TFAM dialysis 
buffer. For heparin affinity chromatography, the flow-through and wash fractions were 
combined and applied to multiple HiTrap Heparin HP 5 ml columns (GE Healthcare) 
equilibrated with a buffer consisting of 85% (v/v) ion exchange buffer A and 15% (v/v) ion 
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exchange buffer B. The protein was eluted with a linear gradient from 15 to 50% ion exchange 
buffer B over 10 CV. Peak fractions corresponding to TFAM were pooled, diluted with ion 
exchange buffer A to approx. 300 mM NaCl and subjected to cation exchange chromatography 
on HiTrap SP HP 5ml columns (GE Healthcare) equilibrated with a buffer containing 85% (v/v) 
ion exchange buffer A and 15% (v/v) ion exchange buffer B. Bound protein was eluted with a 
linear gradient from 15 to 50% ion exchange buffer B over 15 CV. Peak fractions corresponding 
to TFAM were pooled and subjected to a third Ni-NTA step at low imidazole concentration to 
remove trace amounts of TFAM bearing the tag, which were still present as judged by SDS-
PAGE. For this, the sample was supplemented with 2 mM imidazole and applied to a HisTrap 
HP 5 ml column (GE Healthcare) equilibrated with a buffer consisting of 80% (v/v) ion 
exchange buffer A and 20% (v/v) ion exchange buffer B. The column was washed with 3-5 CV 
of buffer and the flow-through and wash fractions were combined and concentrated in a 
centrifugal concentrator (3 kDa cut-off, Amicon). The sample was further purified by size 
exclusion chromatography on a HiPrep 16/600 Superdex 75 pg column (GE Healthcare) 
equilibrated with TFAM size exclusion buffer. Peak fractions corresponding to TFAM were 
pooled and concentrated in a centrifugal concentrator (3 kDa cut-off, Amicon) to 20-25 mg/ml 
final concentration. TFAM was aliquoted, flash-frozen in liquid nitrogen and stored at -80 °C. 
Purification of human TFB2M 
Human TFB2M was expressed in E.coli BL21 (DE3) RIL cells (Agilent) and purified using an 
optimized protocol based on the previously published purification (Sologub et al., 2009). Cells 
were grown in modified ZYP media (see Table 2) at 37 °C and 160 rpm until the OD600 reached 
6.0 units. Expression was induced by addition of 0.1 mM IPTG and carried out at 16 °C for 18 
h. The cells were harvested by centrifugation at 7,800 g for 20min and the cell pellets were 
flash frozen in liquid nitrogen and stored at -80 °C. For purification, cell pellets were thawed 
and resuspended in cold TFB2M lysis buffer. The cells were lysed by ultrasonification (0.4 s 
pulses on, 0.6 s off, 75% amplitude, 15 min total time) and cell debris was pelleted by 
centrifugation at 57,900 g for 30 min twice. 20 ml of Ni-NTA agarose beads (Qiagen) 
equilibrated with TFB2M lysis buffer were added to the supernatant and incubated on a rotating 
wheel at 4 °C for 1.5 h. The beads were washed with 10 times the bead volumes of TFB2M Ni-
NTA wash buffer 30 min followed by 10 bead volumes of lysis buffer to remove high salt. The 
bound protein was eluted in 2.5 bead volumes of TFB2M Ni-NTA elution buffer. Protein 
variants bearing a non-cleavable purification tag were immediately subjected to heparin affinity 
chromatography. For constructs containing a TEV-cleavable 6xHIS-tag, TEV protease (2 mg, 
homemade) was added and the sample was dialyzed against TFB2M dialysis buffer overnight 
using SnakeSkin® dialysis tubing (7 kDa cut-off, Thermo Fisher). To remove un-cleaved 
protein and the 6xHIS-tagged TEV protease, the sample was subjected to a second Ni-NTA 
affinity chromatography step. For this, the sample was supplemented with imidazole to approx. 
60 mM final concentration and applied to a HisTrap HP 5 ml column (GE Healthcare). The 
flow-through was collected and the column was washed with 5 CV of TFAM dialysis buffer. 
The flow-through and wash fractions were combined and subjected to heparin affinity 
chromatography using multiple HiTrap Heparin HP 5ml columns equilibrated with a buffer 
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consisting of 85% (v/v) ion exchange buffer A and 15% (v/v) ion exchange buffer B. The bound 
protein was eluted using a linear gradient from 15% (v/v) to 50% (v/v) over 15 CV. Peak 
fractions containing TFB2M were pooled and concentrated in a centrifugal concentrator (10 
kDa cut-off, Amicon). The sample was then subjected to size exclusion chromatography using 
a Superdex 200 10/300 Increase column (GE Healthcare) equilibrated with TFB2M size 
exclusion buffer. Peak fractions containing TFB2M were pooled, concentrated in a centrifugal 
concentrator (10 kDa cut-off, Amicon) to 20 mg/ml. Purified TFB2M was aliquoted, flash-
frozen in liquid nitrogen and stored at -80 °C. 
Purification of human TEFM 
Human TEFM was expressed in E.coli BL21 (DE3) RIL (Agilent) or Rosetta2 (DE3) cells 
(Merck Millipore). Cells were grown in LB media containing 1% D-glucose at 37 °C and 160 
rpm until the OD600 reached 0.6 units. Expression was induced by addition of 0.15 mM IPTG 
and carried out at 16 °C for 18 h. The cells were harvested by centrifugation at 7,800 g for 20 
min and the cell pellets were flash frozen in liquid nitrogen and stored at -80 °C. For 
purification, cell pellets were thawed and resuspended in cold TEFM lysis buffer. The cells 
were lysed by ultrasonification (0.4 s pulses on, 0.6 s off, 60% amplitude, 10 min total time) 
and the cell debris was pelleted by centrifugation at 57,900 g for 30 min twice. The supernatant 
was loaded on a HisTrap HP 5ml column (GE Healthcare) equilibrated with TEFM lysis buffer 
and the column was washed with 10 CV of TEFM Ni-NTA wash buffer followed by 10 CV of 
TEFM lysis buffer to remove excess salt. TEFM was eluted in 10 CV of TEFM Ni-NTA elution 
buffer and subsequently loaded onto multiple HiTrap Heparin HP 5ml columns (GE 
Healthcare) equilibrated with a buffer containing 85% (v/v) ion exchange buffer A and 15% 
(v/v) ion exchange buffer B. The bound protein was eluted with a linear gradient from 15 to 
50% ion exchange buffer B over 15 CV. Peak fractions corresponding to TEFM were pooled 
and concentrated using a centrifugal concentrator (10 kDa cut-off, Amicon). The protein was 
further purified by size exclusion chromatography using a Superdex 200 Increase 10/300 
column (GE Healthcare) equilibrated with TEFM size exclusion buffer. Peak fractions were 
pooled and concentrated using a centrifugal concentrator (10 kDa cut-off, Amicon) to approx. 
20 mg/ml final concentration. TEFM was aliquoted, flash frozen in liquid nitrogen and stored 
at -80 °C. 
Purification of selenomethionine-labeled proteins 
Selenomethionine-labeled proteins were expressed using the methionine biosynthesis inhibition 
method (Doublié, 2007; Van Duyne et al., 1993) in the same E.coli expression strains as used 
for regular protein expression. An overnight culture of LB media containing the respective 
antibiotics was grown as described above. The overnight culture was used to inoculate 1 l of 
SeMet Base media (Molecular Dimensions) (1:100) supplemented with L-methionine (0.04 
mg/ml). The culture was grown at 37 °C and 140 rpm until the OD600 reached approx. 1.0 units. 
The cells were pelleted by centrifugation at 7,800 g for 20 min and washed twice with 50 ml of 
PBS and resuspended in a further 50 ml of PBS. Protein expression was carried out in SeMet 
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base media (Molecular Dimensions) supplemented with L-selenomethionine (0.04 mg/ml) 
which was inoculated with the washed cell suspension (1:250). The cells were grown at 37 °C 
and 140 rpm until the appropriate OD600 was reached (in the case of TFB2M, an OD600 of 0.75 
was used) and protein expression was induced by addition of IPTG as described above. 
Purification of selenomethionine-labeled proteins was carried out as for the native protein 
variants, with the DTT concentration increased from 2 mM to 5 mM in all buffers (except for 
size exclusion buffers) to prevent oxidation of selenomethionine-residues. 
2.2.3. General crystallization methods 
Microseeding of crystals 
To prepare solutions for microseeding, drops containing initial crystals were diluted with 1-5 
drop volumes of reservoir solution and mixed by pipetting up and down until the crystals were 
visibly crushed. The entire solution was then transferred to a Seed Bead kit (Hampton) and 
further diluted with reservoir solution to a final volume of 50 µl. The Seed Bead tube was 
vortexed in 30 s intervals for a total of 3 min, with incubation on ice in between each interval 
to prevent heating of the sample. The Seed Bead tube was subsequently sonicated in a water 
bath at 4 °C for 2 min. A ten-fold dilution series was prepared from the seed stock using 
reservoir solution. Crystals were typically microseeded by setting up new drops consisting of 
equal volumes of protein solution and reservoir solution to which 0.2–0.5 µl of seeding solution 
were added. 
Cryo-protection and freezing of crystals 
Crystals of the initiation complex and the EC-TEFM complex were cryo-protected by gradually 
increasing the glycerol concentration in the drop. For this, three solutions resembling the 
respective reservoir solution of the drop with increasing glycerol concentrations were prepared 
(6%, 12.5%, 25%, (v/v)). One drop volume of the first solution was added to the drop containing 
crystals and mixed by pipetting until the drop appeared homogenous under the microscope. One 
drop volume was then removed from the drop again. This process was repeated three times for 
each glycerol concentration step. For the final step, as much solution as possible was removed 
from the drop without harming the crystals and the drop was then entirely replaced by the 25% 
glycerol solution. Crystals of the TEFM CTD were cryo-protected in a similar fashion, but in a 
2-step process using reservoir solutions containing 10% and 20% glycerol, respectively. 
Crystals of TFB2M were cryo-protected by increasing the glycerol concentration to 25% (v/v) 
using a single drop-exchange protocol. Following cryo-protection, crystals were fished and 
flash frozen in liquid nitrogen. 
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2.3. Structural basis of mitochondrial transcription 
initiation 
This section contains methods specifically related to the study on the structure of the human 
mitochondrial transcription initiation complex. Only those methods developed and performed 
as part of this thesis are described here, while methods carried out predominantly by the 
collaborators from the Temiakov lab are described in section 5.1.1. Parts of the methods 
described here are currently in the process of peer review for publication: 
 
H.S. Hillen, Y.I. Morozov, A. Sarfallah, D. Temiakov and P. Cramer (2017) Structural basis 
of mitochondrial transcription initiation. Cell, in revision 
 
A detailed list of author contributions can be found on page VI. 
Protein expression constructs 
A construct of human mtRNAP lacking the N-terminal 104 amino acids (∆104 mtRNAP) with 
an N-terminal 6xHIS tag and a TEV cleavage site was constructed from the pProEx-based 
expression plasmid described previously (Sologub et al., 2009). Human TFAM was expressed 
as a construct lacking the mitochondrial localization sequence (res. 1-42) and two cysteine 
residues (C49S and without the C-terminal C246), mutations which have been shown to have 
no effect on activity (Morozov et al., 2014). The construct was cloned from the previously 
described pET22b-based expression plasmid (Morozov et al., 2014) by inserting a TEV 
cleavage site between the N-terminal 6xHIS tag and the coding region. Human TFB2M was 
expressed as a construct lacking either only the predicted mitochondrial localization sequence 
(res. 1-20; ∆20 TFB2M) or lacking the N-terminal 62 residues (∆62 TFB2M). The construct 
was generated from the pTYB11-based expression vector described previously (Sologub et al., 
2009) by removing the intein tag and replacing it with a TEV-cleavable N-terminal 6xHIS tag. 
Compared to wild type TFB2M, the TFB2M crystallization construct TFB2Mcryst lacks 62 
amino acids at the N-terminus and a loop region between residues 268 and 294, for which no 
electron density could be observed in the IC and which was replaced by a short GSSG linker. 
Expression plasmids for structure determination were generated by “Around the Horn” PCR. 
All TFB2M variants used in transcription assays were generated using QuikChange 
Mutagenesis kit (Agilent) in N-his ∆20 TFB2M background. The R601E mtRNAP variant was 
generated using ∆119 mtRNAP background. 
Crystallization of human TFB2M 
Crystals of TFB2M could only be obtained using a truncated variant of the protein, TFB2Mcryst 
(see above for details). TFB2Mcryst was crystallized by the hanging drop vapour diffusion 
method at 20 °C by mixing 1.5 µl of protein solution (13 mg/ml) with 1.5 µl of reservoir solution 
Materials and Methods  
 30 
containing 100 mM HEPES pH 7.5, 200 mM NaCl, 17% PEG3350 and 0.4 µl of seeding 
solution produced from previously grown crystals in a similar condition. Crystals were cryo-
protected by gradually increasing the Glycerol concentration in the drop to 25% (v/v) final and 
flash frozen in liquid nitrogen. 
Reconstitution and crystallization of the IC 
HPLC-purified synthetic DNA oligonucleotides were obtained from IDT. Scaffolds for 
crystallization were annealed by heating complimentary oligonucleotides (LSP: HH NT2 / HH 
TS1; HSP: HH NT6 / HH TS3; Br1: HH NT2 / HH TS1-Br1; Br2: HH NT-Br2 / HH TS50; 
Br3: HH NT2 / HH TS-Br3; Br4: HH NT-Br4 / HH TS1; Br5: HH NT2 / HH TS-Br5; Br6: HH 
NT67 / HH TS-Br6) to 95°C and step-wise cooling to 4°C (1°/90s) at a final concentration of 
0.5 mM in H2O. 
The human IC was reconstituted by incubating tagless ∆104 mtRNAP (35 µM) with a 1.1-fold 
molar excess of scaffold DNA, equimolar amounts of tagless TFAM (43-245 C49S) and a 1.5-
fold molar excess of tagless ∆20 TFB2M in a buffer containing 30 mM Tris-HCl pH 8.0, 200 
mM NaCl, 10 mM MgCl2, 5% glycerol and 10 mM DTT for 20 min at 20 °C. The complex was 
subsequently purified by size exclusion chromatography using a Superdex 200 Increase 3.2/300 
column equilibrated with complex crystallization buffer (10 mM Tris-HCl pH 8.0, 100 mM 
NaCl, 20 mM MgCl2, 10 mM DTT, 1 mM TCEP). Crystals were obtained by the hanging drop 
vapour diffusion method at 20 °C by mixing equal volumes of protein solution and reservoir 
solution containing 100 mM BIS-TRIS pH 6.0, 200 mM L-Proline and 5-7% PEG8000. 
Crystals were cryo-protected by gradually increasing the glycerol concentration in the drop to 
a final of 25% (v/v) and flash-frozen in liquid nitrogen. For selenomethionine labelling and 
subsequent crystallization, a construct of mtRNAP lacking the N-terminal 108 amino acids 
(∆108 mtRNAP) and ∆62 TFB2M were used. 
Data collection, structure determination and refinement 
Diffraction data were collected at beamline X06SA and X10SA at the Swiss Light Source in 
Villigen, Switzerland, with an EIGER 16M detector (Dectris) or a PILATUS 6M detector 
(Dectris), respectively, and at beamline P14 operated by EMBL Hamburg at the PETRA III 
storage ring (DESY Hamburg, Germany) with a Pilatus 6M detector (Dectris). The data was 
processed using XDS (Kabsch, 2010) and scaled  with XSCALE (Kabsch, 2010). For 
selenomethionine and 5-Bromo-Uracil containing crystals, multiple datasets (from a single 
crystal or multiple isomorphous crystals) were merged using XSCALE to improve the 
anomalous signal. 
The crystals of TFB2Mcryst belonged to space group P21 and diffracted to a resolution of 1.75 
Å with two copies of the protein in the asymmetric unit. The structure of TFB2Mcryst was solved 
by molecular replacement in Phaser (McCoy et al., 2007) using a partial model of the yeast 
homolog Mtf1 (PDB ID: 1I4W, residues 134-138; 143-198; 242-281) (Schubot et al., 2001) 
truncated to poly-alanine. Density modification and building of an initial model was done using 
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phenix.autobuild (Adams et al., 2010) and subsequently completed manually in Coot (Emsley 
et al., 2010). The model was subjected to iterative cycles of refinement in phenix.refine (Adams 
et al., 2010) and manual model building in Coot until excellent stereochemistry and a free R-
factor of 20.9% was obtained (Table 12). The final model contains residues 72-90, 97-267 and 
295-396 of the wild-type TFB2M. 
The IC crystals belonged to space group P21, contained two copies of the complex in the 
asymmetric unit, and showed diffraction to 4.5 Å resolution. Initial phases were obtained by 
molecular replacement using Phaser (McCoy et al., 2007) in the PHENIX suite (Adams et al., 
2010) and the human mitochondrial transcription EC (PDB ID: 4BOC) (Schwinghammer et al., 
2013) lacking nucleic acid as search model. The solution was subsequently used as starting 
phases for molecular replacement combined with single-wavelength anomalous diffraction 
(MR-SAD) and automated density modification in PHENIX using diffraction data collected 
from crystals containing selenomethionine-labeled mtRNAP, TFAM and TFB2M and LSP 
DNA. (Table 13) The resulting electron density map showed clear features of nucleic acids and 
proteins in addition to the search model used and was phase extended using the higher 
resolution native dataset in phenix.autobuild. Interpretation of the electron density was 
facilitated by anomalous scattering from selenium and bromine atoms incorporated into 
proteins and DNA, respectively (Figure 11A and B, Table 13 and Table 14). Anomalous 
difference Fourier maps were computed as log-likelihood gradient maps in Phaser (within the 
PHENIX suite) using phases derived from the refined IC model (Read and McCoy, 2011). 
Modelling of the IC was done largely using the experimental map and cross-validated with a 
map generated by MR-SAD with the keyword “phaser_sites_then_phase=True” to obtain a map 
free of model bias. 
Individual domains and secondary structure elements of mtRNAP were rigid body fitted in real 
space manually to fit the experimental electron density. The region of mtRNAP corresponding 
to the specificity loop (residues 1086-1107) showed fragmented density and was modeled based 
on the structure of the T7 RNAP initiation complex.(Cheetham et al., 1999) The density allowed 
for modelling the main chain trace of this element lacking only three residues (1094-1096) at 
the tip, yet the sequence register could not be assigned unambiguously and it was therefore 
modeled as poly-alanine.  
To obtain an initial model of the IC, the crystal structure of TFAM (PDB ID: 3TMM) (Ngo et 
al., 2011) in complex with LSP DNA was fitted into the electron density and the individual 
domains were rigid body fitted locally in real space using Coot (Emsley et al., 2010). The DNA 
emerging from TFAM was extended and adjusted as ideal B-DNA to the expected melting point 
at the beginning of the mismatched region (-4) and rigid body fit locally in real space. The 
experimental density allowed for modelling of two additional bases of the template and three 
of the non-template strand, respectively, past the melting point. The downstream duplex DNA 
showed weaker density and was positioned with the help of anomalous difference peaks from 
crystals containing DNA labelled with 5-bromo-uracile at specific sites (Figure 11B). In the 
crystal form observed, the downstream DNA mediates a crystal contact and may therefore be 
stabilized in the observed conformation. 
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To model TFB2M, the crystal structure of TFB2Mcryst was rigid body fit into the experimental 
IC density. Correct positioning of TFB2M was verified using peaks in an anomalous difference 
Fourier map calculated from the dataset which was used for phasing the IC, which included 
selenomethionine-labelled TFB2M (Figure 11A). Placement of TFB2M led to a single clash 
between the C-terminal tail of TFB2M with the mtRNAP intercalating hairpin and the non-
template DNA (Figure 17). Since this C-terminal region appears to be flexible, the TFB2M 
model was truncated to the last residue with clear density in the IC map (residue 392). 
After positioning of all known protein structures, a residual unexplained density in the 
experimental map remained close to the HMG box B of TFAM with three weak peaks in the 
anomalous difference map for selenium. An anomalous difference map calculated from a 
dataset obtained from crystals in which only mtRNAP was selenomethionine-labeled indicated 
that these peaks originate from residues within the polymerase. Based on a unique “MRM” 
sequence motif found in the thus far not observed N-terminal extension region of mtRNAP and 
secondary structure prediction using PSIPRED (Buchan et al., 2013), a helix spanning residues 
122-146 in mtRNAP was assigned to the unmodeled density, which we termed “tether helix” 
(Figure 15A). 
Refinement of the IC model against the native dataset using phenix.refine with secondary 
structure restraints, reference model restraints and DNA geometry restraints resulted in a model 
with good geometry and a free R-factor of 30.9%. (Table 13) The resulting mFo-DFc map 
showed difference density for some additional features such as the polypeptide path connecting 
the mtRNAP tether helix to the PPR domain and parts of the missing single-stranded non-
template DNA strand, but we refrained from modelling these features due to the limited 
resolution of the data. 
The structure of the HSP IC was solved by molecular replacement using the LSP IC as search 
model and subsequently adjusted to the HSP sequence. The model was refined in phenix.refine 
using a similar protocol as for the LSP IC and led to a final model with good stereochemistry 
and a free R of 33.1%. (Table 15) The identical orientation of TFAM on both LSP and HSP 
was verified by comparing anomalous difference peaks calculated using structure factors from 
crystals containing selenomethionine-labeled TFAM and the respective promoter DNA. (Figure 
15B). 
Figures were prepared using PyMol. Surface charge analysis was performed using the APBS 
plugin for PyMol (Baker et al., 2001) and displayed with +/- 1kT/e.  
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2.4. Mechanism of transcription anti-termination in 
human mitochondria 
This section contains methods specifically related to the study on the mechanism of 
transcription anti-termination in human mitochondria. Only those methods developed and 
performed as part of this thesis are described here (unless stated otherwise), while methods 
carried out predominantly by the collaborators from the Temiakov lab are described in section 
5.2.1. Parts of this section have been published: 
 
H.S. Hillen, A.V. Parshin, K. Agaronyan, Y.I. Morozov, J.J. Graber, A. Chernev, K. 
Schwinghammer, H. Urlaub, M. Anikin, P. Cramer and D. Temiakov (2017) Mechanism of 
transcription anti-termination in human mitochondria. Cell, in press 
 
A detailed list of author contributions can be found on page VI. 
Expression and purification of the components of human 
mitochondrial transcription 
Human mtRNAP (∆119 and ∆150), WT TFAM, ∆20 TFB2M, WT TEFM, and ∆50 TEFM (all 
with non-cleavable 6xHIS-tag) were expressed and purified as described previously 
(Agaronyan et al., 2015; Sologub et al., 2009) with the adaptions described in 2.2.2. Variants 
of these proteins were obtained by site-directed mutagenesis (QuikChange, Agilent) and 
purified as described previously (Morozov et al., 2015). TEFM NTD (residues 36-136) was 
purified by the Temiakov lab using cation exchange chromatography on a MonoS column 
followed by gel-filtration on a Superdex 200 10/300 column. Expression of Bpa-containing 
proteins was performed by the Temiakov lab as described previously (Morozov et al., 2015). 
Selenomethionine-labeled TEFM was purified as described above.  
Crystallization of human TEFM C-terminal domain 
Purified ∆50 TEFM (6.5 mg/ml) was treated with ArgC protease (Promega, 1:1000 w/w) and 
incubated for 60 min at room temperature prior to crystallization trials. Initial hits were obtained 
using the sitting drop vapor diffusion with a well solution containing 100 mM BIS-TRIS pH 
5.5 – 6.5, 200 mM MgCl2 and 25% PEG3350. Large, diffraction-quality crystals were obtained 
by the hanging drop vapor diffusion method by micro-seeding with crushed crystals into fresh 
drops. Crystals appeared within 24 h and grew to full size over the course of two weeks. Crystals 
were cryo-protected by gradually increasing the glycerol concentration to 20% (v/v) and flash 
frozen in liquid nitrogen. 
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Crystallization of the EC/TEFM complex 
Synthetic DNA and RNA oligonucleotides (IDT DNA) HH NT25, HH TS22 and HH RNA14 
were dissolved in H2O and mixed at a final concentration of 0.5 mM. The scaffold was annealed 
by heating the mixture to 95°C and step-wise cooling (1 °C / 90 s) to 4 °C. To form an 
EC/TEFM complex, ∆150 mtRNAP (45 μM) was initially incubated with a 1.1- fold molar 
excess of DNA/RNA scaffold and incubated at 20 °C for 10 min prior to addition of a 2.2-fold 
molar excess ∆135 TEFM and further incubation at 20°C for 10 min. The complex was 
subsequently purified by size exclusion chromatography using a Superdex 200 Increase 3.2/300 
column (GE Healthcare) equilibrated with a buffer containing 10 mM Tris-HCl pH 8.0 at 23 
°C, 100 mM NaCl, 20 mM MgCl2, 10 mM DTT, 1 mM TCEP and 5% (v/v) Glycerol. Peak 
fractions were pooled and used for crystallization. Crystals were obtained by the hanging-drop 
vapour diffusion method by mixing 2.5 μl of protein complex solution with 2.5 μl of reservoir 
solution containing 100 mM BIS-TRIS pH 5.5, 200 mM (NH4)2SO4, 6% PEG3350 and 0.5 μl 
of a seeding solution prepared from crystals previously obtained in an identical condition. 
Crystals appeared as thin blade clusters after 3-4 days. The clusters were carefully broken into 
individual blades and cryoprotected by gradually increasing the glycerol concentration in the 
drop to 25% (v/v) final prior to fishing and freezing in liquid nitrogen. 
Structure determination, model building and refinement 
Diffraction data for TEFM CTD and EC-TEFM complex crystals was collected at beamlines 
X06SA and X10SA at the Swiss Light Source (Villigen, CH) using a Pilatus 6M detector. 
Diffraction data for TEFM NTD crystals was collected at beamline P13 at the PETRA III 
storage ring operated by EMBL (DESY, Hamburg, Germany). Data were indexed and 
integrated using XDS and scaled using XSCALE (Kabsch, 2010). Anomalous substructure 
determination, phasing and density modification was performed using the hkl2map interface 
and SHELXC/D/E (Pape and Schneider, 2004; SheldrickIUCr, 2008), as well as phenix.autosol 
(Adams et al., 2010). To obtain experimental phase information for the TEFM CTD crystals, 
multiple datasets from two isomorphous selenomethionine-containing crystals were merged 
using XSCALE and used for SAD phasing. Heavy atom sites identified by SHELXD were 
manually edited to remove weak occupancy sites and used as input in phenix.autosol for 
phasing and density modification. The obtained electron density map was of excellent quality 
and allowed for manual building of most of the four protein chains in the asymmetric unit. 
(Figure 21) Refinement was carried out against the high-resolution native dataset using 
phenix.refine (Adams et al., 2010) and alternated with manual adjustment in Coot (Emsley et 
al., 2010) until a model with excellent stereochemistry was obtained. Experimental phase 
information for TEFM NTD crystals was obtained in a SAD experiment utilizing native sulfur 
atoms present in cysteine and methionine residues by collecting multiple highly redundant 
datasets from a single crystal at a wavelength of 2.066 Å. Datasets were merged using XSCALE 
and substructure determination, phasing, density modification and phase extension was carried 
out with SHELXC/D/E. The resulting electron density map was readily interpretable and used 
for manual model building. The model was subjected to iterative rounds of refinement in 
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phenix.refine against the high-resolution native dataset collected from the same crystal and 
manual model building in Coot until excellent stereochemistry and R-factors were achieved. 
The final mFo-DFc map displayed some unmodeled difference density between 
crystallographically related molecules, corresponding to unidentified solvent molecules. 
The EC-TEFM structure was solved by molecular replacement in Phaser (McCoy et al., 2007) 
using the human mitochondrial transcription elongation complex (PDB ID: 4BOC) 
(Schwinghammer et al., 2013) and the TEFM CTD structure as search models. The resulting 
electron density was readily interpretable and used to rigid body fit domain movements in 
mtRNAP manually in Coot. The model was subsequently refined in phenix.refine alternated 
with manual adjustment in Coot, with secondary structure restraints and reference model 
restraints enabled until the late stages of refinement due to the low resolution of the data. We 
observed positive difference density corresponding to the previously unresolved single-
stranded region of the non-template strand as well as for parts of the N-terminal extension of 
mtRNAP, which may be involved in forming crystal contacts, but refrained from de novo 
modeling these regions due to the limited resolution. The unbiased Fo-Fc map for the non-
template strand was calculated from a model which never contained any model for the non-
template strand. The final model was refined to good stereochemistry and a free R factor of 
27.6%. 
Mapping of TEFM-mtRNAP interaction using BS3 and EDC cross-
linking 
The EC/TEFM complex was assembled by incubating 10-20 µM ∆150 mtRNAP with a 2.5-
fold molar excess of WT TEFM and a 1.3-fold molar excess of HH RNA14/HH NT19/HH 
TS16 scaffold for 10 min at 20°C. The complex was subsequently purified by size exclusion 
chromatography using a Superdex 200 Increase 3.2/300 column (GE Healthcare) equilibrated 
with buffer containing 20 mM HEPES (pH 8.0 for BS3 or pH 7.5 for EDC), 100 mM NaCl, 20 
mM MgCl2, and 0.5 mM TCEP. The purified complexes (~2 µM) were then incubated with a 
150 to 470-fold molar excess of BS3 (Thermo Fisher) for 30 min at 30 °C or with 2500 to 
15000-fold molar excess of EDC (Thermo Fisher) in the presence of 1 mM N-hydroxy-
sulfosuccinimide for 60 min at 230C. The reactions were quenched by the addition of 200 mM 
(NH4)2HCO3 followed by incubation for 5 min on ice. The products of the reaction were 
resolved using 4-12% SDS-PAGE. 
The following steps were subsequently performed by the Urlaub lab: the cross-linked species 
excised and in-gel digested with trypsin. The tryptic peptides were extracted, dried and 
reconstituted in solution containing 5% v/v acetonitril and 0.1% v/v FA and subjected to liquid 
chromatography-tandem mass spectrometry (LC-MS/MS). The separated peptides were 
analyzed online on a Q-Exactive HF mass spectrometer (Thermo Scientific). The raw data of 
LC-MS/MS analysis were converted to Mascot generic format files with Proteome Discoverer 
2.0.0.802 software (Thermo Scientific) and searched against a protein database by pLink 1.22 
software (Yang et al., 2012) as described in (Pleiner et al., 2015). The results were obtained 
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with 1% false discovery rate followed by manual validation and removal of all tandem spectra 
that did not show confident sequence coverage of both cross-linked peptides. 
Analytical size-exclusion chromatography 
The mitochondrial initiation complex was assembled by incubating ∆119 mtRNAP (20 μM) 
with the LSP promoter template (20 μM) (template strand: HH TS1; non-template strand: HH 
NT2), ∆42 TFAM (43-256, C49S) (20 μM) and ∆20 TFB2M (40 μM) for 10 min at 20°C. To 
analyze binding of TEFM, WT TEFM (60 μM) was added to the IC and incubated for 10 min 
at 20°C. Gel-filtration was performed using a Superdex 200 Increase 3.2/300 size exclusion 
column (GE Healthcare) equilibrated with buffer containing 20 mM Tris-HCl pH 8.0 at 23 °C, 
100 mM NaCl, 20 mM MgCl2, and 2 mM DTT. For the dimer mutant analysis, the ECs (20 
μM) were assembled using R14/TS22HH/NT25HH scaffold (1.1-fold molar excess) for 10 min 
at 20°C. After incubation, the ECs were mixed with 2.2-fold molar excess of WT TEFM or 
TEFM mutant (F244E L248D I252D M256S L260D) and incubated for 10 min at 20°C. Gel-
filtration was performed using a Superdex 200 3.2/300 size exclusion column (GE Healthcare) 
equilibrated with buffer containing 20 mM Tris-HCl pH 8.0 at 23 °C, 200 mM NaCl, 20 mM 
MgCl2, 10 mM DTT and 1 mM TCEP. 
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3. Results and Discussion 
3.1. Structural basis of mitochondrial transcription 
initiation 
Results presented in this section were obtained in collaboration with the Temiakov lab at the 
Department of Cell Biology, Rowan University, Stratford, NJ, USA and are currently under 
peer review for publication: 
 
H.S. Hillen, Y.I. Morozov, A. Sarfallah, D. Temiakov and P. Cramer (2017) Structual basis of 
mitochondrial transcription initiation. Cell, in revision 
 
A detailed list of author contributions can be found on page VI. 
 
For clarity, this results section presents all results of this publication. The structural data was 
obtained as part of this thesis work, while the biochemical data was generated by the 
collaborators. Methods performed as part of this thesis are described in section 2.3 and methods 
predominantly performed by the collaborators are presented in section 5.1.1. 
3.1.1. Abstract 
Transcription in human mitochondria is driven by a single-subunit, factor-dependent RNA 
polymerase (mtRNAP). Despite of its critical role in both expression and replication of the 
mitochondrial genome, transcription initiation by mtRNAP remains poorly understood. Here 
we report crystal structures of human mitochondrial transcription initiation complexes 
assembled on both light and heavy strand promoters. The structures reveal how transcription 
factors TFAM and TFB2M assist mtRNAP to achieve promoter-dependent initiation. TFAM 
tethers the N-terminal region of mtRNAP to recruit the polymerase to the promoter, whereas 
TFB2M induces structural changes in mtRNAP to enable promoter opening and trapping of the 
DNA non-template strand. Structural comparisons demonstrate that the initiation mechanism 
in mitochondria is distinct from that in the well-studied nuclear, bacterial, or bacteriophage 
transcription systems, but that similarities are found on the topological and conceptual level. 
These results provide a framework for studying the regulation of gene expression and DNA 
replication in mitochondria. 
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3.1.2. Results 
Structure of human TFB2M 
To investigate the mechanism of mitochondrial transcription initiation, we first set out to 
complete the set of structures for proteins involved in mitochondrial transcription initiation and 
determined the structure of TFB2M. As extensive crystallization trials using full-length human 
TFB2M did not yield crystals, we designed a variant lacking putatively flexible regions that 
may impair crystallization. This variant, TFB2Mcryst, lacks 62 N-terminal residues and a 
predicted internal loop (residues 268-294) that was replaced by a short GSSG-linker. Functional 
characterization of this TFB2M variant shows that replacement of the internal loop does not 
affect the transcriptional activity of TFB2M (Figure 7A), whereas the N-terminal truncation is 
known to reduce the activity of TFB2M due to its role in interactions with the priming 
nucleotide (Figure 7A) (Sologub et al., 2009). TFB2Mcryst yielded crystals that diffracted to 
1.75 Å resolution (Figure 7B and C). The structure was solved by molecular replacement (Table 
12). The final model shows very good stereochemistry and contains residues 72-396 of TFB2M 
with the exception of a short linker (91-96). 
 
Figure 7: Biochemical characterization and crystallization of a human TFB2M variant. 
(A) Functional characterization of the effect of truncations used to obtain a crystallizable TFB2M 
variant. Replacement of the loop between b6 and b7 (residues 268-294) does not affect transcriptional 
activity, while removal of 62 amino acids from the N-terminus results in a decrease of activity by 40%, 
consistent with previous reports that the N-terminal region of TFB2M plays a role in priming RNA 
synthesis (Sologub et al., 2009). (B)  Exemplary initial crystal hit from commercial crystallization 
screens in a condition similar to the final crystal growth condition. (C) Optimized crystal used for 
structure determination. 
The structure (Figure 8) shows that TFB2M resembles the paralogous mitochondrial 
methyltransferase TFB1M (Guja et al., 2013) and the yeast mitochondrial transcription 
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initiation factor Mtf1 (Schubot et al., 2001) (Figure 9A and B). As predicted from sequence 
homology, the N-terminal domain (residues 72-305) adopts a fold resembling S-adenosyl-
methinonine-dependent methyltransferases with a central seven-stranded b-sheet flanked on 
either side by three a-helices (Martin and McMillan, 2002). Similar to TFB1M and Mtf1, 
TFB2M deviates from the canonical methyltransferase fold by an insertion between b6 and b7, 
which corresponds to the region replaced with the GSSG linker in the crystallization construct 
(Guja et al., 2013; Schubot et al., 2001). In addition, TFB2M displays a prominent loop 
insertion between b3 and a4 not found in either of the two other proteins. The C-terminal 
domain (residues 306-396) consists of four alpha helices and an extended C-terminal tail 
(residues 389-396), which is likely flexible in solution as clear density for this region was only 
observed for one of the two copies in asymmetric unit. The structure of TFB2M completes the 
set of high-resolution structures of proteins involved in mitochondrial transcription initiation. 
 
Figure 8. Structure of human TFB2M. 
(A) Schematic representation of TFB2M. The N-terminal domain is colored in marine blue, the C-
terminal domain in slate and the C-terminal tail in orange. Regions visible in the electron density of the 
TFB2Mcryst crystals are indicated by a solid black line. The dashed black line represents the internal loop 
region replaced by a GSSG-linker in order to obtain a crystallizable construct. (B) Ribbon representation 
of the human TFB2M structure. Coloring as in (A) with secondary structure elements indicated. 
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Figure 9. Structural comparison of TFB2M homologs. 
(A) Structural comparison of human TFB2M (marine blue) and S.cerevisiae Mtf1(lightpink) (PDB ID: 
1I4W) (Schubot et al., 2001). The proteins were aligned over 256 residues with an r.m.s.d of 3.9 Å. 
While both proteins have a loop insertion between b6 and b7, human TFB2M has an additional loop 
insertion between b3 and a4. Note that the C-terminal tail is not fully resolved in the structure of Mtf1. 
(B) Structural comparison of human TFB2M (marine blue) and M.musculus TFB1M (palegreen) (PDB 
ID: 4GC5) (Guja et al., 2013). The proteins were aligned over 264 residues with an r.m.s.d of 3.9 Å. 
Compared to TFB2M and Mtf1, the insertion between b6 and b7 is small in TFB1M. Furthermore, 
TFB1M displays a protruding alpha-helix in the N-terminal region which is not predicted to be present 
in TFB2M. Note that the C-terminal tail is not fully resolved in the structure of TFB1M and the N-
terminal region is not fully resolved in TFB2M. 
  
Structural basis of mitochondrial transcription initiation 
 41 
Structure determination of the mitochondrial transcription initiation 
complex 
We then assembled a transcriptionally active IC consisting of TFAM, TFB2M, mtRNAP, and 
either LSP or HSP DNA containing a pre-melted region spanning register -4 to +3, which 
corresponds to the DNA region initially unwound around the transcription start site +1 
(Ramachandran et al., 2016) (Figure 10A and B). After extensive optimization, crystals of the 
IC were obtained that diffracted to 4.5 Å resolution (Figure 10C and D). The IC crystal structure 
was determined by a combination of molecular replacement and anomalous diffraction 
(Methods and Table 13, Table 14), which led to an interpretable electron density map (Figure 
11C). The known structures of mtRNAP (Schwinghammer et al., 2013) and TFAM (Ngo et al., 
2011) were fitted into the electron density and the newly obtained TFB2M structure could be 
unambiguously placed. Correct positioning of TFB2M was verified using an anomalous 
difference Fourier map that revealed selenium peaks for all nine methionine residues (Figure 
11A). Most of the DNA could be built, except for parts of the single-stranded region, and the 
correct sequence register was confirmed using anomalous diffraction from 5-Bromo-Uracil 
labeled DNA scaffolds (Figure 11B and Table 14). This led to an atomic model for the IC 
refined to a free R-factor of 30.9% (Table 13). We also solved a 4.5 Å resolution crystal 
structure of the IC assembled on the HSP promoter (Table 15). This structure was essentially 
identical to the LSP IC (r.m.s.d. = 0.4 Å over 10,531 atoms) (Figure 11D) and in the following 
we discuss only the LSP IC. 
 
Figure 10. Reconstitution and crystallization of the human mitochondrial IC. 
(A) Reconstitution of the human mitochondrial transcription initiation complex. Shown is a 
representative size exclusion chromatogram of the final purification step prior to crystallization. The 
peak containing the IC is indicated. SDS-PAGE analysis of the peak fraction demonstrates 
stoichiometric presence of mtRNAP, TFAM and TFB2M. The nucleic acid scaffold which was used to 
assemble the LSP IC is depicted schematically below with each base represented as a circle and the 
mismatch bubble around the transcription start site indicated. The template strand is colored blue, the 
non-template strand cyan. (B) Activity of the IC used for structure determination. Transcription 
initiation activity was assayed using radiolabeled ATP and a DNA template resulting in synthesis of 4- 
and 5-nt RNA. dsDNA: double stranded DNA; mismatch: -4 to +3 mismatched template as depicted in 
(A). (C) Initial crystal hit from commercial crystallization screen. (D) Exemplary image of the optimized 
crystal form which showed X-ray diffraction to 4.5 Å resolution. 
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Figure 11. Structure determination of the human mitochondrial IC 
(A) Positioning of the high-resolution TFB2M crystal structure in the IC structure. The TFB2M structure 
is shown as ribbon representation with coloring as in Figure 8. Peaks in the anomalous difference Fourier 
map calculated from the crystals containing selenomethionine labeled proteins are shown as green mesh 
at 3.5 σ. All selenium peak positions coincide with methionine residues in the positioned TFB2M 
structure. (B) Confirmation of sequence register assignment for DNA by anomalous diffraction from 5-
Bromo-Uracil labeled DNA. The final refined model of the IC is shown transparently as ribbon 
representation with a 2mFo-DFc map around the DNA shown as grey mesh at 1.0 σ. Helices are depicted 
as cylinders. Anomalous difference Fourier maps are depicted as red mesh at 4.0 σ. Shown are the 
maps from six different 5-Bromo-Uracil labeled DNA scaffolds (Table 14 and Methods). (C) 
Comparison of electron densities for the functionally important a8 helix of TFB2M. The 2mFo-DFc map 
for the high-resolution TFB2M structure is shown at 1.0 σ (top) and the experimental electron density 
for the IC is shown at 1.0 σ (bottom). (D) Structure of the IC assembled using HSP promoter DNA. 
Important structural elements are indicated and colored as for the LSP IC in Figure 12. The structure of 
the IC is nearly identical on LSP and HSP promoter DNA. 
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IC structure reveals locations of TFAM, TFB2M and DNA on mtRNAP 
The IC structure (Figure 12) reveals that mtRNAP is largely unchanged compared to the 
previously reported EC structure (Schwinghammer et al., 2013), with the exception of the 
fingers domain, which adopts the “clenched” conformation observed in the apo enzyme (Ringel 
et al., 2011). Whereas the position of the downstream DNA duplex in the IC is identical to that 
observed in the EC, the upstream DNA occupies a different location, running along the NTD 
of mtRNAP. The conserved intercalating hairpin of mtRNAP separates the DNA strands at the 
upstream edge of the open DNA region observed in the active center cleft of the polymerase 
(Figure 12B and Figure 13A). 
TFB2M contacts the intercalating hairpin and covers the junction between the upstream DNA 
duplex and the open DNA region (Figure 12B and Figure 13A). TFAM binds DNA 16-39 nt 
upstream of the transcription start site and induces a ~180° bend into DNA, resembling the free 
TFAM-DNA complex (Ngo et al., 2011; Rubio-Cosials et al., 2011). In agreement with cross-
linking data (Morozov et al., 2014), TFAM does not contact TFB2M, but binds the N-terminal 
domain (NTD) of mtRNAP at helix D. In addition to the severe upstream bending of the DNA 
induced by TFAM binding, the trajectory of the DNA is changed by ~45° between mtRNAP 
and TFAM (Figure 13B), and the downstream DNA duplex encloses an angle of ~135° relative 
to the upstream duplex at the point of DNA melting (Figure 13B). 
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Figure 12. Structure of the human mitochondrial transcription initiation complex. 
(A) Schematic representation of mtRNAP, TFAM and TFB2M. Important structural elements are 
indicated with flanking residue numbers. Regions with interpretable electron density in the IC crystal 
structure are indicated by a solid black line. Regions with density of insufficient quality for model 
building are indicated by a dashed black line. The color code is used throughout. (B) Ribbon 
representation of the IC structure assembled on LSP DNA. Important structural elements are indicated. 
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Figure 13. Promoter DNA interactions in the IC and DNA bending. 
(A) Schematic representation of protein-DNA interactions. DNA bases of the LSP promoter are depicted 
as circles in blue and cyan for the template and non-template strand, respectively. DNA bases lacking 
density in the IC crystal structure are depicted as hollow circles. Protein regions interacting with the 
DNA are indicated with coloring as in Figure 12. (B) DNA bending observed in the IC structure. Ribbon 
representation of the IC LSP structure with mtRNAP and TFAM in the background and DNA in the 
foreground. Helices are depicted as cylinders. TFB2M was omitted for clarity. Approximate angles 
between DNA duplexes are indicated.  
TFAM recruits mtRNAP to promoter DNA 
The IC structure explains how TFAM recruits mtRNAP to promoter DNA (Gaspari et al., 2004; 
Morozov et al., 2014; Posse et al., 2014). The HMG Box B domain of TFAM interacts with a 
newly observed “tether” helix in the N-terminal extension of mtRNAP, thereby anchoring 
mtRNAP to the promoter (Figure 14 and Figure 15A). The C-terminal tail of TFAM is located 
close to the PPR domain and residues 444-462 of mtRNAP (D-helix), consistent with published 
biochemical, genetic and cross-linking data (Dairaghi et al., 1995b; Morozov and Temiakov, 
2016; Morozov et al., 2015) (Figure 14). These contacts enable TFAM to recruit mtRNAP and 
position its active site over the transcription start site for de novo RNA synthesis (Dairaghi et 
al., 1995a; Morozov et al., 2014). In agreement with cross-linking data (Morozov and 
Temiakov, 2016), TFAM binding is identical in the structure of the HSP IC (Figure 15B). 
There, similarly to the LSP IC, TFAM binds to the region that is located 16-39 bp upstream to 
the HSP transcription start site, in agreement with earlier foot-printing data (Fisher et al., 1987). 
This indicates that the two transcription units in human mitochondria possess similar 
architecture, in contrast to previous reports that suggested no role of the TFAM C-terminal tail 
in LSP activation (Uchida et al., 2017) and opposite orientations of TFAM relative to mtRNAP 
in the IC assembled on HSP DNA (Ngo et al., 2014). 
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Figure 14. TFAM recruits mtRNAP to promoter DNA. 
Close-up view of the interaction between mtRNAP and TFAM in the LSP IC. Coloring as in Figure 12. 
Residues in TFAM and the region in mtRNAP previously shown to be functionally important for 
initiation or identified as crosslinking-points are shown in magenta  (Morozov et al., 2014; 2015). The 
trajectory of the polypeptide chain of the N-terminal extension based on observed difference density is 
indicated as a dashed line. 
Structural basis of mitochondrial transcription initiation 
 47 
 
Figure 15. Identification of the tether helix and architecture of the IC at HSP. 
(A) Identification of the mtRNAP tether helix. (Left) The 2mFo-DFc electron density for the LSP IC is 
shown as grey mesh at 1.0 σ with the final model shown as ribbon representation. An anomalous 
difference Fourier map calculated from the dataset used for phasing is displayed as green mesh at 3 σ. 
(Right) Secondary structure prediction for the N-terminal extension region of mtRNAP encompassing 
the tether helix calculated with PSIPRED (Buchan et al., 2013). Modeling of the predicted alpha helix 
consisting of mtRNAP residues 122-146 leads to methionine residues at the experimentally determined 
positions close to the helix (M135, M137 and M146). Selenomethionine-labeling of only mtRNAP in 
the IC confirms that these peaks originate from methionine residues within mtRNAP. (see Methods)  
(B) Comparison of the TFAM structure and DNA binding in the LSP IC and HSP IC structure. TFAM 
is shown as ribbon representation in red, template DNA in blue and non-template DNA in cyan. 
Anomalous difference Fourier maps calculated from crystals containing selenomethionine labeled 
TFAM in the LSP or HSP IC, respectively, are shown as green mesh at 5 σ. Two strong selenium peaks 
were observed in both maps, corresponding to M215 and M222 of TFAM. The comparison demonstrates 
that TFAM binds to both promoter sequences in identical orientations. 
TFB2M assists mtRNAP in DNA opening 
The IC structure also reveals how TFB2M assists mtRNAP in promoter opening and 
stabilization of open DNA (Morozov et al., 2015; Posse and Gustafsson, 2016; Ramachandran 
et al., 2016). First, TFB2M binds the duplex DNA around base -7 with its conserved arginine 
residues R330 and R331 (Figure 16A and Figure 17). Mutation of these residues to alanine 
severely impairs transcription initiation (Figure 16C). Second, TFB2M induces conformational 
changes in mtRNAP that stabilize open DNA. Comparison of the IC and the apo mtRNAP 
structure indicates that TFB2M binding induces a rotation of the PBD of mtRNAP (residues 
420-520 and 557-637), which includes the intercalating hairpin. This rotation moves the 
intercalating hairpin by ~7 Å and positions it between DNA strands (Figure 16A and Figure 
17). The intercalating hairpin is further buttressed by TFB2M helix a8, which contains residues 
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that are essential for activity (Morozov et al., 2015), including residue H326, which is critical 
for transcription initiation (Figure 16A and C and Figure 17). 
The PBD also harbors a “lever” loop (residues 588-604), a structural element which is adjacent 
to the intercalating hairpin and found in mtRNAP but not in phage RNAPs. The lever loop is 
essential for initiation (Morozov et al., 2015) and likely plays a key role in TFB2M-induced 
rotation of the core NTD. The lever loop would clash with bound TFB2M if it adopted the 
position observed in free mtRNAP (Figure 16A). In the IC, the lever loop interacts with loop 
a9-a10 in TFB2M (residues 341-347), and this may stabilize the rotated NTD core. Indeed, 
mutation of an arginine residue in the lever loop (R601E) results in decreased transcription 
initiation (Figure 16C). 
 
 
Figure 16. TFB2M stabilizes open DNA and traps the non-template strand. 
(A) TFB2M binding induces structural rearrangements in mtRNAP. Ribbon representation of DNA, 
mtRNAP and TFB2M around the point of DNA melting in the LSP IC. Helices are depicted as cylinders. 
Functionally important residues in TFB2M are shown as sticks. The palm domain (residues 646-1230) 
of free mtRNAP  (PDB ID: 3SPA; transparent pale green) (Ringel et al., 2011) was superimposed on 
the IC. For clarity, only residues 420-520 and 557-637 of mtRNAP are shown. Grey and green dashed 
lines indicate the trajectory of unresolved parts of the mtRNAP lever loop in the IC and apo mtRNAP 
structures, respectively. Arrows indicate the movement induced by TFB2M binding. (B) Nucleic acid 
binding by TFB2M. The surface of TFB2M is colored according to electrostatic potential with positive 
and negative potential in blue and red, respectively. DNA is shown in cartoon view. Upstream DNA and 
mtRNAP were omitted for clarity. (C) Activity of structure-based point mutants of mtRNAP and 
TFB2M in transcription assays. 
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Comparison with the free TFB2M structure reveals that the C-terminal tail of TFB2M (residues 
389-396) has apparently moved to accommodate the intercalating hairpin of mtRNAP in the 
position observed in the IC (Figure 17). The tail may contribute to stabilizing the intercalating 
hairpin because deletion of eight amino acids from the C-terminus of TFB2M leads to a notable 
reduction in activity (Figure 16C). 
Finally, TFB2M traps the non-template DNA strand in the open DNA region. This was 
previously suggested for Mtf1 (Paratkar and Patel, 2010) and is reminiscent, on the topological 
level, of the bacterial initiation factor sigma (Feklistov and Darst, 2011; Helmann and 
Chamberlin, 1988; Zhang et al., 2012). The NTD of TFB2M contributes an extensive positively 
charged surface that guides the DNA non-template strand away from the template strand 
(Figure 16B). Three conserved positively charged residues (R198, K201 and K202) protrude 
from the a5 helix of TFB2M towards the non-template strand and are required for efficient 
transcription initiation (Figure 16A and C, Figure 17). Further interactions may be mediated by 
the positively charged residues K153, R157, K163 and K206, which line the projected path of 
the non-template strand. Notably, three of these residues are located in the TFB2M-specific 
loop between b3 and a4, possibly contributing to the specificity of TFB2M as a transcription 
initiation factor compared to TFB1M, which plays no role in transcription initiation (Litonin et 
al., 2010; Metodiev et al., 2009). 
 
 
Figure 17. Structural basis of DNA melting and open DNA stabilization. 
Close up view of the interaction of the TFB2M C-terminal domain with the intercalating hairpin of 
mtRNAP and the DNA. Nucleic acid and protein are depicted as ribbon representation with coloring as 
in Figure 12. The trajectory of the C-terminal tail of TFB2M (res. 393-396) observed in the TFB2M 
crystal structure but removed from the IC model is indicated as a dashed orange line. The presumably 
flexible tail would clash with the intercalating hairpin and the non-template DNA in the conformation 
observed in the free TFB2M structure. 
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Comparison to T7 RNAP initiation 
Comparison of the mitochondrial IC structure to the structure of the T7 RNAP IC (Cheetham 
et al., 1999) reveals possible reasons for the requirement of initiation factors in mitochondria. 
Promoter recognition by T7 RNAP is achieved in part through sequence-specific DNA contacts 
at registers -5 to -11 formed by the specificity loop (Figure 18A and C). In contrast, the 
specificity loop in mtRNAP shows only fragmented density in the DNA major groove around 
registers -9 to -7, arguing against a prominent role in promoter recognition. Consistent with 
this, LSP and HSP share no sequence homology in this region and DNA base mutations hardly 
change initiation activity (Gaspari et al., 2004). In addition to the specificity loop, T7 RNAP 
engages with promoter DNA via the AT-rich recognition loop, which inserts into the upstream 
DNA minor groove between registers -17 and -13 (Cheetham et al., 1999). (Figure 18A and C).  
The structure of the IC demonstrates that mtRNAP does not form sequence specific contacts 
with promoter DNA in this region. Instead, only interactions between the PPR domain of 
mtRNAP and the upstream DNA backbone were detected (Figure 13A). Thus, recruitment of 
mtRNAP to DNA-bound TFAM apparently substitutes for the lack of extensive DNA 
interactions as compared to T7 RNAP. Opening of the DNA duplex by T7 RNAP is facilitated 
by the intercalating hairpin, which separates the two DNA strands at the upstream edge of the 
DNA bubble. In the apo mtRNAP structure, this element has been observed in a conformation 
incompatible with promoter melting (Ringel et al., 2011). In the mitochondrial IC, however, 
the intercalating hairpin and specificity loop are arranged as in the T7 RNAP IC (Figure 18B). 
This suggests that binding of TFB2M induces an initiation-competent conformation of 
mtRNAP (Figure 18A and B). In summary, comparison of the mitochondrial IC and the T7 
RNAP IC suggests that TFAM compensates for the lack of prominent RNAP-promoter 
interactions upstream of the point of DNA opening and that TFB2M facilitates promoter 
opening by positioning a key structural element in mtRNAP in a fashion reminiscent of T7 
RNAP. 
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Figure 18. Comparison of human mitochondrial IC and T7 RNAP IC. 
(A) (Left) Ribbon depiction of the LSP IC. MtRNAP is shown in grey with the intercalating hairpin in 
purple and the specificity loop in yelloworange. (Right) Ribbon depiction of the T7 RNAP initiation 
complex (PDB ID: 1CEZ) (Cheetham et al., 1999). Coloring as for the mitochondrial IC and with the 
AT-rich recognition loop in red. The topology around the point of DNA melting is similar in both 
complexes. (B) Ribbon representation of structural elements of human mtRNAP interacting with the 
DNA around the point of DNA melting. Coloring as in Figure 12 with base numbering indicated. The 
intercalating hairpin is positioned with the help of TFB2M to melt the DNA duplex and the specificity 
loop of mtRNAP runs along the DNA groove between bases -7 to -9. (C) Ribbon representation of the 
corresponding structural elements of T7 RNAP interacting with the DNA around the point of DNA 
melting in the T7 RNAP initiation complex (PDB ID 1CEZ) (Cheetham et al., 1999). 
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Transition from initiation to elongation 
After RNA chain initiation, mtRNAP must lose its interactions with TFAM and TFB2M in 
order to transition to the elongation phase. In the case of T7 RNAP, this initiation-elongation 
transition is accompanied by substantial refolding of the polymerase, which destroys the PBD 
(Tahirov et al., 2002; Yin and Steitz, 2002). In contrast, comparison of the mitochondrial IC 
with the EC structure (Schwinghammer et al., 2013) demonstrates that the mtRNAP 
conformation remains largely unchanged and indicates rearrangements of the DNA during the 
initiation-elongation transition. In the EC, upstream DNA is repositioned and occupies the 
binding site of TFB2M, which must therefore dissociate during the transition (Figure 19). 
TFB2M dissociation is also required for binding of the elongation factor TEFM (Figure 19), as 
revealed in a recent structure of the EC bound by TEFM (Hillen et al., Cell, in press). The 
transition further creates a RNA exit channel underneath the intercalating hairpin, which 
remains in an open conformation and now separates the exiting RNA from the DNA template 
(Schwinghammer et al., 2013). Thus, TFB2M positions the intercalating hairpin for initiation, 
and this position is largely maintained during subsequent elongation. This concept of pre-
organization of the polymerase conformation by an initiation factor has been observed for 
prokaryotic RNAP (Zhang et al., 2012). Taken together, these structural comparisons 
demonstrate the transitions that accompany promoter escape and highlight the distinct 
mechanisms employed by mtRNAP as compared to T7 RNAP. 
 
 
Figure 19. Transition from the initiation phase to the elongation phase of transcription. 
(Left) Structure of the LSP IC. TFAM and mtRNAP are depicted transparently for clarity. The 
movement of the upstream DNA upon transition to the EC is indicated with an arrow. (Right) Structure 
of the human mitochondrial transcription elongation complex with the elongation factor TEFM bound 
(see chapter 3.2). MtRNAP is depicted transparently for clarity. The position of the downstream DNA 
duplex is identical in both the IC and the EC. The TFB2M binding site on mtRNAP is occupied by the 
upstream DNA and TEFM in the EC, demonstrating that a pronounced rearrangement of the upstream 
DNA must take place during the transition from initiation to elongation and that binding of TFB2M and 
TEFM to mtRNAP are mutually exclusive. The position of the intercalating remains in the open 
conformation. 
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3.1.3. Discussion 
In this study we extend our previous structural work on the  mitochondrial transcription from 
elongation (Schwinghammer et al., 2013) (see also section 3.2) to initiation mechanisms. Our 
structures of the ICs demonstrate the conserved architecture of the transcription complexes that 
assemble at divergent human mitochondrial promoters and support the sequential model of 
transcription initiation (Morozov et al., 2014) (Figure 20). First, recruitment of mtRNAP to 
TFAM-bound promoter DNA positions mtRNAP at the transcription start site. This explains 
the critical role of the distance between the TFAM-binding site and the start site in initiation 
(Dairaghi et al., 1995a). Subsequent binding of TFB2M induces DNA opening and stabilizes 
open DNA with the use of conformational changes and binding energy. Initial RNA synthesis 
may then be facilitated by the N-terminal region of TFB2M (residues 21-71), which is mobile 
in the IC structure but can be cross-linked to the initiating nucleotide (Sologub et al., 2009). 
Comparison of the IC with our recent EC structure bound to the mitochondrial elongation factor 
TEFM (Hillen et al., Cell, in press; see also section 3.2) demonstrates that TFB2M and TEFM 
binding to mtRNAP are mutually exclusive. The transition from initiation to elongation is 
accompanied by a dramatic re-arrangement of the upstream DNA instead of refolding of the 
polymerase, as observed for the distantly related T7 RNAP. These results not only provide the 
molecular basis for initiation, they also indicate changes that occur during the initiation-
elongation transition and indicate that release of TFB2M is a prerequisite for TEFM recruitment 
to mtRNAP. 
Our structural data show how the initiation mechanism of mtRNAP differs from that of phage 
T7 RNAP and multisubunit RNAPs. Whereas T7 RNAP does not depend on initiation factors, 
multisubunit RNAPs depend on additional factors for initiation, but these are not homologous 
to TFAM and TFB2M, neither on the sequence level nor the structural level. There are, 
however, conceptual and distant similarities between all initiation systems. In particular, 
mtRNAP uses its intercalating hairpin for DNA opening, like T7 RNAP, although the hairpin 
must be positioned by the initiation factor TFB2M. Also, TFB2M traps the non-template strand 
in the open DNA region, in a manner that is topologically similar to the sigma factor that is 
required by bacterial RNAP for initiation (Feklistov and Darst, 2011; Murakami and Darst, 
2003; Zhang et al., 2012). Taken together, the transcription initiation system in mitochondria is 
unique, but some aspects of it show distant similarities with the bacteriophage and the bacterial 
systems. 
In conclusion, our results illuminate the architecture of the IC and provide the structural basis 
of mitochondrial transcription initiation. The mitochondrial initiation system employs 
mechanisms of initiation that are clearly distinct from those observed for nuclear, bacterial or 
bacteriophage RNAPs. This likely reflects the need for regulating mitochondrial transcription, 
which is not only required for the expression of essential genes and synthesis of ribosomal and 
transfer RNA, but also to generate RNA primers for replication of the mitochondrial genome 
(Agaronyan et al., 2015; Gustafsson et al., 2016). 
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Figure 20. Model for transcription initiation in human mitochondria. 
The TFAM binding site and the transcription start site (TSS) are indicated. TFAM (red) binding bends 
the DNA upstream of the TSS and leads to recruitment of mtRNAP (grey) to form the closed pre-
initiation complex. Binding of TFB2M (blue) leads to melting of the DNA duplex and the bending of 
the downstream DNA observed in the open initiation complex. Promoter escape and transition to the 
elongation complex involve repositioning of the upstream DNA duplex (dashed arrow) and binding of 
TEFM (raspberry), which occupies a similar site on mtRNAP as TFB2M in the IC. 
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3.2. Mechanism of transcription anti-termination in 
human mitochondria 
Results presented in this section were obtained in collaboration with the Temiakov lab at the 
Department of Cell Biology, Rowan University, Stratford, NJ, USA and with the Urlaub lab at 
the Max-Planck-Institute for Biophysical Chemistry and have been published: 
 
H.S. Hillen, A.V. Parshin, K. Agaronyan, Y.I. Morozov, J.J. Graber, A. Chernev, K. 
Schwinghammer, H. Urlaub, M. Anikin, P. Cramer and D. Temiakov (2017) Mechanism of 
transcription anti-termination in human mitochondria. Cell, in press 
 
A detailed list of author contributions can be found on page VI. 
 
For clarity, this results section presents all results of this publication. Structure determination 
and chemical cross-linking using BS3 and EDC was performed as part of this thesis work, while 
analysis of cross-links by mass spectrometry was performed by the Urlaub Lab and biochemical 
assays, pBpa and DSG cross-linking were performed by the Temiakov lab. Methods performed 
as part of this thesis work are described in section 2.4 and methods and additional data obtained 
predominantly by the collaborators are presented in section 5.2.1 and 5.2.2, respectively. 
3.2.1. Abstract 
In human mitochondria, transcription termination events at a G-quadruplex region near the 
replication origin are thought to drive replication of mtDNA by generation of an RNA primer. 
This process is suppressed by a key regulator of mtDNA – the transcription factor TEFM. We 
determined the structure of an anti-termination complex in which TEFM is bound to 
transcribing mtRNAP. The structure reveals interactions of the dimeric pseudonuclease core of 
TEFM with mobile structural elements in mtRNAP and the nucleic acid components of the EC. 
Binding of TEFM to the DNA forms a downstream "sliding clamp", providing high processivity 
to the elongation complex. TEFM also binds near the RNA exit channel to prevent formation 
of the RNA G-quadruplex structure required for termination and thus synthesis of the 
replication primer. Our data provide insights into target specificity of TEFM and mechanisms 
by which it regulates the switch between transcription and replication of mtDNA.  
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3.2.2. Results 
TEFM contains two structured domains 
Our initial crystallization trials did not produce crystals of full-length TEFM. Sequence based 
homology prediction suggested that human TEFM contains at least two regions with distinct 
structural organization (Minczuk et al., 2011), possibly interspersed by less well-ordered 
domains. Protease treatment is known to improve chances of crystallization of proteins with 
flexible regions (Dong et al., 2007). We therefore probed whether TEFM contains unstructured 
regions that may interfere with its crystallization by using limited proteolysis with trypsin, LysC 
and ArgC proteases. These experiments revealed two stable regions representing the N-terminal 
domain (NTD, ~10 kDa) and the C-terminal domain (CTD, ~26 kDa) of TEFM, while the 
region between these domains (the inter-domain linker) was sensitive to proteolysis (Figure 
21A). Limited proteolysis of TEFM with ArgC prior to crystallization yielded large, well- 
diffracting crystals of the CTD (Figure 21B). The structure was subsequently solved at 1.9 Å 
resolution by single-wavelength anomalous diffraction (SAD) using selenomethionine-labeled 
protein (Table 16, Figure 21C). The TEFM CTD crystals belong to space group C2 and contain 
four molecules in the asymmetric unit with only minor differences between the individual 
molecules (Ca RMSD < 1 Å over 200 residues). To obtain the crystal structure of the TEFM 
NTD, we expressed this domain separately and obtained large, rod-like crystals of space group 
P43212 containing one molecule in the asymmetric unit (Figure 21B). The structure of the NTD 
was solved at a resolution of 1.3 Å using the anomalous signal of the naturally occurring sulphur 
atoms (native-SAD) (Table 16, Figure 21D). The crystal structures of the NTD and the CTD 
were refined to free R-factors of 19.7 and 22.8, respectively, and both showed excellent stereo 
chemical quality (Table 16). 
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Figure 21. Domain organization, crystallization and structure determination of human TEFM. 
(A) Limited proteolysis of TEFM. (Top) Cleavage of TEFM with proteases occurs in the inter-domain 
linker. (Bottom) Schematics of cleavage in the inter-domain linker of TEFM as determined by mass 
spectrometry. (B) (Left) Exemplary optimized crystal of the TEFM N-terminal domain. (Right) 
Exemplary optimized crystals of the TEFM C-terminal domain. (C) Structure determination of the 
TEFM CTD. (Top) Ribbon representation of the structure of the TEFM CTD with one monomer colored 
in raspberry and the other in chocolate. Secondary structure elements are indicated. Methionine residues 
substituted with selenomethionine in the crystals used for phasing are indicated and shown as sticks. An 
anomalous difference Fourier map calculated using the dataset used for phasing is shown as mesh at 5 
σ in yellow. (Bottom) The unbiased experimental electron density used for building the initial model is 
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shown as mesh (marine blue) at 1 σ around representative regions shown as sticks (sheets β1, β2, β3 
and the dimerization interface composed of α10 from each monomer). (D) Structure determination of 
the TEFM NTD. Left. Ribbon representation of the structure of the TEFM NTD colored in orange. 
Secondary structure elements are indicated. Sulphur-containing residues M116 and C130 are indicated 
and shown as sticks and an anomalous difference Fourier map calculated using the dataset used for 
phasing is shown as mesh at 5 σ in pink. Right. Unbiased experimental electron density used for building 
initial model is shown as marine blue mesh at 1 σ around representative helix α5. 
Structure of TEFM 
In the two crystal forms, we observed interpretable electron density for residues 57-134 (NTD) 
and residues 153-356 (CTD), which comprise 87% of the full-length, mature TEFM (Table 16). 
Our structures lack 21 N-terminal residues, 3 C-terminal residues, and a 19-amino acid linker 
region, which connects the two domains. The linker contains six lysine and two arginine 
residues and appears to be disordered in the CTD structure. The TEFM CTD forms a dimeric 
assembly of monomers containing an RNase H-like fold that is characteristic of members of 
the Holliday junction resolvase family of enzymes (Figure 22B and Figure 23) (Wyatt and 
West, 2014). This family includes a large number of RuvC-like resolvases from bacteria, 
viruses, and mitochondria (Ariyoshi et al., 1994; Górecka et al., 2013; Roe et al., 1998). 
Structural alignment suggests that the closest structural homolog of TEFM CTD is 
Schizosaccharomyces pombe mitochondrial Holliday junction resolvase, Cce1 (Ydc2) 
(Ceschini, 2001). While TEFM and Cce1 share little in sequence homology, the structures 
contain a common core fold consisting of five b-strands and four C-terminal helices (Figure 
22D). Compared to Cce1, TEFM lacks a protruding three-helix region, and two N-terminal 
helices and two loops (a12-a13; a13-a14) are expanded (Figure 22D) (Sigala and Tsaneva, 
2003). Similar to Cce1, dimerization of the TEFM CTD is mediated by a hydrophobic interface 
mainly formed by a contact between the a10 helices (residues 244–266) from the two CTD 
monomers.  
A unique feature of TEFM, not observed thus far in any related bacterial or mitochondrial 
Holliday junction resolvase, is the presence of a compact globular N-terminal domain (Figure 
22B and Figure 23). The structure of the NTD reveals that this domain adopts a tandem helix-
hairpin-helix fold ([HhH]2) found in a number of DNA binding proteins. HhH domains have 
been implicated in non-sequence-specific double stranded DNA binding and have been found 
in bacterial and eukaryotic transcription factors and other DNA binding proteins (Close et al., 
2011; Johnson et al., 2008). Although lacking apparent sequence homology, the TEFM NTD 
superimposes well with the HhH domain of the bacterial Tex protein (Ca RMSD = 1.4 Å over 
56 residues, PDB ID: 3BZC, (Johnson et al., 2008)) (Figure 22E). Taken together, TEFM 
exhibits a previously unseen combination of distinct structural domains – the Holliday junction 
resolvase-like CTD core flanked by two globular HhH domains. 
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Figure 22. Crystal structure of human TEFM. 
(A) Schematic representation of human TEFM with residue numbers indicated. Domains identified by 
sequence-based homology prediction are depicted in different colors: mitochondrial targeting sequence 
(MTS): blue; N-terminal domain (NTD): orange; C-terminal domain (CTD): raspberry, inter-domain 
linker: grey. (B) A ribbon model of TEFM with the major domains and structural elements indicated. 
The C-terminal dimeric domain (CTD) is in brown/raspberry, the N-terminal domains (NTD) in orange. 
The inter-domain linker is represented by a dashed, grey line. (C) Schematics of the primary and 
secondary structures of TEFM. (D) Structural alignment of TEFM CTD (raspberry) and fission yeast 
Holliday junction resolvase Cce1 (PDB ID: 1KCF) (Ceschini, 2001) (grey). (E) Structural alignment of 
TEFM NTD (orange) and bacterial (P. aeroginosa) transcription factor TEX (PDB ID: 3BZC) (Johnson 
et al., 2008)(cyan). 
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Figure 23. Secondary structure topology of human TEFM. 
Schematic representation of secondary structure elements in TEFM. Alpha-helices are shown as 
cylinders, ß-sheets as arrows. Important structural features are indicated. Coloring as in Figure 22A. 
Functional role of TEFM domains 
TEFM has been previously implicated in anti-termination activity and was shown to affect 
mtRNAP stability and processivity (Agaronyan et al., 2015; Minczuk et al., 2011; Posse et al., 
2015). To determine the functional role of TEFM domains in these activities, we constructed 
variants representing the CTD alone (∆159 TEFM, residues 160-360), the CTD with a part of 
the linker (∆144 TEFM, residues 145-360) and the CTD with the linker (∆135 TEFM, residues 
136-360) (Figure 24A). In the anti-termination assay, transcription of template DNA containing 
the CSBII region results in termination of RNA synthesis by mtRNAP in the absence of TEFM, 
whereas its addition results in accumulation of run-off products (Figure 24B, lanes 1-4). We 
found that the NTD of TEFM is not required for anti-termination activity (Figure 24B, lanes 5-
7). Removal of 10 amino acids of the linker along with the NTD results in significant loss of 
anti- termination activity (Figure 24B, lanes 8-10), while deletion of the entire linker subdomain 
abolished anti-termination (Figure 24B, lanes 11-13). TEFM variants containing single or 
multiple substitutions in the linker were defective to various extents in anti-termination activity, 
and substitution of amino acid residues 149-153 resulted in loss of activity (Figure 24C and D). 
We therefore conclude that the inter-domain linker is required for anti-termination activity of 
TEFM.  
We next analyzed which part of TEFM affects its ability to stabilize the EC (Figure 24E). In 
this assay, ECs are halted 35 bp downstream from a promoter (in the absence of CTP) for 60 
min prior to a “chase” to run-off transcription. In the absence of TEFM, halted ECs are not 
stable and accumulation of 35-mer RNA product is observed (Figure 24E, lane 1). Addition of 
TEFM, however, results in stabilization of the EC, prevents high mtRNAP turn-over and, 
consequently, causes nearly complete extension of 35 nt RNA to run-off (Figure 24E, lanes 2- 
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Figure 24. Functional role of TEFM domains. 
(A) Schematic representation of the TEFM NTD truncation mutants and inter-domain linker substitution 
mutants used. Residues substituted are underlined with a black bar and the replacing residues are shown 
in blue beneath. (B) TEFM CTD with the linker are required for anti-termination activity. Transcription 
assays were performed using a PCR template containing LSP and the CSBII region. The control reaction 
(lane 1) contains no TEFM. The reaction products were resolved using 20% PAGE containing 6M Urea. 
(C, D) Anti-termination activity of TEFM variants having substitutions in the inter-domain linker.         
(E) The NTD of TEFM is not required for the EC stability. The ECs assembled in the presence or 
absence of TEFM variants were halted 35 nt downstream of the transcription start site by omitting CTP. 
Upon incubation, the complexes were chased with CTP and the products of the reaction resolved using 
20% PAGE containing 6M Urea. The region of the gel containing the 35 nt RNA is shown. (F) Only 
the CTD of TEFM is required for mtRNAP processivity. Transcription was performed using a linearized 
plasmid template containing the LSP promoter to generate ~4000 nt run-off product. 
3). As in the experiments described above, deletion of the NTD did not affect TEFM 
stabilization activity (Figure 24E, lanes 4-5), while loss of both NTD and inter-domain linker 
rendered TEFM incapable of EC stabilization (Figure 24E, lanes 6-7). Finally, we examined 
whether the TEFM variants were able to support mtRNAP processivity on long templates 
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(Figure 24F). In the absence of TEFM, mtRNAP is not able to produce detectable 4,000 nt long 
run-off RNA products. In contrast, run-off synthesis was observed in the presence of TEFM or 
TEFM variants lacking the NTD (Figure 24F, lanes 2-3). In the presence of TEFM CTD, 
mtRNAP was still able to generate long RNA transcripts, suggesting that the CTD, even without 
the inter-domain linker, is sufficient for stimulating processivity (Figure 24F, lane 4). 
Structure determination of TEFM-mtRNAP elongation complex 
To obtain the crystal structure of an anti-termination complex, in which elongating mtRNAP is 
bound to TEFM, we first defined the topology of the nucleic acid scaffold in the EC by RNase 
I and DNase I foot-printing (Figure 25A). In the absence of TEFM no clear RNA footprint was 
detected, likely due to the relative instability of the halted ECs. In contrast, in the presence of 
TEFM, a distinct footprint of about 19 nt of protected RNA was observed suggesting that TEFM 
stabilizes the EC by interacting with the 5' end of the exiting transcript (Figure 25A). Removal 
of the NTD did not significantly alter the TEFM footprint, identifying the CTD and the linker 
domain as primary RNA-interacting regions (Figure 35A and B).  
TEFM has previously been shown to interact with the DNA in the EC (Agaronyan et al., 2015). 
To determine the TEFM footprint on DNA, we assembled ECs using an RNA-DNA scaffold 
and probed TEFM protection by DNase I (Figure 25B). In the presence of TEFM, the protected 
region was significantly larger than for the EC alone, and included about 12 bp of upstream 
DNA and 14 bp of downstream DNA (Figure 25B and C). We did not detect any changes in 
DNA protection when the ∆135 TEFM variant was used, suggesting that the NTD does not 
strongly associate with DNA (Figure 35C). However, a TEFM variant lacking both NTD and 
the linker did not produce a clear DNA foot-print (Figure 35D). Overall, binding of TEFM to 
the EC significantly increases the region of nucleic acid protection (Figure 25C), consistent 
with our previous findings (Agaronyan et al., 2015).  
To crystallize the anti-termination complex, we used the ∆135 variant of TEFM, which is fully 
functional in anti-termination assays, and ∆150 mtRNAP assembled into an EC on an RNA-
DNA scaffold derived from the foot-printing experiments above. Crystals of the EC-TEFM 
complex belonged to space group C2, contained two copies of the EC-TEFM complex in the 
asymmetric unit and diffracted to 3.9 Å resolution. The structure was solved by molecular 
replacement and could be refined to a free R-factor of 27.6% (Table 17, Methods). 
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Figure 25. Topology of the anti-termination complex. 
(A) TEFM protects 19-20 nt of RNA from RNase 1 cleavage in the EC-TEFM complex. The ECs were 
halted 35 bp downstream of the LSP promoter prior to RNase 1 treatment. Positions of the RNA markers 
(18 and 27 nt) are indicated by grey lines. (B) TEFM protects the downstream and the upstream DNA 
in the EC. The EC was assembled using R14/TS26/NT26A scaffold (see 5.2.1) in the absence or 
presence of TEFM prior to DNase I treatment. The length of the DNA markers (15 and 34 nt, the leftmost 
lane) is indicated. The grey bar represents the DNA region protected by TEFM. (C) Schematics of the 
RNA and DNA protection regions (shown in grey) in the anti-termination complex shown on scaffold 
used in (B).  
Architecture of the TEFM-mtRNAP elongation complex 
The structure revealed that the TEFM CTD dimer forms an extensive network of interactions 
with all components of the EC by binding mtRNAP at the open side of the RNA-DNA hybrid 
cavity (Figure 26A and B). The primary point of interaction between mtRNAP and TEFM is 
the intercalating hairpin (Figure 26C), a mobile element in the N-terminal domain of mtRNAP 
involved in separation of RNA from the RNA-DNA hybrid and thus maintenance of the trailing 
edge of the transcription bubble (Schwinghammer et al., 2013). Two invariant aromatic residues 
in the intercalating hairpin, Y610 and F612, and the conserved residue Q617 project into a 
hydrophobic cleft on the surface of TEFM, the walls of which are formed by helices adjacent 
to the b-strand core (Figure 26C). 
The structure of the EC-TEFM complex reveals that the homodimeric form of TEFM observed 
in the CTD crystals also occurs when TEFM is bound to mtRNAP (Figure 26A and B). To 
investigate whether dimerization of TEFM is required for its activity, we modified the 
hydrophobic interface between the TEFM monomers to prevent their association by 
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substituting five residues in the a10 helix (Figure 27A). In contrast to the wild type TEFM, the 
resulting protein eluted as a monomer during size exclusion chromatography and did not bind 
to the EC (Figure 27B). No anti-termination activity was observed with the mutant monomeric 
TEFM, confirming that dimerization of TEFM is required for its activity (Figure 27C). 
TEFM makes extensive interactions (~1000 Å2) with the downstream DNA duplex of the EC. 
The positively charged surface of one of the TEFM monomers covers the otherwise exposed 
DNA and along with mtRNAP sequesters it in a fashion resembling the DNA "clamping" 
observed in multi-subunit eukaryotic and bacterial RNAPs (Figure 26D, Figure 28A and B). 
This clamping may explain the stabilization and higher processivity of ECs in the presence of 
TEFM (Agaronyan et al., 2015).  
 
 
Figure 26. Structure of the anti-termination complex. 
(A,B) TEFM binding to the EC. MtRNAP (ribbon model) is shown with the major domains colored: 
Thumb: bright orange, Palm: lime-green, NTD: grey, PPR: teal, Fingers domain: pink. RNA is shown 
in red, template DNA strand in blue, non-template DNA strand in cyan. Intercalating hairpin and 
specificity loop (modeled) of mtRNAP are highlighted in purple and yelloworange, respectively. (C) 
Close-up view of the TEFM binding site at the intercalating hairpin of mtRNAP. TEFM is shown as 
surface representation. Conserved residues (yellow) in mtRNAP are shown as sticks. (D) TEFM 
interacts with the RNA-DNA scaffold in the EC. TEFM (ribbon representation) binds at junctions of the 
RNA-DNA hybrid and interacts with downstream and upstream DNA. The +1 template DNA base is 
not paired to its non-template counterpart, indicating the post-translocated conformation state of the EC. 
Note the proximity of the inter-domain linkers (residues 149-159, yellow) to the DNA duplexes; 
positively charged residues implicated in interaction with DNA are shown as sticks. 
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Figure 27. Dimerization of TEFM is required for EC binding and anti-termination activitiy. 
(A) Close-up view of the dimerization interface of TEFM. Coloring and representation as in Figure 1B. 
The α10 helix of each monomer is highlighted, with the rest of the protein shown transparently. 
Hydrophobic residues forming the dimerization interface that were subjected to mutagenesis are shown 
as sticks. (B) Mutation of the TEFM residues contributing to the dimerization interface results in a 
monomeric form of TEFM that cannot bind EC.  Upper panel: A monomeric TEFM mutant (∆35 TEFM 
F244E L248D I252D M256S L260D) was purified and used for analytical size exclusion experiments. 
The mutant TEFM elutes as a monomer (blue), while the WT TEFM elutes as a dimer (red). Middle 
panel: Incubation of the EC with WT TEFM leads to a distinct shift of the peak representing the EC, 
indicating formation of a stoichiometric complex (2:1 TEFM:EC).  In contrast, incubation of the EC 
with the monomeric TEFM mutant does not lead to a change in retention volume as compared to the 
individual components (Lower panel). (C) The monomeric TEFM mutant does not prevent termination 
at CSBII. Transcription assays were performed using the PCR template containing LSP and the CSBII 
region. The control reaction (lane 1) contains no TEFM. The reaction products were resolved using 20% 
PAGE containing 6M Urea.  
The positively charged TEFM surface extends to the other monomer contributing to a much 
smaller interaction surface with the upstream than with the downstream DNA (Figure 28A and 
B). Consequently, the electron density for the downstream DNA duplex was strong, whereas 
the density for the upstream DNA duplex was weaker due to higher conformational flexibility 
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(Figure 28C). Furthermore, we observed difference density corresponding to the single-
stranded region of the DNA non-template strand in the transcription bubble, which wraps 
around the opposite side of the dimer axis of TEFM formed by the a10 helices (Figure 28C). 
This region of the DNA was invisible in the previous structure of the EC (Schwinghammer et 
al., 2013) due to conformational flexibility but seems to be stabilized in the EC-TEFM complex. 
However, we refrained from modelling it due to the limited resolution of the complex structure. 
Thus, in addition to interacting with the downstream DNA, TEFM also stabilizes the EC by 
sequestering the single-stranded portion of the non-template strand of DNA (Figure 26D). 
Although visible only partially in the EC-TEFM structure, both inter-domain linkers of TEFM 
are located in close proximity to the DNA suggesting that the NTDs of TEFM may reside near 
or at the downstream and upstream duplexes (Figure 26D). 
 
 
Figure 28. Properties of the anti-termination complex. 
(A) Surface charge distribution in TEFM. Surface charge analysis of TEFM reveals an extensive 
positively charged surface facing the nucleic acid scaffold in the EC-TEFM complex. (MtRNAP is not 
shown). (Blue: positive charge; red: negative charge). DNA is shown in cartoon view with coloring as 
in Figure 26A. Vacuum electrostatic potential was calculated with Pymol. (B) TEFM interactions with 
the downstream DNA contribute to the formation of the "sliding clamp". TEFM (raspberry) and 
mtRNAP (grey) are shown in surface representation. (C) Electron density for nucleic acids in the anti-
termination complex. The final model of the non-template DNA, template DNA and RNA is shown as 
sticks in cyan, blue and red, respectively. The TEFM CTD is shown as surface representation in 
raspberry. The 2mFo-DFc electron density for the nucleic acid included in the model is shown as grey 
mesh at 1 σ. An unbiased mFo-DFc map for the region corresponding to the single-stranded portion of 
the non-template strand (not modeled) is shown as green mesh at 3 σ. The expected trajectory of the 
missing non-template bases is indicated by a dashed line. 
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Thus, it is plausible that the positively charged residues in the linker contribute additional 
interaction points with the upstream and downstream DNA, thereby anchoring TEFM to the 
EC (Figure 26D). This could be important for the anti-termination activity because binding of 
TEFM to the EC must outweigh the energetically favorable formation of stable secondary 
structure such as a G-quadruplex. Indeed, substitutions of the charged residues in the linker 
region or its deletion have a profound effect on transcription anti-termination as demonstrated 
above (Figure 24). 
Implication for mtRNAP translocation 
Binding of TEFM to the EC does not cause noticeable structural changes in the elongation 
factor (Ca RMSD = 0.48 Å over 389 residues). Superimposition of mtRNAP in the EC and the 
EC-TEFM complex reveals that the C-terminal catalytic domain remains unchanged, whereas 
the PPR domain and the N-terminal core domain are slightly rotated outwards and the "fingers" 
domain adopts a markedly different orientation (Figure 26A, Figure 29A). The latter, however, 
is not caused by TEFM binding per se, as the observed changes are attributed to the different 
translocational state of mtRNAP. Indeed, the “n+1” template strand base in the EC-TEFM 
complex is not paired to the corresponding non-template strand base and instead is found in a 
"pre-insertion" site of mtRNAP, indicative of the post-translocated state of the EC (Figure 26D) 
(Temiakov et al., 2004). The O/Y helices of the fingers domain are rotated ~15°, respectively, 
as compared to the pre-translocated complex (Schwinghammer et al., 2013), and thus the active 
site of mtRNAP is found in the "open" conformation, previously observed in T7 RNAP ECs 
(Figure 29B and C) (Tahirov et al., 2002; Yin and Steitz, 2002). Overall, the conformation of 
the fingers domain and the position of the 3’ end of RNA in mtRNAP closely matches those in 
the T7 RNAP post-translocated complex. Comparison of the available structures of mtRNAP 
(the apo form, pre-translocated EC and post-translocated EC) suggests a rotation of the O/Y 
helices around an axis that is nearly parallel to the O helix (Figure 29D). This rotation allows 
for delivery of the cognate substrate bound to the n+1 template base into the insertion site and 
the closing of the active site required for catalysis (Temiakov et al., 2004; Yin and Steitz, 2004). 
The mechanism of translocation therefore appears to be highly conserved between 
mitochondrial and phage RNAPs.  
Considering the conformational changes in mtRNAP observed in the EC-TEFM structure, we 
employed a pyrophosphorolytic assay to probe whether TEFM can affect the translocation state 
of the EC (Figure 29E). Pyrophosphate (PPi) binds only to ECs in which mtRNAP is in a pre-
translocated conformation and drives a reaction that is reverse to RNA synthesis. In the absence 
of TEFM, RNA was readily shortened by 2 nucleotides, suggesting pyrophosphorolytic activity 
of this EC (Figure 29E, lanes 3-7). In contrast, in the presence of TEFM the sensitivity of the 
EC was significantly decreased suggesting stabilization of the post-translocated state, 
consistent with our structural observations (Figure 29E, lanes 9-13).  
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Figure 29. MtRNAP adopts the post-translocated conformation in the anti-termination complex. 
(A) Comparison of mtRNAP structure in the EC and the anti-termination complex. The structure of 
mtRNAP in the anti-termination complex is shown as ribbon representation with subdomains colored 
as in Figure 26A. The structure of the EC (PDB ID: 4BOC) (Schwinghammer et al., 2013) was 
superimposed using the C-terminal catalytic domain (residues 643-1230) and is shown in identical 
coloring at 50% opacity. Arrows indicate movements necessary to transform from the EC to the anti-
termination conformation. While the palm and thumb subdomains assume identical positions, the fingers 
domain is rotated in the post-translocated anti-termination complex to a conformation analogous to the 
one observed in the T7 post-translocated state (Temiakov et al., 2004). In addition, the NTD and PPR 
domains of mtRNAP adopt a more open conformation in the anti-termination complex than in the EC. 
(B,C) Orientation of the O/Y helices of the fingers domain of mtRNAP relative to the 3' end of RNA in 
the post-translocated (B) and pre-translocated (C, PDB ID: 4BOC) (Schwinghammer et al., 2013) ECs. 
(D) Movement of the O/Y helixes in the fingers domain of mtRNAP accompanies formation of the EC 
and RNA translocation. MtRNAPs from the apo form (PDB ID: 3SPA) (Ringel et al., 2011), pre-
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translocated EC (PDB ID: 4BOC) (Schwinghammer et al., 2013) and post-translocated EC-TEFM (this 
work) were superimposed using the conserved palm domain (residues 643-1230). (E) TEFM stabilizes 
the post-translocated state of the EC. A pyrophosphorolytic assay was performed using EC (lanes 3-7) 
and EC-TEFM (lanes 9-13). Control (lane 1) - the EC. The assembled complexes were nearly 100% 
active as evident by efficient extension of the RNA primer by GTP (lanes 2,8). 
Mapping of TEFM-mtRNAP interactions by cross-linking 
Since interactions between mtRNAP and TEFM may involve structural elements that are 
mobile and thus only partially visible in the EC-TEFM structure, we set to map them using an 
array of cross-linking methods coupled with mass spectrometry, chemical mapping, and 
mutational analysis. We employed a long range cross-linker BS3 
(bis(sulfosuccinimidyl)suberate, 11.4 Å), a medium range cross-linker DSG (disuccinimidyl 
glutarate, 7.7 Å), a short-range cross-linker Bpa (<4 Å) and a "zero-length" cross-linker EDC 
(1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (Leitner et al., 2010; Morozov et al., 2015).  
Mass spectrometry analysis of the long-range cross-links obtained with BS3 and DSG revealed 
proximity of the inter-domain linker (residues K144, K153 and K156) of TEFM (Figure 30A, 
Figure 36A) to the specificity loop (residues K1087 and K1089) of mtRNAP - a structural 
element implicated in promoter specificity and formation of the RNA exit pore in single subunit 
RNAPs (Schwinghammer et al., 2013; Temiakov et al., 2000). We also detected a single 
interaction point between functionally important TEFM domains (CTD/linker) and mtRNAP 
(Figure 30A) using the EDC "zero-length" cross-linking, which relies on modification of D-K 
and E-K salt bridges (Rivera-Santiago et al., 2015). This interaction involves surface residue 
E214 (or E215) in TEFM and the exposed residue K1089 in the specificity loop of mtRNAP. 
To confirm these findings and to further map the interaction interface, we used the photo 
reactive amino acid p- benzoyl-phenylalanine (Bpa) incorporated into different positions within 
mtRNAP (Figure 30B, Figure 36B). Consistent with the EDC cross-linking data, we found that 
substitution of residues V1088 and I1091 in the specificity loop of mtRNAP resulted in efficient 
cross-linking with TEFM (Figure 30B). In addition, we detected a strong cross-link (~30%) to 
TEFM when Bpa was placed at position 610 in the intercalating hairpin of mtRNAP, in 
agreement with the structural data (Figure 30B and Figure 26C). Both the specificity loop and 
the intercalating loop are found in close proximity to each other in the EC, and although the tip 
of the specificity loop is not fully resolved in the EC-TEFM structure, it can be confidently 
placed in proximity to TEFM based upon RNA-mtRNAP cross-linking data (Figure 30D) 
(Schwinghammer et al., 2013).  
To refine the interaction interface between mtRNAP and TEFM, we used a reciprocal approach 
and incorporated the Bpa probe into various positions in TEFM (Figure 30C, Figure 36B and 
C). We detected efficient cross-linking when Bpa was positioned in an unstructured, solvent 
exposed loop (the “docking loop”, residues 305-315) at the distal end of the CTD dimer (Figure 
30D). There, several TEFM Bpa variants (Bpa308, 309, 310, and 312) produced efficient  
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Figure 30. TEFM interactions revealed by cross-linking. 
(A) Interaction regions in TEFM and mtRNAP revealed by chemical cross-linking and mass 
spectroscopy. The TEFM CTD is shown as a ribbon model; mtRNAP is depicted schematically as a bar 
with the major domains indicated as in Figure 26A. Cross-linked residues in TEFM are shown as sticks 
(yellow), lines represent the respective target residues/regions in mtRNAP. The colors of the lines 
indicate the cross-linking reagent used. (B) TEFM interacts with the specificity loop and the 
intercalating hairpin of mtRNAP. The ECs were assembled using mtRNAP containing Bpa at positions 
indicated and 32P-labeled TEFM. The efficiency of cross-linking is indicated beneath the gel, size of 
molecular weight markers (kDa) is shown to the left of the gel. (C) Bpa cross-link reveals interaction of 
the docking loop of TEFM with mtRNAP. The ECs were assembled using 32P-labeled mtRNAP and 
TEFM containing Bpa at positions indicated. (D) Location of the mapped regions on EC-TEFM 
structure. Cross-linking sites on TEFM (surface representation) are highlighted in yellow, the specificity 
loop (modeled; ribbon view) of mtRNAP is shown in yelloworange. The N-terminal extension domain 
of mtRNAP implicated in cross-linking with the docking loop of TEFM is shown as a dash line 
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(chartreuse). The RNA is extended by 9 nucleotides to indicate a probable RNA exit channel according 
to the RNA cross-linking data (Agaronyan et al., 2015; Schwinghammer et al., 2013). (E,F)  TEFM can 
efficiently cross-link only to the EC. Cross-linking was performed using 32P-labelled TEFM, 1088Bpa-
mtRNAP (E) or 610Bpa-mtRNAP (F). The reaction mixtures contained mtRNAP (apo, lane 2), 
mtRNAP, TFAM and LSP (pre-initiation complex, lane 3), mtRNAP, TFAM, TFB2M and LSP 
(initiation complex, lane 4) or mtRNAP and RNA/DNA scaffold (EC, lane 5).  The control reaction 
(lane 1) contained TEFM only. 
(>30%) cross-linking to mtRNAP, suggesting an additional point of interaction between the 
two proteins (Figure 30A and C). We found that 308Bpa TEFM cross-links to two regions of 
mtRNAP that involve residues 120-150 in the N-terminal extension region of mtRNAP (65% 
of the cross-link) and residues 364-602, located in the palm subdomain, near to the PPR domain 
(35% of the cross- link) (Figure 37A to G).  
Interestingly, the region 120-150 in mtRNAP (not present in the mtRNAP construct used to 
determine the EC-TEFM structure) constitutes the binding site for transcription initiation factor 
TFAM (Morozov et al., 2014), suggesting that binding of TEFM contributes to the transition 
from the initiation to the elongation phase of transcription. To demonstrate that TEFM binding 
is specific to the elongation phase of transcription, we assembled different transcription 
complexes - the pre-initiation complex, the initiation complex and the EC - using Bpa-modified 
mtRNAP variants (Figure 30E and F). Efficient cross-linking between mtRNAP and TEFM 
was only observed when the EC was formed (Figure 30E and F). In agreement with these data, 
analytical size exclusion chromatography demonstrated that TEFM does not efficiently bind to 
the initiation complex (Figure 31). To conclude, the cross-linking data above corroborate the 
EC-TEFM structure and expand the comprehensive map of interactions between TEFM and 
mtRNAP during transcription elongation. 
 
 
Figure 31. TEFM does not bind to the initiation complex. 
Elution profile and SDS-PAGE of analytical size-exclusion chromatography of the initiation complex 
(LSP/mtRNAP/TFAM/TFB2M) in the presence of TEFM. Fractions analyzed by SDS-PAGE are 
indicated as colored bars in the chromatogram and below the SDS gel. 
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Mechanisms of transcription termination and anti-termination at CSBII 
Human mtDNA encodes a G-rich sequence followed by an 8 bp "spacer" region and a 9 bp AU- 
rich region that precedes the termination point and constitutes the RNA-DNA hybrid in the EC 
(Figure 32A). CD spectroscopy experiments have confirmed that the G-rich region in RNA is 
sufficient to form a strong G-quadruplex structure (Wanrooij et al., 2012), which may fold into 
a parallel-stranded structure having three G-tetrad layers (Figure 32B) (Mukundan and Phan, 
2013). The spacer region appears to be dispensable as it can be removed without affecting 
efficiency or site of termination (Figure 32C). However, when the AT-rich region in the CSBII 
sequence was changed to a GC-rich region, no termination was observed at the usual point, 
suggesting the importance of the weak RNA-DNA hybrid in transcription termination at CSBII 
(Figure 32D). Instead, multiple points of termination downstream of the usual termination site 
were observed, all of which corresponded to the occurrence of U-stretches in the RNA (Figure 
32D). This indicates that efficient termination at CSBII depends on the formation of a G-
quadruplex at the point at which it is most disruptive to the EC (i.e. in proximity to the RNA-
DNA hybrid). Termination at the G-quadruplex in human mitochondria is therefore reminiscent 
of transcription termination in bacteria and T7-like phages, where secondary structure in the 
RNA (hairpin) is thought to destabilize the EC and a U-stretch is required for its disruption 
(Epshtein et al., 2007; Gusarov and Nudler, 1999; Ma et al., 2005). 
The structure of the anti-termination complex combined with cross-linking and RNase foot-
printing data suggests that TEFM binds near the RNA exit channel and “guides” the emerging 
transcript from the region of its separation from the DNA to the point where RNA reaches a 
length of about 18-20 nucleotides (Figure 24, Figure 25, Figure 26, Figure 32). TEFM interacts 
with two mobile elements in mtRNAP - the intercalating hairpin and the specificity loop (Figure 
30B and D), which were shown to contribute critically to EC stability (Schwinghammer et al., 
2013). Modeling of an RNA G-quadruplex into the EC structure suggests that this bulky 
secondary structure would clash with both the specificity loop and the intercalating hairpin 
(Figure 32E). This would likely result in displacement of these elements and pulling of RNA 
from the active site, thus causing dissociation of mtRNAP from the DNA (Figure 32E). In 
contrast, binding of TEFM to the intercalating hairpin and specificity loop occludes the space 
in the EC where formation of the G-quadruplex would have the most dramatic impact on the 
complex stability (Figure 32F). Interestingly, mtRNAP does not efficiently terminate at hairpin 
termination signals, such as bacterial TrpA and T7 terminator TΦ (Figure 38), possibly due to 
the relatively small size of these hairpins (~23Å in diameter vs. ~36 Å for the G-quadruplex), 
which may not be sufficient to disrupt mtRNAP elements at the point of termination (Figure 
32E and F). 
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Figure 32. Mechanism of transcription termination at CSBII. 
(A) Schematics of the RNA transcript encoded in the CSBII region in human mitochondria. The G-
quadruplex region (G6AG8 variant) is highlighted in red, the points of termination are indicated by 
asterisks. (B) Schematic depiction of a possible RNA G-quadruplex structure having a single nucleotide 
bulge. (C) The spacer region of CSBII is dispensable for termination of transcription.  Transcription 
assays were performed using promoter templates with the WT and mutated CSBII sequence, in which 
the spacer region was deleted. (D) The U-run encoded in the CSBII region is required for transcription 
termination. The transcription assay was performed using the WT and modified CSBII sequence 
(GC>>AT), in which the AT-rich sequence proximal to the termination site was substituted to the GC-
rich sequence. (E) RNA G-quadruplex structure clashes with the specificity loop and intercalating 
hairpin of mtRNAP. The model is obtained by extending the RNA in mtRNAP EC with the 16 
nucleotide-long G-quadruplex (PDB ID: 2M4P) (Mukundan and Phan, 2013). The G-quadruplex (red) 
is shown formed in vicinity of the trailing edge of transcription bubble in EC (surface representation). 
The specificity loop is modeled based on TEFM-mtRNAP Bpa cross-linking data. (F) Structure of the 
anti-termination complex (surface representation). Coloring as in Figure 26A. 
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3.2.3. Discussion 
The bipartite role of TEFM in transcription elongation and anti-
termination 
The structure of the anti-termination complex explains how TEFM increases the processivity 
of mtRNAP. First, TEFM enhances interaction of the EC with the downstream DNA, 
contributing to a sliding clamp, a characteristic feature of a processive polymerase. Second, 
TEFM sequesters the single-stranded portion of the non-template DNA strand, thus preventing 
collapse of the transcription bubble. Third, because of the binding of TEFM to the specificity 
loop and the intercalating hairpin, which contributes to the formation of the RNA exit channel, 
the anti-termination complexes possess a much higher stability and processivity, as required for 
synthesis of genome-size RNA transcripts. Finally, TEFM may stabilize the post-translocation 
state of the EC, which is known to enhance RNAP processivity by promoting forward 
translocation and preventing pausing and arrest of transcription complexes on various 
sequences (Herbert et al., 2010).  
The G-rich sequence found in CSBII is predicted to form a G-quadruplex structure and is likely 
the major cause of EC destabilization leading to termination of RNA synthesis and primer 
formation for mtDNA replication. Two hypotheses involving the nature of the G-quadruplex in 
human mitochondria have been advanced – that formation of the quadruplex involves a hybrid 
between the NT DNA strand and the RNA and, alternatively, that the quadruplex involves only 
RNA (Wanrooij et al., 2010; 2012). Analysis of the mtRNAP EC structure suggests that 
formation of the hybrid quadruplex structure is highly unlikely due to steric hindrance provided 
by mtRNAP, which separates the RNA from the DNA-RNA hybrid and diverts it away from 
the upstream DNA (Schwinghammer et al., 2013). Consistently, substitution of GMP to 7-
deazaGMP (which disrupts G-quadruplex formation) in DNA does not affect termination at 
CSBII, suggesting that a RNA quadruplex is solely responsible for termination (Kuzmine et al., 
2001; Wanrooij et al., 2012).  
The efficiency of termination at CSBII has been demonstrated to depend upon the arrangement 
of the G residues in this region, which is highly polymorphic in the human mtDNA population. 
Thus, the more commonly occurring sequences - G6AG8 and G6AG7 (30% of the population) 
- exhibit significantly higher efficiency of termination as compared to the relatively rare 
G5AG8 and G5AG6 sequences (Kang et al., 2016; Tan et al., 2016). This suggests that the 
strength of the G-quadruplex is likely a primary contributor to the efficiency of transcription 
termination and thus to replication and maintenance of mtDNA copy number (Agaronyan et 
al., 2015). The more common G-quadruplex sequences in human mtDNA allow assembly 
similar to a three-layer G-quadruplex structure having a single nucleotide insertion (bulge) 
(Mukundan and Phan, 2013) (Figure 32B). This would result in a bulky structure forming inside 
the RNA exit channel of mtRNAP, likely causing disruption of the EC. Lack of termination of 
mtRNAP at hairpin terminators, at which a related T7 RNAP efficiently terminates, suggests 
that weaker secondary structures are tolerated by mtRNAP. This phenomenon may be attributed 
to the biological role of mtRNAP, which must transcribe through extensive secondary structures 
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of ribosomal and transfer RNAs. The structure of the anti-termination complex reveals that 
TEFM binds at the junction between the RNA-DNA hybrid and the upstream DNA, near the 
RNA exit channel (Figure 26A and B). This is predicted to prevent formation of the G-
quadruplex structure near the point of RNA separation from the RNA-DNA hybrid, the 
mtRNAP region that defines EC stability. Formation of the G-quadruplex past this point would 
not impose as dramatic an effect on EC stability and, as consequence, cause efficient 
termination (Figure 32D). The anti-termination mechanism for TEFM is thus reminiscent to 
that of the phage lambda protein N and bacterial transcription factor RapA, both of which bind 
at the RNA exit channel and prevent RNA hairpin formation within the bacterial RNAP EC 
(Gusarov and Nudler, 2001; Liu et al., 2015).  
TEFM as a dedicated transcription factor 
Since the TEFM CTD shows high structural similarity to RuvC-like resolvases, the question as 
to whether it possesses a nuclease activity may have significant bearings on the mechanism of 
replication in human mitochondria. Indeed, the closest structural homologs of TEFM, S.pombe 
and S.cerevisiae Cce1, are functional resolvases (Doe et al., 2000; Lockshon et al., 1995). Yeast 
cells deficient in Cce1 exhibit a dramatic increase in mtDNA aggregation (Doe et al., 2000; 
Piskur, 1997). The crystal structure of the TEFM CTD dimer reveals two putative nuclease 
sites, which are similar in overall shape to the active sites of Cce1 (Figure 33A and B). S.pombe 
Cce1 uses three negatively charged catalytic residues (D320, E117 and D46) to coordinate Mg 
ions required for nuclease activity (Ceschini, 2001). In TEFM, the two corresponding residues, 
D342 and E232, are preserved; however, the third catalytic residue is altered to valine (V174), 
which is conserved in TEFM from all species (Figure 33A and B). The structure suggests that 
this substitution renders TEFM unable to coordinate a Mg ion. Indeed, no electron density 
compatible with a bound divalent cation was observed in our structure even though 
crystallization conditions included 200 mM MgCl2. We therefore conclude that the nuclease 
sites in TEFM are degenerate and not functional. Indeed, considering that mammalian 
mitochondrial genomes are among the smallest, it is plausible that during evolution and transfer 
of many mitochondrial genes to the nucleus the resolvase function became non-essential for 
mtDNA maintenance. In contrast, preservation of a functional Holliday junction resolvase in 
yeast mitochondria is related to its essential function during replication, as the heritable mtDNA 
units in S. cerevisiae consist of genomes linked via recombination junctions (Doe et al., 2000; 
Lockshon et al., 1995). Although lacking nuclease activity, TEFM evolved to retain the ability 
of a Holliday junction resolvase to bind DNA, as the protein establishes simultaneous contacts 
with the RNA-DNA hybrid duplex and the downstream and upstream DNA regions of the 
transcription bubble (Figure 26A, B and D). These three duplexes of the EC are sharply bent 
relative to each other and resemble the topology of the DNA junctions, at which RuvC-like 
resolvases operate (Górecka et al., 2013). 
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Target specificity of TEFM 
Many transcription factors can recognize a particular conformation of RNAP allowing for 
transient regulation of its activity (Washburn and Gottesman, 2015). This is clearly the case for 
TEFM, as the cross-linking data and analytical gel filtration assay suggest that TEFM can 
efficiently bind to the EC, but not to the pre-initiation complex, initiation complex or the apo 
mtRNAP (Figure 33C, Figure 30E and F). Our structural data provide an explanation for this 
observation. In the EC, the orientation of the two major structural elements of mtRNAP that 
bind TEFM - the intercalating hairpin and the specificity loop - are fixed by interactions with 
the DNA and RNA (Figure 26A and B). In contrast, in the apo mtRNAP structure, both loops 
are disordered (Ringel et al., 2011) and therefore cannot contribute to the efficient binding of 
TEFM (Figure 30E and F). In the preIC and the IC the intercalating hairpin and specificity loop 
are likely engaged in interactions with promoter DNA and may not be fully accessible to TEFM 
(Morozov et al., 2015). Once mtRNAP completes the transcription cycle and dissociates from 
mtDNA, TEFM can no longer bind to the mtRNAP efficiently, and dissociates prior to 
engagement of mtRNAP in transcription initiation (Figure 33C). 
Our data on the mechanism of TEFM anti-termination activity, EC stabilization, mtRNAP 
processivity enhancement, and target specificity provide the molecular basis for the proposed 
role of TEFM in regulation of the switch between transcription and replication in human 
mitochondria (Agaronyan et al., 2015). Future experiments should be directed towards 
deciphering whether this regulation includes post-translational modifications of TEFM or 
changes in TEFM concentration in mitochondria by expression, degradation or other, yet 
unidentified factors. 
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Figure 33. TEFM is a pseudo-resolvase. 
(A,B) TEFM is a pseudo-resolvase. Putative active sites of human TEFM (A) and fission yeast Holliday 
junction resolvase Cce1 (B) are shown in similar orientation (ribbon representation). One of the 
magnesium-coordinating residues involved in catalysis in Cce1, D46, is replaced by the conserved 
residue V174 in TEFM. Two arginine residues conserved in all TEFM (R278 and R293, red sticks) are 
engaged in salt bridges with E232 and D342, effectively neutralizing their negative charge required for 
metal ion binding. An additional positive charge is contributed by K310 from the docking loop of a 
crystallographically related TEFM molecule (grey). (C) Schematics of the transcription cycle in human 
mitochondria. During initiation, mtRNAP is recruited to promoter by interactions with TFAM. 
Subsequent binding of TFB2M results in formation of the initiation complex. Transition to the 
elongation phase of transcription occurs upon release of TFB2M and recruitment of TEFM, required for 
processive elongation. At the end of the transcription cycle, mtRNAP dissociates from mtDNA, which 
triggers release of TEFM. Structures shown are of TFAM/LSP (PDB ID: 3TMM) (Ngo et al., 2011; 
Rubio-Cosials et al., 2011), the IC and the TFB2M models (Morozov et al., 2015), EC  (PDB ID: 4BOC) 
(Schwinghammer et al., 2013), EC-TEFM (this work) and apo mtRNAP (PDB ID: 3SPA) (Ringel et al., 
2011). 
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4.  Conclusion and Outlook 
Expression and replication of the human mitochondrial genome depends on the mitochondrial 
transcription machinery. Thus, mitochondrial transcription is at the heart of cellular energy 
production and mitochondrial organelle maintenance. In multi-subunit RNAP transcription 
systems, initiation and elongation are the two most regulated steps, and this is likely to also be 
the case in mitochondria. However, since this system shares no homology with other factor-
dependent transcription systems, the mechanistic interplay of the various factors with mtRNAP 
during initiation and elongation remained elusive, largely due to the lack of structural 
information. 
 
Figure 34. Structural view on the human mitochondrial transcription cycle. 
Schematic depiction of the transcription cycle in human mitochondria. Structures are shown in ribbon 
representation with transparent surfaces. Note that structures are not shown to scale. Sources of 
structures used: TFAM: PDB ID: 3TMM (Ngo et al., 2011); mtRNAP: PDB ID: 3SPA (Ringel et al., 
2011); mTERF1 PDB ID: 3MVA (Yakubovskaya et al., 2010); EC: PDB ID: 4BOC  (Schwinghammer 
et al., 2013); TFB2M – this work; TEFM – this work; initiation complex – this work; TEFM-elongation 
complex – this work. 
In this study, we extend our knowledge of human mitochondrial transcription by solving the 
structures of TFB2M and TEFM as well as of two important functional complexes, the initiation 
complex and the elongating anti-termination complex. Taken together, these data complement 
the previously elucidated structures and allow us to depict the transcription cycle in human 
mitochondria with all thus-far known players using structural snapshots of the individual steps 
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(Figure 34). Comparison of the structures presented here with their functional equivalents from 
other transcription systems illustrates that mitochondrial transcription is evolutionarily unique, 
but nonetheless utilizes comparable strategies as other systems to achieve the individual steps 
in transcription. This indicates that the mechanisms employed by transcriptional machineries 
and their regulation are dictated by the biophysical properties of nucleic acids and the 
biochemistry of the reaction catalyzed during RNA synthesis. 
Taken together, these data represent major advances towards understanding the mechanistic 
basis underlying mitochondrial gene expression and lay the groundwork for future structural 
and biochemical studies aimed at fully understanding the mechanistic details and regulation of 
this important process. 
4.1. Towards high-resolution structural data on the 
mitochondrial IC 
The crystal structure of the human mitochondrial transcription initiation complex presented in 
this work unravels the architecture of the complex, explains how mtRNAP is tethered to the 
promoter by TFAM and suggests how TFB2M acts to stabilize the open promoter complex. 
Due to the limited resolution, however, some details remain elusive. In particular, we were not 
able to observe density for the entire melted template DNA strand. High-resolution structural 
data is necessary to visualize the interactions of the template DNA between positions -4 and +2 
with the active site of mtRNAP. This will give further mechanistic insights, as it is likely that 
promoter recognition is in part achieved by interactions of mtRNAP with bases -2 and -3 in the 
template strand DNA (unpublished biochemical data by the Temiakov Lab). 
A second interesting question that will require higher resolution structural data in order to be 
answered concerns the interaction between TFB2M and the single-stranded non-template DNA 
strand. While the data presented in this work clearly show that TFB2M interacts with this region 
of the DNA, details of the interaction remain invisible at the obtained resolution. Does TFB2M 
merely stabilize the single strand non-specifically by interacting with the phosphate backbone, 
or are there more specific interactions involved, such as base-flipping and stacking interactions? 
Notably, bacterial s-factor, whose function seems to share conceptual similarities to TFB2M, 
recognizes specific bases (-35 and -11) within the non-template strand by base-flipping 
(Feklistov and Darst, 2011; Zhang et al., 2012). 
To address these open questions, high-resolution structural data is needed. Although it was not 
possible to obtain such data during the course of this work, the structures presented here may 
guide future efforts towards obtaining such data. Two possible avenues to achieve this are 
imaginable, and may be combined if necessary. 
Firstly, the structure of the IC may be used to guide future optimized crystallization trials. 
Limited diffraction of macromolecular crystals is usually caused by intrinsic disorder within 
the crystal lattice, and this in turn is often caused by flexible regions in the macromolecule or 
by imperfect packing within the crystal. In some cases, these parameters can be improved by 
optimizing the protein and DNA variants used. Although many potential modifications, both 
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pre- and post-crystallization, have been tested over the course of this work, no crystals 
displaying improved diffraction properties could be obtained. However, the newly obtained 
structure can be used to narrow down future attempts to obtain novel crystal forms. With the 
knowledge of how TFB2M interacts with mtRNAP and the DNA, one possibly promising 
direction would be to attempt crystallization of an mtRNAP-TFB2M-DNA complex, thus 
reducing size and complexity of the sample. An important result of the work presented here is 
the identification of an individually crystallizable variant of TFB2M. This paves the way for 
future structural experiments to obtain a more detailed picture of the interaction of TFB2M with 
nucleic acid. It seems particularly attractive to attempt co-crystallization of this variant with a 
single-stranded DNA molecule resembling the non-template strand in the IC, as this is likely to 
yield a more detailed picture of the involved interactions. 
Secondly, another approach to obtain high-resolution structural data would be to employ a 
completely different method. Until recently, X-ray crystallography has dominated the structural 
biology field, as it was the only method capable producing structural data of large 
macromolecular assemblies at atomic resolution. This situation, however, has drastically 
changed over the last few years (Kühlbrandt, 2014). With the advent of direct detector 
technology and powerful new software, cryo-electron microscopy has advanced to the point 
where it can be used to routinely obtain structural data at near-atomic resolution. Thus, cryo-
electron microscopic analysis of the mitochondrial initiation complex may be a more feasible 
avenue to obtain high-resolution structural data, as it circumvents the necessity to search for a 
crystal form with better diffraction properties. This approach bears the advantage that structural 
heterogeneity can be addressed in silico by sorting particles into different classes, ideally 
obtaining structural snapshots of different naturally occurring conformations. 
4.2. A complete picture of mitochondrial transcription 
initiation 
The structure of the open initiation complex represents a major milestone in our understanding 
of mitochondrial transcription. However, in order to gain a complete picture of this process, 
structural snapshots of two additional steps of initiation would be of particular interest. 
Firstly, the closed pre-initiation complex consisting of mtRNAP, TFAM and promoter DNA 
would provide valuable insight into the mechanism of promoter binding. From the currently 
available data, it is not possible to infer what this complex looks like. In particular, it is unknown 
whether the marked distortion in the DNA between TFAM and mtRNAP is induced by binding 
of the polymerase already in the closed DNA state, or whether the observed trajectory is a 
hallmark of the open DNA. Modeling of a closed DNA duplex into the open promoter complex 
structure obtained in this study reveals a clash of the downstream DNA with the fingers domain 
in mtRNAP. This is not surprising, as the trajectory of the downstream duplex is dramatically 
shifted in the open complex. It is, however, not known whether this movement occurs 
spontaneously upon DNA opening or whether it is induced by the polymerase. Unfortunately, 
structure determination of this complex may prove difficult, as the interactions in the preIC may 
be of very transient nature, making the complex inherently unstable. Indeed, experiments 
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conducted during this thesis work indicate that both the preIC as well as the IC are significantly 
less stable when formed on a fully duplexed DNA, as compared to the artificial mismatch 
bubble used for structure determination. 
The second important snapshot missing is that of an initially transcribing complex (ITC), 
consisting of mtRNAP, TFAM, TFB2M, promoter DNA and a short piece of RNA. Such 
complexes have been isolated and characterized structurally for other transcription systems 
(Cheetham and Steitz, 1999; Cheung et al., 2011; Engel et al., 2017) and provide important 
mechanistic insights into de novo RNA synthesis. Comparison of the open IC structure and the 
EC-TEFM structure obtained in this work demonstrates a profound structural rearrangement of 
the upstream DNA during promoter escape. However, the mechanism of how this 
rearrangement is induced remains speculative, and it would therefore be highly instructive to 
obtain structural information of the IC with different lengths of initial RNA chains synthesized. 
A structure of an ITC or an open complex bound to an incoming nucleotide is also likely to 
expand our knowledge on the functions of TFB2M, as its N-terminus has been cross-linked to 
the priming nucleotide (Sologub et al., 2009). This region did not show clear density in the open 
IC structure, indicating that it is mobile in the absence of the priming nucleotide. Thus, 
formation of a complex with a non-hydrolyzable nucleotide analogue or a short initial RNA 
chain may stabilize the TFB2M N-terminus and make it amenable to structural analysis. 
Taken together, such future studies aimed at obtaining structural snapshots of each step of 
transcription initiation hold promise to ultimately allow generation of a comprehensive “movie” 
of the events leading to RNA synthesis. 
4.3. Further studies on TEFM function and regulation 
The structures of TEFM and the EC-TEFM complex presented in this study clarify how this 
factor enhances transcriptional processivity of mtRNAP and confers resistance against 
premature termination at CSBII. It remains an open question, however, what the precise role of 
the N-terminal domain of TEFM is, as it is dispensable for the transcriptional functions studied 
here. It is possible that other regions in the mitochondrial genome exist that were not explicitly 
analyzed in this study, but which require the N-terminal domain of TEFM for regulated 
transcription. Another possibility is that this domain is involved in an additional, thus far 
uncharacterized function of TEFM. 
Another important aspect not yet understood is how TEFM is recruited to the polymerase, and 
how its activity is regulated. The biochemical and cross-linking data indicates that TEFM binds 
to mtRNAP following promoter escape and initiation factor clearance, but the precise sequence 
of events is not known. Clearly, the switch between transcription and replication in 
mitochondria must be regulated, and the most obvious target for regulation would be TEFM 
itself. 
Therefore, future research should be focused on determining whether the activity of TEFM is 
dependent on post-translational modifications or whether its concentration in mitochondria is 
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regulated according to cellular needs. In addition, it should be investigated whether TEFM has 
additional, not yet recognized functions and interaction partners in vivo. 
4.4. Evolutionary aspects of mitochondrial transcription 
The fact that mitochondria utilize a bacteriophage-like RNAP instead of a multi-subunit RNAP 
related to eubacterial RNAPs is both surprising and puzzling. The evolutionary origin of this 
enzyme has not been conclusively established (Cermakian et al., 1997), but it is noteworthy 
that not only the mitochondrial RNA polymerase but also the replicative helicase and the DNA 
polymerase seem to be of bacteriophage origin (Shutt and Gray, 2006) and almost all eukaryotes 
utilize this machinery in their mitochondria. There are, however, notable exceptions, such as 
the freshwater flagellate Reclinomonas americana, whose mitochondrial genome is among the 
highest in coding gene content and contains several genes homologous to eubacterial multi-
subunit polymerase genes (Lang et al., 1997). Although it is not known whether their gene 
products serve as a functional RNA polymerase, this finding raises interesting questions on the 
evolutionary origin of the bacteriophage-like mitochondrial transcription and replication 
systems. 
The structural data obtained in this study highlight a further evolutionarily interesting aspect, 
as they provide two examples of functionally and evolutionarily unrelated protein folds being 
utilized for a function in mitochondrial transcription. The structure of TFB2M confirms its 
relationship to SAM-dependent rRNA methyltransferases and the structure of the initiation 
complex demonstrates how conserved properties of this fold, such as single-stranded 
oligonucleotide binding via a positively charged patch, are elegantly utilized for a function in 
transcription initiation. The fold of the transcriptionally active C-terminal part of TEFM closely 
resembles that of Holliday Junction resolvases, yet no resolvase or nuclease activity could be 
detected by us and others (Minczuk et al., 2011). Instead, the property of Holliday Junction 
resolvase domains to bind cruciform duplex-single strand nucleic acid junctions is apparently 
repurposed to yield a processivity factor for mitochondrial transcription. Interestingly, a similar 
situation may have arisen for the metazoan mitochondrial DNA polymerase g, which associates 
with the accessory factor b for processive DNA replication. DNA polymerase b shows 
sequence- and structural homology to class IIa aminoacyl tRNA synthetases (Fan et al., 1999; 
2006). 
4.5. Clinical relevance of mtRNAP structures  
In addition to the insights gained about TEFM function, the structure of the EC-TEFM complex 
further complements our previous knowledge of the mechanism of mitochondrial transcription 
elongation. In the previously solved EC structure, mtRNAP is in the pre-translocated state 
(Schwinghammer et al., 2013). The EC-TEFM complex structure now reveals the post-
translocated state of mtRNAP. This is an important finding, as it demonstrates that the catalytic 
mechanism of RNA chain elongation is indeed conserved between bacteriophage and 
mitochondrial RNAPs. In the case of T7 RNAP, the availability of post-translocated elongation 
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complex crystals proved to be a prerequisite to obtaining structures of the polymerase with 
incoming substrate NTPs or product complexes (Tahirov et al., 2002; Temiakov et al., 2004; 
Yin and Steitz, 2002; 2004). Thus, crystallization of mtRNAP in this state paves the way for 
structural investigations of the interactions between the polymerase and incoming substrate 
nucleotides. 
The next step will therefore be to attempt co-crystallization of the EC-TEFM complex with 
non-hydrolyzable substrate analogues, such as a,b-methylene-ATP, in order to obtain a 
structural snapshot of the molecular interactions that govern substrate selection. This may be of 
broad interest for clinical applications, as recent studies suggest that some of the severe side 
effects observed in clinical trials of antiviral ribonucleosides, which inhibit viral RNA 
polymerases, are due to off-target effects on mitochondrial RNA polymerase (Arnold et al., 
2012; Feng et al., 2016). Hence, structure-guided drug design may prove powerful for the 
development of small molecule compounds capable of selectively inhibiting only viral 
polymerases, ultimately leading to new treatments for human diseases such as Hepatitis C. 
 
  
Appendix  
 84 
5. Appendix 
5.1. Extended Materials and Methods for the initiation 
study 
5.1.1. Extended Methods for the initiation study 
This section contains methods specifically related to the study on the structure of the human 
mitochondrial transcription initiation complex, which were performed by our collaborators in 
the Temiakov lab. Parts of the methods described here are currently in the process of peer 
review for publication: 
 
H.S. Hillen, Y.I. Morozov, A. Sarfallah, D. Temiakov and P. Cramer (2017) Structural basis 
of mitochondrial transcription initiation. Cell, in revision 
 
A detailed list of author contributions can be found on page VI. 
Transcription assays 
Standard transcription reactions were carried out using PCR-amplified DNA templates 
containing the LSP promoter (region -60 to +20) as described previously (Morozov et al., 2015). 
The reactions contained DNA templates (50 nM), ∆119 mtRNAP (50 nM), Cys-less TFAM (50 
nM), ∆20 TFB2M (50 nM) in a transcription buffer containing 40 mM Tris-HCl pH 7.9, 10 
mM MgCl2 and 10 mM DTT in the presence of ATP (0.3 mM), GTP (0.3 mM), UTP (0.01 
mM) and 0.3 µCi [g-32P] UTP (800 Ci/mmol). To assay the activity of the IC assembled on pre-
melted LSP, the reaction was performed in the presence of ATP (0.3 mM), GTP (0.3 mM) and 
0.3 µCi [g-32P] ATP (800 Ci/mmol) to generate 4-5 nt RNA products. Reactions were carried 
out at 35 °C for 30 min and stopped by addition of an equal volume of 95% formamide/0.05 M 
EDTA. The products were resolved by 20% PAGE containing 6 M urea and visualized by 
PhosphorImager (GE Healthcare).  
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5.1.2. Extended figures and tables of the initiation study 
This section contains tables related to the X-ray crystallographic analysis, which was performed 
as part of this thesis. The data in this section are currently under peer review for publication: 
 
H.S. Hillen, Y.I. Morozov, A. Sarfallah, D. Temiakov and P. Cramer (2017) Structural basis 
of mitochondrial transcription initiation. Cell, in revision 
 
A detailed list of author contributions can be found on page VI. 
 
Table 12. X-Ray data collection and refinement statistics for TFB2Mcryst structure. 
 TFB2Mcryst 
Data collection  
Space group P21 
Cell dimensions    
 a, b, c (Å) 44.0, 165.7, 44.7 
 a, b, g (°)  90.0, 98.0, 90.0 
Resolution (Å) a 50 – 1.75 (1.79 – 1.75) a 
Rmeas 0.048 (2.874) 
I/s(I) 20.17 (0.75) 
CC1/2 100.0 (37.7) 
Completeness (%) 97.8 (97.5) 
Redundancy 7.1 (7.0) 
  
Refinement  
Resolution (Å) 42.1 – 1.75 
No. reflections 62087 
Rwork / Rfree 0.175 / 0.209 
No. atoms  
    Protein 4627 
    Ligand/ion (Cl-, Glycerol)  8 
    Water 411 
B factors (Å2)  
    Protein 52.24 
    Ligand/ion 85.22 
    Water 63.26 
R.m.s. deviations  
    Bond lengths (Å) 0.006 
    Bond angles (°) 0.84 
Ramachandran  
 Preferred/allowed/ 
 disallowed (%) 
97.50 / 2.14 / 0.36 
a Values in parentheses are for the highest-resolution shell. 
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Table 13. X-Ray data collection, phasing and refinement statistics for IC LSP structure 
 IC LSP Native IC LSP SeMet 
all proteinsb 
IC LSP SeMet 
mtRNAP 
IC LSP SeMet 
TFAM 
Data collection     
Space group P21 P21 P21 P21 
Cell dimensions       
 a, b, c (Å) 103.9, 197.0, 
137.2 
103.9, 198.3, 
136.1 
103.8, 198.8, 
138.0 
103.6, 197.1, 
136.6 
 a, b, g  (°) 90, 99.87, 90 90.0, 99.9, 90.0 90.0, 100.0, 90.0 90.0, 99.8, 90.0 
Wavelength 0.99998 0.97856 0.97864 0.97856 
Resolution (Å)a 50 – 4.50 (4.61 
– 4.50) a 
50 – 4.99 (5.11 
– 4.99) 
50 – 5.60 (5.74 
– 5.60) 
50 – 5.50 
(5.63 – 5.50) 
Rmeas 0.061 (1.857) 0.167 (5.241) 0.094 (2.590) 0.086 (2.490) 
I/s(I) 14.46 (1.33) 19.94 (1.14) 14.53 (1.13) 24.71 (1.58) 
CC1/2 
Completeness (%) 
99.8 (54.0) 
98.7 (96.1) 
99.9 (51.3) 
99.8 (99.2) 
100.0 (55.2) 
99.0 (99.3) 
100 (72.4) 
99.3 (99.0) 
Redundancy 7.1 (7.0) 63.4 (56.0) 11.6 (11.9) 28.6 (28.6) 
     
Refinement     
Resolution (Å) 49.59 – 4.50    
No. reflections 31982    
Rwork / Rfree 0.273 / 0.309    
No. atoms     
    Macromolecules 28,039    
    Ligand/ion -    
    Water -    
B factors (Å2)     
    Macromolecules 350.1    
    Ligand/ion -    
    Water -    
r.m.s deviations     
    Bond lengths (Å) 0.004    
    Bond angles (°) 0.92    
Ramachandran     
 Preferred/allowed/ 
 disallowed (%) 
95.86 / 3.40 / 
0.73 
   
a Values in parentheses are for the highest-resolution shell. 
b Diffraction data from two crystals were merged. 
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Table 14. X-Ray data collection statistics for IC LSP Bromine derivatives. 
 IC LSP 
Bromine 1b 
IC LSP 
Bromine 2 b 
IC LSP 
Bromine 3 
IC LSP 
Bromine 4 
Data collection     
Space group P21 P21 P21 P21 
Cell 
dimensions   
    
 a, b, c (Å) 103.6, 196.7, 
137.1 
103.9, 195.6, 
137.1 
103.5, 196.4, 
137.1 
103.9, 197.7, 
137.7 
a, b, g  (°) 90.0, 99.7, 90.0 90.0, 99.8, 90.0 90.0, 99.7, 90.0 90.0, 99.6, 90.0 
Wavelength 0.91930 0.91930 0.91930 0.91882 
Resolution (Å)a 50 – 6.00 (6.15 
– 6.00)a 
50 – 6.00 (6.15 
– 6.00) 
50 – 6.00 (6.15 
– 6.00) 
50 – 6.01 
(6.15 – 6.01) 
Rmeas 0.154 (1.401) 0.094 (1.010) 0.073 (1.137) 0.115 (3.226) 
I/s(I) 11.84 (1.38) 16.47 (2.52) 10.29 (1.25) 15.27 (0.84) 
CC1/2 
Completeness (%) 
99.9 (73.2) 
99.7 (99.5) 
100.0 (84.1) 
99.7 (99.7) 
99.9 (65.6) 
98.7 (99.5) 
100.0 (51.9) 
99.7 (99.2) 
Redundancy 12.8 (10.9) 12.5 (13.4) 3.6 (3.7) 21.2 (21.0) 
 
 
 
IC LSP 
Bromine 5 
 
IC LSP 
Bromine 6 
  
Data collection     
Space group P21 P21   
Cell 
dimensions   
    
 a, b, c (Å) 104.3, 196.7, 
137.7 
102.7, 196.4, 
137.3 
  
a, b, g  (°) 90.0, 99.8, 90.0 90.0, 99.8, 90.0   
Wavelength 0.91880 0.91880   
Resolution (Å)a 50 – 6.01 (6.16 
– 6.01) 
50 – 7.00 (7.17 
– 7.00) 
  
Rmeas 0.08 (1.86) 0.09 (1.89)   
I/s(I) 23.05 (1.63) 21.22 (1.83)   
CC1/2 
Completeness (%) 
100.0 (79.2) 
99.6 (98.0) 
100 (79.4) 
99.7 (99.8) 
  
Redundancy 21.1 (20.5) 21.0 (22.0)   
a Values in parentheses are for the highest-resolution shell. 
b Diffraction data from two crystals were merged. 
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Table 15. X-Ray data collection, phasing and refinement statistics for IC HSP structure. 
  
IC HSP Native 
IC HSP 
SeMet TFAM 
Data collection   
Space group P21 P21 
Cell dimensions     
 a, b, c (Å) 103.6, 197.7, 
134.3 
103.9, 199.4, 134.6 
 a, b, g  (°) 90, 99.39, 90 90, 99.57, 90 
Wavelength 0.97864 0.97895 
Resolution (Å)a 50 – 4.50 (4.61 – 
4.50) a 
50 – 6.50 (6.66 – 6.50) 
Rmeas 0.087 (2.232) 0.152 (2.146) 
I/s(I) 13.38 (1.11) 15.67 (1.58) 
CC1/2 
Completeness (%) 
100.0 (50.2) 
99.1 (99.6) 
99.9 (67.3) 
99.7 (100.4) 
Redundancy 7.0 (7.3) 21.3 (22.0) 
   
Refinement   
Resolution (Å) 49.49 – 4.50  
No. reflections 31416  
Rwork / Rfree 0.289 / 0.331  
No. atoms   
    Macromolecules 28045  
    Ligand/ion   -  
    Water -  
B factors (Å2)   
    Macromolecules 322.63  
    Ligand/ion -  
    Water -  
r.m.s deviations   
    Bond lengths (Å) 0.004  
    Bond angles (°) 0.91  
Ramachandran   
 Preferred/allowed/ 
 disallowed (%) 
95.60 / 3.54 / 0.87  
a Values in parentheses are for the highest-resolution shell. 
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5.2. Extended Materials and Methods for the elongation 
study  
5.2.1. Extended Methods for the elongation study 
This section contains methods specifically related to the study on the mechanism of 
transcription anti-termination in human mitochondria and carried out predominantly by the 
collaborators from the Temiakov lab. Parts of the methods described here have been accepted 
for publication: 
 
H.S. Hillen, A.V. Parshin, K. Agaronyan, Y.I. Morozov, J.J. Graber, A. Chernev, K. 
Schwinghammer, H. Urlaub, M. Anikin, P. Cramer and D. Temiakov (2017) Mechanism of 
transcription anti-termination in human mitochondria. Cell, in press 
 
A detailed list of author contributions can be found on page VI. 
Limited proteolysis of TEFM and analysis of the cleavage products 
TEFM was subjected to limitied proteolysis using trypsin (Sigma, protease/TEFM ratio 1: 
20,000 w/w), ArgC protease (Sigma, 1:1000 w/w), LysC protease (Sigma, 1:1000 w/w) for 1 h 
at RT. Products of protease digestion of TEFM were dissolved in a solution containing 5% 
acetonitrile and 0.1% tetrafluoroacetic acid (TFA) and purified using C4 ZipTip. The peptide 
mixtures were analyzed using a Bruker MicroFlex MALDI-TOF instrument in sinapinic acid 
matrix with R=5000. 
Crystallization of human TEFM N-terminal domain 
TEFM NTD (10 mg/ml) was crystallized using the sitting drop vapor diffusion method and 
Crystallization Screen solution 15 (Hampton Research) containing 30% PEG4000, 0.2 M 
ammonium acetate, 0.1 M sodium acetate pH 4.0 to produce large (0.05 mm x 0.05 mm x 0.8 
mm) needle-like crystals. The crystals were flash-frozen using stabilization solution containing 
30% PEG4000, 15% PEG400, 0.1 M ammonium acetate and 0.05 M sodium acetate pH 4.0. 
Promoter templates for transcription assays 
Templates for transcription anti-termination assays containing the LSP promoter and CSBII 
region were prepared by PCR amplification as described previously (Agaronyan et al., 2015). 
For the processivity assay, plasmid DNA (pT7blue) containing the LSP promoter region (-
70/+70LSP_pT7blue) (Morozov et al., 2015) was linearized using the XhoI nuclease. The 
template was purified using phenol-chloroform extraction followed by ethanol precipitation. 
For termination assays, T7 phage terminator TΦ and bacterial terminator TrpA were cloned 
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into LSP-containing plasmid (-70/+70LSP_pT7blue) 70 bp downstream of transcription start 
site. For the halted complex assays and RNA foot- printing, a variant of the LSP-promoter 
template (“+35LSP”) with the initial transcribed sequence 
AAAGATAAAATTTGAAATGGTAGTTGTTTAAGTTGC was used. 
Transcription assays 
Standard transcription reactions were carried out using PCR-amplified DNA templates (50 
nM), mtRNAP (50 nM), TFAM (50 nM), TFB2M (50 nM) in a transcription buffer containing 
40 mM Tris-HCl pH 7.9, 10 mM MgCl2 and 10 mM DTT in the presence of ATP (0.3 mM), 
GTP (0.3 mM), UTP (0.01 mM) and 0.3 µCi[a-32P] UTP (800 Ci/mmol). Reactions were 
carried out at 35 °C for 60 min and stopped by addition of an equal volume of 95% 
formamide/0.05 M EDTA. The products were resolved by 20% PAGE containing 6 M urea and 
visualized by PhosphorImager (GE Healthcare). In the processivity assay, the reactions (10 µl) 
were stopped by addition of 190 µl of stop buffer containing 20 mM Tris-HCl pH 8.0, 150 mM 
NaCl, 20 mM EDTA, 1% SDS and 20 µg/ml proteinase K. After incubation at 55 °C for 1 h 
the RNA products were extracted with phenol/chlorophorm/isoamyl alcohol mixture followed 
by ethanol precipitation and resolved by 6% PAGE containing 6 M urea. 
Nuclease foot-printing assays 
For RNA foot-printing, ECs were halted 35 bp downstream of the promoter start site by 
omitting CTP from the transcription reaction and treated with RNase 1f (New England Biolabs) 
for 5 min at RT. For DNA foot-printing, the ECs were assembled using R14/TS36/NT36 
scaffold, incubated for 14 min with TEFM at RT and treated with DNase I (New England 
Biolabs) for 5 min at RT. The sequences of the oligos (IDT DNA) are as follows (5' to 3'): 
AGUCUGCGGCGCGC (RNA14), 
GGGCTTAGTTCGTCTGGCGTGCGCGCCGCTACACCATGTTTGCTGACC (TS26), 
GGTCAGCAAACATGGTGTAAGTATTACGACGCCAGACGAACTAAGCCC 
(NT26A) The reactions were stopped by addition of an equal volume of 95% formamide/0.05 
M EDTA and resolved by 20% PAGE containing 6 M urea. 
Cross-linking using artificial photo reactive amino acid (Bpa) 
The ECs (0.5 µM) were assembled using R14/TS2/NT2 scaffold (Schwinghammer et al., 2013) 
and mtRNAP. TEFM (1 µM) was added to the EC and incubated for 15 min at RT. The cross-
linking was activated by UV irradiation at 312 nm for 30 min at RT. 
Protein-DNA photo cross-linking 
The cross-linking was performed as described in (Agaronyan et al., 2015) using a tag-less 
variant of mtRNAP (∆108 mtRNAP, (Morozov et al., 2014)) and RNA-DNA scaffold, 
containing a 32P-labeled DNA strand with a 4-thio UMP probe. 
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Mapping of TEFM-mtRNAP interaction using disuccinimidyl glutarate 
(DSG) cross-linking 
To map the TEFM binding site, EC-TEFM complex (5 µM in 40 mM Na-HEPES pH 7.5) was 
treated with a mixture of DSG/[2H4]-DSG (0.6 mM DMSO solution, ProteoChem) and the 
products of the reaction separated using 7% Tris-glycine SDS PAGE. The cross-linked species 
were excised from the gel and subjected to trypsin digestion in 100 mM NH4HCO3 buffer 
overnight at 37 °C. The products of the digestion reaction were extracted from the gel with 
CH3CN-0.1% TFA in water (9:1), dried in vacuum, re-dissolved in 10 mg/ml CHCA matrix in 
CH3CN-0.1% TFA in water (1:1), and the resulting solution applied on target for MALDI-TOF 
mass spectrometry. Mass spectra were taken on a MicroFlex LRF spectrometer (Bruker). 
Positively charged ions (M+H+) were analyzed in the reflector mode (m/z 1000 to 4000) and 
cross-linked peptides identified using xBobcat mass matching search engine 
(http://prottools.ethz.ch/orinner/public/htdocs/xquest/index_review.html). 
Mapping of the Bpa-TEFM cross-linking sites in mtRNAP 
For mapping with the HRV 3C protease (Pierce), the ECs were assembled using ∆119 
mtRNAPs with the engineered 3C cleavage sites (LEVLFQGP) - 3C-PPR mtRNAP 
(substitution of residues 358-364, cleaved at Q363), 3C-thumb mtRNAP (insertion after residue 
H745, cleaved at Q751) and 3C-lever-loop mtRNAP (insertion after residue K596, cleaved at 
Q602). All these mtRNAP variants also contained an engineered protein kinase (PKA) site at 
the N-terminus (MGHHHHHHRRASV...) (Morozov et al., 2015). Upon UV irradiation, the 
ECs (0.5 µM) were incubated with 3C protease (1:1 w/w ratio) for 15-25 h at 40 °C and the 
products of the reaction resolved using 4-12% SDS PAGE (Invitrogen). NTCB mapping of the 
TEFM sites in mtRNAP was performed as described in (Morozov et al., 2015). The TEFM-
mtRNAP cross-link was excised from the gel, eluted with 0.2% SDS for 1 h at 4 °C and 
precipitated with 80% acetone. The dried material was dissolved in solution containing 0.2% 
SDS prior to the NTCB treatment. 
Pyrophosphorolytic assay 
The ECs (250 µM) were assembled using RNA10/TS1/NT1 scaffold (RNA10: 
CUGCGCGCAU; TS1: GGGTCCTGTCTGAAATCGACATCGCCGC; NT1: 
CGATTTCAGACAGGACCC) for 10 min at room temperature in the presence or absence of 
TEFM (500 µM). The reactions were incubated with pyrophosphate (50-500 µM) for 30 min 
at room temperature and stopped by the addition of formamide/EDTA containing buffer. The 
samples were resolved by electrophoresis in 20% PAGE in the presence of 6 M urea and 
visualized by PhosphoImager. 
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5.2.2. Extended figures and tables of the elongation study 
This section contains extended figures related to the study on the mechanism of transcription 
anti-termination in human mitochondria, which were generated by our collaborators in the 
Temiakov lab. In addition, it contains tables related to the X-Ray crystallographic analysis 
performed as part of this thesis. Parts of the methods described here have been accepted for 
publication: 
 
H.S. Hillen, A.V. Parshin, K. Agaronyan, Y.I. Morozov, J.J. Graber, A. Chernev, K. 
Schwinghammer, H. Urlaub, M. Anikin, P. Cramer and D. Temiakov (2017) Mechanism of 
transcription anti-termination in human mitochondria. Cell, in press 
 
A detailed list of author contributions can be found on page VI. 
 
 
Figure 35. TEFM interacts with RNA and DNA in the EC. 
(A) TEFM lacking the NTD domain protects 19-20 nt of RNA from RNase 1 cleavage in the anti-
termination complex. The ECs were halted 35 bp downstream of the LSP promoter in the presence of 
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WT or ∆135 TEFM and treated with RNase 1 for 5 min at RT. (B) TEFM lacking the NTD domain and 
the inter-domain linker does not protect RNA from RNase 1 cleavage. The experimental conditions were 
as described above. (C) TEFM lacking the NTD domain protects the downstream and the upstream 
DNA in the EC. The EC was assembled using R14/TS26/NT26 scaffold in the absence of TEFM or in 
the presence of WT or ∆135 TEFM prior to DNase I treatment for 5 min at RT. (D) TEFM lacking the 
NTD domain and the inter-domain linker leaves no clear footprint in the DNAse I protection assay. The 
experimental conditions were as described above.  
 
Figure 36. List of cross-linked peptides detected and activity of TEFM mutants. 
(A) List of peptides representing inter-protein cross-links between mtRNAP and TEFM detected by BS3 
(black), EDC (blue) and DSG (red). (B) List of pBpa-substitions made in mtRNAP and TEFM with 
their respective cross-linking efficiencies. (C) Anti-termination activity of various TEFM mutants.  
Crosslinker Protein 1 Protein 2 Residue 1 Residue 2 peptide times detected
BS3 mtRNAP TEFM 755 144 KAELR(1)-KSPENR(1) 4
BS3 mtRNAP TEFM 1089 144 VKQIGGGIQSITYTHNGDISR(2)-KSPENR(1) 6
BS3 mtRNAP TEFM 1089 153 VKQIGGGIQSITYTHNGDISR(2)-KLLKPDIER(1) 3
BS3 mtRNAP TEFM 1089 144 VKQIGGGIQSITYTHNGDISR(2)-LLKPDIER(3) 6
EDC mtRNAP TEFM 632 42 NVQQIGILKPHPAYVQLLEK(19)-KITPNVTFCDENAKEPENALDK(1) 6
EDC mtRNAP TEFM 632 42 NVQQIGILKPHPAYVQLLEK(19)-KITPNVTFCDENAK(1) 6
EDC mtRNAP TEFM 755 56 KAELR(1)-EPENALDK(1) 7
EDC mtRNAP TEFM 1089 84 VKQIGGGIQSITYTHNGDISR(2)-ELEAFR(1) 3
EDC mtRNAP TEFM 1089 101 VKQIGGGIQSITYTHNGDISR(2)-SINIVEHR(6) 3
EDC mtRNAP TEFM 755 101 KAELR(1)-SINIVEHR(6) 21
EDC mtRNAP TEFM 1206 124 ETLQAVPKPGAFDLEQVK(1)-YKSTVQVCNSILCPK(2) 30
EDC mtRNAP TEFM 1089 214 VKQIGGGIQSITYTHNGDISR(2)-GIYSSSVYLEEISSIISK(10) 7
EDC mtRNAP TEFM 1089 215 VKQIGGGIQSITYTHNGDISR(2)-GIYSSSVYLEEISSIISK(11) 22
DSG mtRNAP TEFM 1087 153 LDSKVK(4)-KLLKPDIER(1) N/A
DSG mtRNAP TEFM 1087 156 LDSKVK(4)-KLLKPDIER(4) N/A
Figure S5. Related to Figure 5
T421Bpa <1%
T433Bpa <1%
C591Bpa <1%
R601Bpa <1%
Y607Bpa <1%
Y610Bpa 30%
Q616Bpa <1%
Q617Bpa <2%
E682Bpa <1%
Q728Bpa <1%
R770Bpa <1%
S774Bpa <1%
E778Bpa <1%
E889Bpa <1%
E890Bpa <1%
K988Bpa <1%
V1088Bpa 30%
I1091Bpa 25%
K1189Bpa <1%
Bpa-mtRNAP
R89Bpa <1%
K137Bpa <1%
R140Bpa <1%
K142Bpa <1%
S145Bpa <1%
F150Bpa ~10%
K153Bpa ~10%
K156Bpa ND*
E162Bpa ~5%
E214Bpa ND
K222Bpa ~5%
I308Bpa 30%
L309Bpa 30%
K310Bpa 30%
D312Bpa 30%
BpaTEFM
mtRNAP cross-linkefficiency
*ND - not detected due to
low binding to mtRNAP
TEFM cross-linkefficiency
WT 100%
sub140-144 50%
K142A/K144A 95%
sub149-153 5%
K153A/K156A 100%
F150A/L151G 100%
F150S/L151S 100%
R149A/R152A 80%
R152A/R153A 40%
K137Bpa NT*
R140Bpa NT
K142Bpa NT
S145Bpa 100%
F150Bpa NT
K153Bpa NT
K156Bpa <50%
TEFM A-T activity
* not tested
CB
A
D E
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Figure 37. Mapping of interactions between TEFM and mtRNAP. 
(A) The docking loop of TEFM cross-links to two distinct sites in mtRNAP. Cross-linking was 
performed using a 32P-labeled Bpa308 TEFM variant and mtRNAP having an engineered cleavage site 
for the 3C protease introduced into the proline-rich linker domain (cleavage after residue 363). The 
cleavage reaction revealed that the majority of the cross-link to the 308BpaTEFM (~65%) is located to 
the N-terminus of the 3C site, i.e. in the N-terminal extension region/PPR domain of mtRNAP (residues 
120-364). (B) Fine mapping of the N-terminal cross-linking site in mtRNAP. Cross-linking was 
performed using Bpa308 TEFM and 32P-labeled ∆119 mtRNAP. Upon cross-linking, the radioactive 
species were separated using 6% SDS PAGE. MtRNAP-TEFM cross-link and mtRNAP were excised 
from the gel, eluted and subjected to cleavage by NTCB (cuts at Cys residues). The products of the 
reaction were resolved using 4-12% PAGE (Invitrogen). N-terminal cleavage pattern is observed for 
mtRNAP (lanes 1,2); the identity of every band representing labeled peptide was verified using the 
molecular weight standards (Mark 12, Invitrogen). Cleavage of the mtRNAP-TEFM cross-link results 
in appearance of adducts (indicated by the blue arrows), that are a TEFM mass (~37 kDa) larger than 
the corresponding peptides observed for mtRNAP. The cleavage pattern of the cross-link (lanes 3,4) is 
consistent with the location of the N-terminal cross-link between residues 120-178 in mtRNAP. Blue 
numbers (left side of the gel) represent apparent molecular weights of the three most N-terminal 
mtRNAP peptides involved in TEFM cross-linking; blue numbers to the right are molecular weights of 
the corresponding adducts. Note that the large molecular weight C-terminal cross-linked species are not 
resolved in this gel. (C) Fine mapping of the TEFM-mtRNAP NTD cross-link. The cross-linking was 
performed using a Bpa308 TEFM variant and 32P-labeled ∆44 mtRNAP (mature mtRNAP) with the 
engineered hydroxylamine cleavage site (NG) at residue 150. Upon the cleavage reaction, appearance 
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of the labeled species (~55 kDa) corresponding to TEFM cross-linked to the region 44-150 in the NTD 
of mtRNAP was observed. Taken together with the data obtained in the NTCB experiment above, this 
suggests that TEFM interacts with the region 120-150 in the mtRNAP NTD. Note that the C-terminal 
cross-link is not visible in this experiment as the labeling of mtRNAP is due to the engineered PKA site 
at the N-terminus of mtRNAP. (D) Schematic illustration of the variants of mtRNAP used in 
experiments shown in Panel A-C. The red rectangle indicates the N-terminal cross-link to 32P-labeled 
TEFM (or 32P-labeled mtRNAP to TEFM); The yellow rectangle represents the C-terminal mtRNAP 
cross-link due to 32P-labeled TEFM. (E) TEFM does not efficiently cross-link to the ∆150 mtRNAP. 
Cross-linking was performed using a 32P-labeled Bpa308 TEFM variant and ∆119 (lane 1) or ∆150 (lane 
2) mtRNAP. (F) Mapping of the C-terminal cross-linking site in mtRNAP. Cross-linking was performed 
using a 32P-labeled Bpa308 TEFM variant and mtRNAPs with the engineered cleavage site for the 3C 
protease introduced into the thumb domain (cleavage after residue 751, lanes 1,2) or into the lever loop 
(cleavage after residue 602, lanes 3,4). The identified cross-linked adducts are indicated by black arrows. 
Grey arrows mark the expected position of the cross-linked species that correspond to the minor (< 5-
10%) cross-linking sites. Cleavage of 3C-751-mtRNAP results in appearance of a single band, 
representing the region 120-751 of mtRNAP. Cleavage of 3C-602-mtRNAP results in appearance of a 
band, which represents the region 120-602 of mtRNAP. These data, taken together with the data 
suggesting the location of the C-terminal cross-linking site between residues 365-1230 (panel A), 
indicate the location of the C-terminal crosslink in region 364-602 of mtRNAP. (G) Schematic 
illustration of the variants of mtRNAP used in experiments shown in Panel A and F. The red rectangle 
indicates the N-terminal cross-link to 32P-labeled TEFM; the yellow rectangle represents the C-terminal 
mtRNAP cross-link due to 32P-labeled TEFM. 
 
Figure 38. MtRNAP does not terminate at TrpA and TΦ hairpin terminators. 
(A) Transcription assay performed using a PCR template containing the LSP promoter (lane1) and the 
LSP promoter and TrpA terminator (lane 2). The position of the expected termination product is 
indicated with the black arrow; efficiency of termination at this point is indicated beneath the gel. (B) 
Transcription assay performed using a PCR template containing the LSP promoter (lane1) and the LSP 
promoter and TΦ terminator (lane 2). The position of the expected termination product is indicated with 
the black arrow; efficiency of termination at this point is indicated beneath the gel.   
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Table 16. X-Ray data collection and refinement statistics for human TEFM. 
 TEFM CTD 
native 
TEFM CTD 
SeMet-SADb 
TEFM NTD 
native 
TEFM NTD 
S-SAD 
Data collection     
Space group C2 C2 P43212 P43212 
Cell dimensions       
 a, b, c (Å) 98.48, 112.54, 
88.84 
97.57, 112.79, 
88.84 
47.67, 47.67, 
93.40 
47.72, 47.72, 93.32 
a, b, g  (°) 90.00, 110.13, 
90.00 
90, 109.76, 
90.00 
90, 90, 90 90, 90, 90 
Wavelength 1.0000 0.9765 1.0000 2.0664 
Resolution (Å)a 46.23 – 1.90 (1.94 
– 1.90)a 
48.32 – 2.68 
(2.74 – 2.68)  
42.46 – 1.30 
(1.33 – 1.30)  
42.49 – 2.10 
(2.14 - 2.10)  
Rmeas  0.056 (2.78) 0.24 (3.50) 0.107 (4.67) 0.096 (2.51) 
I/s(I) 17.92 (0.79) 9.45 (0.62) 20.26 (0.60) 41.67 (7.74) 
CC1/2 
Completeness (%) 
100.0 (35.3) 
98.1 (89.5) 
99.7 (32.6) 
99.7 (98.8) 
100.0 (41.3) 
99.7 (98.1) 
100.0 (95.1) 
99.4 (96.1) 
Redundancy 6.60 (5.04) 11.86 (6.25) 25.05 (24.01) 37.62 (25.64) 
     
Refinement     
Resolution (Å) 46.23 – 1.90  42.46 – 1.30  
No. reflections 70117  27057  
Rwork / Rfree 0.195 / 0.228  0.190 / 0.197  
No. atoms     
 Protein 6724  692  
 Ligands 24  4  
 Water 129  80  
B factors (Å2)     
 Protein 67.33  27.16  
 Ligands 79.72  56.01  
 Water 57.78  38.21  
r.m.s deviations     
 Bond lengths (Å) 0.003  0.009  
 Bond angles (°) 0.51  0.95  
Ramachandran     
Preferred/allowed/ 
 disallowed (%) 
 
97.5 / 2.5 / 0.0  98.7 / 1.3 / 0.0  
a Values in parentheses are for highest-resolution shell. 
bThe data reflect the merged results from several crystals  
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Table 17. X-Ray data collection and refinement statistics for the EC-TEFM complex. 
                                                                EC-TEFM Complexb 
Data collection     
Space group C2 
Cell dimensions       
 a, b, c (Å) 224.53, 155.55, 164.19 
a, b, g  (°) 90.00, 113.59, 90.00 
Wavelength 1.0000 
Resolution (Å)a 49.16 – 3.90 (4.00 – 3.90)a 
Rmeas  0.258 (2.187) 
I/s(I) 9.72 (1.44) 
CC1/2 
Completeness (%) 
99.7 (54.5) 
99.6 (97.7) 
Redundancy 13.12 (12.50) 
     
Refinement     
Resolution (Å) 48.87 – 3.90 
No. reflections 46930 
Rwork / Rfree 0.243 / 0.276 
No. atoms     
 Macromolecules 25122 
 Ligands 0 
 Water 0 
B factors (Å2)     
 Macromolecules 160.94 
 Ligands 0 
 Water 0 
r.m.s deviations     
 Bond lengths (Å) 0.004 
 Bond angles (°) 0.63 
Ramachandran  
Preferred/allowed/ disallowed (%) 94.2 / 5.1 / 0.6 
a Values in parentheses are for highest-resolution shell. 
 bThe data reflect the merged results from two datasets. 
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